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The prolyl hydroxylase domain (PHD) proteins serve as critical regulators of the 
cellular response to tissue hypoxia, like that present in the early venous 
thrombus, through regulation of hypoxia-inducible factor 1α (HIF1α) stability. 
This study sought to determine: (i) the expression of PHD1, PHD2 and PHD3 at 
the gene and protein level during natural thrombus resolution; (ii) the effect of 
gene specific deletion of Phd2 on thrombus resolution; (iii) the effect of pan-
PHD inhibition on thrombus resolution; and (iv) the contribution of endogenous 
VEGFR signalling to thrombus resolution. 
 
All three PHD isoforms were expressed in the naturally resolving thrombus at 
the gene and protein level. Gene expression of Phd1 remained invariant while 
Phd2 and Phd3 expression demonstrated distinct temporal patterns. PHD 
isoforms were localised to the cellular component of the thrombus, with 
morphological analysis suggesting expression in both neutrophils and 
macrophages. Constitutive heterozygous Phd2 gene deletion failed to increase 
HIF1α stabilisation as was not associated with increased thrombus resolution. 
Inducible homozygous Phd2 gene deletion significantly enhanced HIF1α 
nuclear accumulation and transcriptional activity but thrombus resolution was 
unchanged. Pharmacological inhibition of PHD isoforms with novel small 
molecule inhibitor, AKB-4924 and JNJ-42041935, signficantly increased HIF1α 
nuclear accumulation and transcriptional activity. Treatment with these inhibitors 
significantly increased thrombus neovascularisation but thrombus resolution 
was unaffected. Blocking of endogenous VEGFR signalling using the pan-
VEGFR inhibitor axitinib significantly impaired thrombus resolution. Axitinib 
treated thrombi remained larger and more occlusive for an extended period of 
time and this was associated with significant reductions in thrombus 
neovascularisation, macrophage recruitment and collagen deposition. 
 
Inhibition of PHD activity promotes thrombus neovascularisation, but other 
mechanisms are likely to regulate the removal of thrombus. Studies of thrombus 
resolution in Phd2 gene specific knockouts indicate that PHD2 activity does not 
play a major role in thrombus resolution. However, endogenous VEGFR 
signalling activity, downstream of HIF, is necessary for thrombus resolution.  
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Chapter 1 General Introduction 
1.1 Deep Vein Thrombosis 
 
Deep vein thrombosis (DVT) is a common condition with an annual incidence of 
approximately 1 in a 1000 in the general population1, 2. In the United Kingdom 
DVT is responsible for more deaths per annum than breast cancer, road traffic 
accidents, hospital inquired infections and HIV combined3. Common sequalae 
of DVT include pulmonary embolism (PE) and chronic venous insufficiency or 
post thrombotic syndrome (PTS), which are significant sources of mortality and 
morbidity respectively.  
 
PE occurs when thrombus material from an incident DVT breaks off from the 
original nidus and travels to the pulmonary arterial tree where it can become 
lodged, occluding the pulmonary artery or distal branches (Fig 1.1). PE results 
in hypo-perfusion of the lung and right ventricular pressure overload. The 
incidence of PE in the general population is estimated to be between 2-
4/10,000/yr4. The prognosis of patients diagnosed with acute PE is poor with a 









Figure 1.1 Pulmonary embolism 




Venous thrombi resolve naturally by a process of organisation that ultimately 
leads to vein recanalisation6. Incomplete thrombus resolution can contribute to 
venous insufficiency through a combination of residual vein obstruction and 
valvular incompetence, causative factors in the development of PTS. PTS is 
common in patients after an episode of DVT, occurring in 20-45% of patients7, 8. 
PTS is characterised by chronic leg pain, oedema and skin changes result in 
chronic leg ulceration in over 30% of patients (Fig 1.2)9. Management of this 

























1.2 Current treatment 
 
Anticoagulation, using low molecular weight heparin followed by warfarin, is the 
standard treatment for patients with DVT. These drugs whilst efficacious in the 
prevention of secondary thrombotic events do not accelerate natural resolution 
of the initial thrombus. The advent of pharmacological thrombolysis and neo-
adjuvant mechanical thrombectomy has facilitated the removal of acute thrombi, 
however, few patients currently receive this treatment strategy. 
 
1.2.1 Anticoagulants 
Warfarin is an indirect vitamin K antagonist that inhibits vitamin K epoxide 
reductase required for the reduction of vitamin K11. Activation of both the 
intrinsic and extrinsic coagulation cascades requires vitamin K mediated 
carboxylation of coagulation factors II, VII, IX and X (Fig 1.3). Contrastingly 
vitamin K dependent carboxylation is required for activation of the endogenous 
anticoagulants protein C and protein. Loss of carboxylation as a result of 
warfarin treatment results in a net inactivation of the coagulation cascade. 
 
Unfractioned heparin is a potent anticoagulant with the capacity to bind and 
activate antithrombin III, a natural anticoagulant that inactivates factors IIa, Xa 
and IXa. Unfractioned heparin is of limited clinical utility as it must be 
administered intravenously, has a narrow therapeutic range and is associated 
with a significant risk of haemorrhage. Low molecular weight heparin (LMWH), 
ranging from 5 to 30kDa in molecular weight, was initially developed as a 
prophylactic agent for the prevention of DVT. LMWH are now routinely used in 
patients with DVT to prevent clot propagation and to treat underlying 
hypercoagulation. LMWH, when compared with unfractioned heparin, offers 
improved pharmacokinetic stability, can be administered by subcutaneous 
injection, has a lower risk of hemorrhage and has a high efficacy. 
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Figure 1.3 Schematic representation of the coagulation cascade  
The classical coagulation cascade involves the step-wise activation of a series 
of pro-enzyme in both the contact activation (extrinsic) and tissue factor 
(intrinsic) pathways resulting in thrombin activation and generation of cross-
linked fibrin (common pathway). A number of agonists (green arrow) and 
antagonists (red arrow) have been identified that further regulate flux through 
the cascade. 
1.2.2 Thrombolysis  
Catheter directed thrombolysis is a powerful approach for the treatment of acute 
venous thrombi. Intravascular administration of agents such as urokinase 
plasminogen activator (uPA), tissue-type plasminogen activator (tPA) and 
streptokinase facilitate dissolution of the clot by cleaving plasminogen to form 
plasmin, the major fibrinolytic enzyme. Thrombolysis is most effective in 
patients with acute illeofemoral DVT (<14days since the onset of symptoms). 
Contraindications for thrombolysis include patients with a recent history of 
trauma, stoke, major surgery or active internal haemorrhage. Neo-adjuvant 
mechanical thrombectomy may also be used in conjunction with catheter 
directed thrombolysis to physically disrupt organised components of the 
thrombus. 
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1.3 Thrombus formation 
 
Venous thrombi are laminar structures, composed of layers of granular 
leukocytes (neutrophils) and platelets (Lines of Zahn) encompassed by an 
erythrocyte mass trapped in a fibrin mesh (Fig 1.4)12. Three main factors, 
referred collectively as Virchow’s triad, contribute towards thrombogenesis: 
endothelial disturbance, reduced blood flow and blood hypercoagulability (Fig 
1.5)13. It is thought that the presence of at least two of these factors is sufficient 













Figure 1.4 Laminar structure of a human thrombus 
Martius scarlet blue stained section of a human venous thrombus with typical 
laminar striations of fibrin (red) in an erythrocyte rich mass (yellow). 
 
1.3.1 Reduced blood flow 
Thrombi often form in deep veins of the lower limbs where gravitational stasis is 
greatest14. Reduced blood flow is also observed in patients suffering from 
paralysis or prolonged periods of bed rest15. The loss of pulsatile venous flow 
may impinge on normal valve function and result in stasis of blood within the 
valve cusp16. Loss of oxygen exchange within the valve cusp leads to the 












Figure 1.5 Virchow triad 
A triad of factors, first described by Rudolph Virchow in 1856 (reduced blood 
flow, endothelial injury and hypercoagulability) are thought to contribute to the 
generation of thrombosis in the veins. 
 
 
1.3.2 Endothelial injury 
Under physiological conditions the vascular endothelium suppresses 
coagulation and inflammation by: generating prostacyclins and nitric oxide that 
inhibit platelet aggregation18; expressing heparin sulphate and thrombomodulin 
on their surface that facilitate the inactivation of  thrombin19. Endothelial 
disturbance, whether activation, dysfunction or damage, decreases the 
production of these endogenous anti-coagulants resulting in a local pro-
thrombotic state. Endothelial disturbance may occur as a result of physical 
trauma or systemic inflammation. 
 
1.3.3 Hypercoagulability 
A number of inheritable thrombophilias, including factor V Leiden, prothrombin 
gene mutation, protein C and S deficiency, predispose patients to DVT20-22. The 
frequency of factor V Leiden in the population is approximately 5%, however 
this phenotype is found in 20% patients with DVT23. There are a number of 
acquired risk factors such as malignancy, the use of oral contraceptives, 











1.4 Cellular and molecular regulators of venous 
thrombus resolution 
 
Venous thrombi resolve through natural processes that involve accumulation of 
inflammatory cells and other, less defined, nucleated cells; neovascularisation 
and tissue organisation that eventually lead to vein recanalisation and 
restoration of blood flow (Fig 1.6) 6, 25. Venous thrombi in man resolve to varying 
degrees, with a significant proportion of patients exhibiting impaired or 
incomplete thrombus resolution26, 27. 
 
Figure 1.6 Thrombus resolution 
The acute erythrocyte rich venous thrombus is largely occlusive and undergoes 
extensive remodelling resulting in gradual recanalisation (Recan) of the vessel 
lumen as a result of tissue organisation and neovascular channel (NC) 
formation that restores blood flow through the thrombosed vessel. 
 
1.4.1 Extracellular matrix 
During venous thrombus resolution the extracellular matrix (ECM) undergoes 
extensive remodelling (Fig 1.7). Fibrin, deposited during formation, is the major 
ECM component found in acute venous thrombi and forms a mesh that traps 
successive layers of erythrocytes and leukocytes28. Endogenous degradation of 
fibrin is mediated by a series of enzymes that constitute the fibrinolytic system. 
Plasmin, generated by the proteolytic activation of plasminogen, is the main 
active fibrinolytic enzyme29. Two proteases, tissue plasminogen activator (tPA) 
and urokinase plasminogen activator (uPA), are responsible for the generation 
of plasmin30, 31. The activity of tPA and uPA is controlled by negative regulators 






Studies of thrombus resolution in animals deficient for uPA observed an almost 
complete absence of thrombus resolution demonstrating the importance of 
endogenous fibrinolytic activity32. Interestingly, tPA activity was not required as 
knockouts of this protease did not demonstrate impaired thrombus resolution 
and suggests the two enzymes have distinct biological activity32. Accelerated 
resolution of thrombi transfected with adenoviral uPA further reinforces the 
importance of this process32. The plasminogen activator inhibitors (PAIs) 1 and 
2 serve to limit the endogenous activity of tPA and uPA. Deletion of either PAI 
gene significantly enhances venous thrombus resolution33. 
 
As the thrombus resolves collagen is deposited in significant quantities. 
Collagen is likely remodeled in the resolving venous thrombus by a family of 
serine proteases with diverse proteolytic activities, the matrix 
metalloproteinases (MMPs)34. Protein expression and activity of MMP2 and 
MMP9 has been detected in the resolving venous thrombus35, 36. MMP activity 
plays an important role in the resolution of venous thrombi. Deletion of MMP2 
significantly impairs venous thrombus resolution, whereas increased MMP9 
activity enhances this process37. This is further supported by the reduced 
thrombus resolution observed MMP2/MMP9 double knockouts and MMP9 
knockouts treated with an MMP2 inhibitor38. Other ECM components may also 
be present in the resolving venous thrombus, however, a complete analysis of 
the ECM has yet to be undertaken. 
 
1.4.2 Neutrophils 
Neutrophils, the most abundant leukocyte in the circulation, are present in large 
numbers in the acute thrombus25. Depletion of neutrophils significantly impairs 
the resolution of venous thrombi in vivo highlighting the important contribution of 
this cell type39. Activated neutrophils are an important source of the fibrinolytic 
enzyme uPA and its receptor (uPAR)40. In vitro experiments suggest that 
neutrophil mediated thrombolysis occurs in an uPA/uPAR dependent manner40, 
41. This finding is supported in vivo as deletion of uPA in the bone marrow, 





Figure 1.7 Molecular and cellular regulators of venous thrombus 
resolution 
Resolution of venous thrombi is a highly dynamic process thought to involve a 
number of processes including extensive neutrophil / macrophage dependent 
remodelling of extracellular matrix components such as fibrin or collagen and 
development of neovascular channels that together aid in recanalisation of the 




























1.4.3 Monocyte/ macrophages 
The monocyte/macrophage is found in increasing numbers in the resolving 
venous thrombus25. Blocking the recruitment of monocyte/macrophages into the 
thrombus through knockout of surface receptors, CXCR2 or CCR2, impairs 
thrombus resolution42, 43. Conversely, administration of CXCR2 and CCR2 
ligands, IL8 or MCP1, enhance venous thrombus resolution44. CCR2 
expression is required for monocyte chemotaxis and mobilisation from the bone 
marrow45, 46, while the IL8 and MCP1 mediate monocyte adhesion to the 
vascular endothelium and thereby facilitate migration from the intravascular 
space to tissues47. These findings suggest that monocyte mobilisation, 
chemotaxis and adhesion are important processes for the recruitment of these 
cells to the thrombus. 
 
Other chemokines also play an important role in monocyte/ macrophage 
mediated resolution of venous thrombi (Fig 1.7). Vascular endothelial growth 
factor A (VEGFA) is abundantly expressed in the naturally resolving venous 
thrombus 48. Gene mediated over expression and direct injection of VEGFA 
results in increased macrophage recruitment and accelerated thrombus 
resolution49-51. 
 
1.4.4 Endothelial cells 
The formation of neovascular channels is a hallmark of the organising venous 
thrombus in both experimental models and man (Fig 1.7)52. Thrombus 
neovascular channels are lined by cells that stain positively for endothelial 
markers such as CD31 and vWF52. VEGF signalling is also important for the 
development of neovascular channels53. VEGFA overexpression in the 
thrombus was found to significantly increase neovascular channel formation49-
51. This likely occurs in a VEGF receptor 2 (VEGFR2) dependent manner as 
thrombus neovascularisation is impaired in endothelial cell specific Vegfr2 
knockouts54. Channel formation may be supported by a subset of pro-
angiogenic monocytes expressing Tie255. Tie2 expressing monocytes, co-
expressing the macrophage marker CD68 and the endothelial cells marker 
VEGFR2, are recruited from the bone marrow into the thrombus and 
accumulate in neovascular channel rich regions of the thrombus56. However, 
the contribution of neovascular channels towards thrombus resolution is a 
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source of contention. While increased neovascularisation is consistently 
observed in treatments that accelerate thrombus resolution49-51, 57 interventions 
in which only neovascularisation was increased, such as treatment with basic 
fibroblast growth factor, failed to accelerate thrombus resolution58. It remains to 
be seen whether thrombus neovascularisation is required for resolution. 
 
1.5 Tissue hypoxia 
 
In disease states hypoxia can be characterised as an insufficiency in the supply 
of molecular oxygen to tissues. Tissue hypoxia is a hallmark of a number of 
human pathophysiologies including tumourigenesis59, myocardial infarction60 
and thrombosis57. The presence of hypoxia may stem from either the blockage 
of blood vessels that perfuse pre-existing tissues, as in myocardial infarction, or 
alternatively from the presence of metabolically active avascular tissues, such 
as is the case in cancer and thrombosis. 
 
With respect to venous thrombosis hypoxia, present in the cusp of venous 
valves, is thought to play an important role during formation 61 but is also likely 
to be involved in subsequent resolution. Measurement of oxygen tension in 
murine venous thrombi has shown that newly formed thrombus is acutely 
hypoxic compared to that of venous blood57. Oxygen tension in the thrombus 
rises with time, which may be a function of increasing organisation and 
recanalisation. 
 
Tissue hypoxia triggers a number of alterations in cellular activity in an attempt 
to adapt to conditions of low oxygen availability. Among the best-studied 
adaptation is the shift in metabolism towards non-oxidative anaerobic 
glycolysis62. Changes in cellular metabolism in co-ordination with other anti-
apoptotic adaptations serve to enhance survival of cells under hypoxic 
conditions63. Of particular relevance to thrombus resolution hypoxia is also 
closely associated with the formation of angiogenic channels and the 
recruitment of macrophages64, 65. Interrogation of this cellular adaptation at the 
molecular level has identified a family of transcription factors, the hypoxia 
inducible factors (HIFs), as critical regulators of this response66. 
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1.6 Hypoxia inducible factor 
 
HIF protein subunits form a family of basic helix-loop-helix Per Arnt Sim domain 
containing transcription factors. The functional unit of HIF is a heterodimer 
consisting of a constitutively expressed subunit (HIFβ) and an oxygen sensitive 
subunit (HIFα). Three separate loci have been identified (Hif1, 2, 3) for each 
subunit. All HIFα paralogues possess a centrally located oxygen dependent 
degradation domain (ODDD)67. The ODDD contains two proline residues, 
Pro402 and Pro564 in HIF1α, that are subject to hydroxylation by a family of 
prolyl hydroxylase domain (PHD) enzymes and factor inhibiting HIF (FIH) in an 
oxygen-dependant manner68.  
 
1.6.1 HIF1α  
HIF1α is a 120kDa protein encoded by the Hif1a gene present on chromosome 
14 in man. HIF1α protein demonstrates a high level of evolutionary 
conservation sharing ~90% amino acid homology between mouse and man. 
HIF1α represents the prototypical alpha subunit the domain structure of which 
was characterized in the mid 90s (Fig 1.8)69, 70. The HIF1α N terminal region 
contains bHLH and PAS domains accompanied by a nuclear translocation 
sequence (NLS). The HIF1α C terminal region contains the ODDD domain, 
including an N terminal transactivation domain (NTAD), a C terminal 
transactivation domain (CTAD) and an additional NLS. 
 
Hif1a gene and HIF1α protein expression has been detected in a range of 
human tissues including the brain, liver, heart, spleen, kidney and liver71. A 
number of transcriptional regulators that mediate hif1a gene expression have 
been identified and include nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFκB), and members of the nuclear factor of activated T-cells  
(NFAT) family of transcription factors72. Active HIF1α, localised to the nucleus 
and complexed with HIF1β, upregulates a broad range of genes based on the 













Figure 1.8 HIF subunit domain architecture 
All HIF subunits have been found to contain highly conserved nuclear 
localisation sequences (NLS), βhelix-loop-helix (bHLH), per arnt sim (PAS) 
domains and C terminal trans-activation domains (CTAD). HIF-α subunits also 
possess an oxygen dependent degradation domains (ODDD) containing an N 
terminal trans-activation domain (NTAD). Both HIF1α and HIF2α contain an 
additional NLS and trans-activation domain towards the C terminus. 
 
 
HIF1α is required for development, as mice deficient for HIF1α (HIF1α-/-) 
demonstrate impaired cardiac and vascular development and die mid-gestation 
at E10.573. Cell specific HIF1α-/- mice have been used to investigate a number 
of cellular processes. Myeloid specific HIF1α-/- mice demonstrate impaired 
recruitment of these cells to sites of inflammation suggesting that HIF1α 
expression is required for mounting the monocyte and neutrophil response to 
inflammation in vivo74, 75. HIF1α is also essential for the development and 
maintenance of populations of haematopoietic stem cell, precursors for the 
myeloid lineage76, 77. Deletion of Hif1a in Tie2 expressing cells, which includes 
endothelial and haematopoietic cells, results in reduced mobilisation of bone 
marrow derived cells and impaired wound revascularisation78. 
 
In the resolving venous thrombus increased stabilisation of HIF1α, achieved by 
treatment with the PHD inhibitor l-mimosine, was found to significantly increase 
thrombus resolution in a murine model57. L-mimosine treatment, as well as 
reducing thrombus volume, significantly increased vein lumen receanalisation, 
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macrophage content, neovascularisation and was associated with increased 
expression of the HIF1α target gene Vegfa57. However, direct injection of the 
adenoviral construct CA5 into the thrombus, resulting in an equivalent increase 
in HIF1α stabilisation, did not affect accelerate venous thrombus resolution79. 
 
Conversely, pharmacological destabilisation of HIF1α, using the anti-angiogenic 
agent 2-methoxyestradiol (2ME), has been used to demonstrate the importance 
of basal HIF1α transcriptional activity. 2ME is a naturally occurring estrogen 
metabolite first described as an inhibitor of microtubule formation80. The HIF1α 
destabilizing effects of 2ME observed in vivo are thought to be secondary to 
loss of microtubule formation81. Treatment with 2ME decreased thrombus 
resolution, vein lumen recanalisation, macrophage content and 
neovascularisation, and was associated with impaired nuclear accumulation of 
HIF1α and reduced VEGF protein expression82.  
 
Pharmacological manipulation of HIF1α demonstrates the importance of the 
hypoxic response in mediating thrombus resolution. However, the 
pharmacological agents used thus far have limited specificity and a number of 
HIF1α independent effects may have been involved. Alternate more targeted 
strategies may provide further evidence for the direct role of HIF1α in thrombus 















Table 1.1 Selected HIF1α target genes 
Gene Protein name Ref 
CHEMOKINES AND CHEMOKINE RECEPTORS 
CXCR4 chemokine (C-X-C motif) receptor 4 83 
ENG endoglin 84 
PDGFB platelet-derived growth factor beta polypeptide 85 
TGFA transforming growth factor, alpha 86 
VEGFA vascular endothelial growth factor A 87 
VEGFR1 vascular endothelial growth factor receptor 1 88 
EXTRACELLULAR MATRIX 
P4HA1 procollagen-4-prolyl hydroxylase 89 
LOX lysyl oxidase 90 
MMP14 matrix metallopeptidase 14  91 
MMP2 matrix metallopeptidase 2  91 
PLAUR plasminogen activator, urokinase receptor 92 
PAI1 plasminogen activator inhibitor 1 92 
METABOLISM 
ALDOA aldolase A, fructose-bisphosphate 93 
ENO1 enolase 1, (alpha) 93 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 94 
GLUT1 glucose transporter 1 89 
LDHA lactate dehydrogenase A 93 
PFKL phosphofructokinase, liver 95 
PGK1 phosphoglycerate kinase 1 95 
PKM2 pyruvate kinase, muscle 95 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 96 
HYPOXIA 
PHD2 prolyl hydroxylase domain containing protein 2 97 
PHD3 prolyl hydroxylase domain containing protein 3 98 
CITED2 cbp/p300-interacting transactivator 99 
VASOACTIVE 
EDN1 endothelin 1 100 
NOS2A nitric oxide synthase 2 (inducible) 101 
NOS3 nitric oxide synthase 3 (endothelial) 102 
HMOX1 heme oxygenase 1 103 
ERYTHROPOIESIS 










HIF2α is a 95kDa protein encoded by the Epas1 gene present on chromosome 
2 in man. HIF2α demonstrates a high level of evolutionary conservation sharing 
~90% amino acid homology between mice and man. Despite the highly similar 
domain structure observed between HIF1α and HIF2α these proteins share only 
50% amino acid homology. Mice deficient for HIF2α also die at mid-gestation 
(E9.5-15) as a result of impaired vascular development105-107. These studies 
suggest that while HIF2α knockout mice reach a latter stage of embryogenesis 
than HIF1α-/-, HIF2α is still essential during development.  
 
HIF2α has also been found to regulate a number of post-developmental 
processes. HIF2α, and to a lesser extent HIF1α regulate erythropoeitin (EPO) 
production, with deletion of Hif2a in hepatocytes resulting in reduced EPO 
production in response to an anemic insult108. As with HIF1α, HIF2α is an 
important regulator of angiogenesis as endothelial deletion of Hif2a results in 
reduced vascularisation of ischaemic limbs and tumours109. However, a number 
of HIF2α specific processes such as iron absorption have also been described. 
Expression of the divalent metal transporter 1 (DMT1), required for iron influx is 
regulated by HIF2α but not HIF1α110. Furthermore, HIF2α-/- results in impaired 
neutrophil apoptosis that is not observed in HIF1α-/- neutrophils111. Comparison 
of gene arrays in HIF1α and HIF2α overexpression systems reveals distinct 




HIF3α is a 72kDa protein encoded by the Hif3a gene present on chromosome 
19 in man. Two variants of HIF3α have been described that are generated by 
the alternate splicing of Hif3a mRNA, neonatal and embryonic PAS (NEPAS) 
and inhibitory PAS (IPAS)114, 115. All three variants are considered 
transcriptional repressors. HIF3α and NEPAS form heterodimers with HIF1β 
and bind to HREs but the lack of a CTAD significantly reduces the 
transcriptional activity of these factors compared to HIF1α and HIF2α116. IPAS 
forms heterodimers with other HIFα subunits and lacks both a CTAD and NTAD 
preventing binding to HREs and rendering this variant transcriptionally 
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inactive117. The ability of IPAS to bind both HIF1α and HIF2α enables this 
variant to act as a transcriptional repressor of these subunits. 
 
Homozygous Hif3a gene knockouts are viable, unlike those for HIF1α or HIF2α, 
demonstrating only mild cardiac and pulmonary defects118. In agreement with 
the role of HIF3α as a transcriptional repressor gene deletion results in 
increased expression of HIF1α and HIF2α transcriptional targets118. Conditional 
deletion of Hif3a in the epithelium has demonstrated the requirement of HIF3α 
for normal lung development and revealed novel HRE-independent 
transcriptional responses119. 
 
1.6.4 Regulation of HIF 
Given the vital role of HIF signalling in marshalling the cellular response to 
tissue hypoxia activity of this transcription factor is tightly regulated. Under 
normoxic conditions HIFα is subject to hydroxylation by PHD enzymes (Fig 1.9). 
Hydroxylated HIFα forms a complex with von Hippel Lindau (VHL)120 and 
elongin C121. The HIF-VHL-Elongin C complex may be stabilised by 
spermidine/spermine N1-acetyltransferase 2 (SSAT2)122. Recruitment of the E3 
ubiquitin ligase complex123 and subsequent polyubiquitination of HIFα targets 
the protein for degradation by the proteasome124. 
 
Under hypoxic conditions oxygen becomes a limiting factor for the activity of 
PHD enzymes and unhydroxylated HIFα translocates to the nucleus125, where 
HIFα subunits form heterodimers with HIFβ paralogues126. Both HIF1α and 
HIF2α heterodimerisation with HIF1β has been observed experimentally127. 
Formation of HIFα and HIFβ heterodimers, by interaction of the beta helix loop 
helix (bHLH) and Per Arnt Sim (PAS) domains, is essential for HIF 
transcriptional activity128, through binding of specific DNA sequence known as 
hypoxic response elements (HREs). The HRE contains two distinctive 
structures; a HIF binding site with the consensus sequence (A/G)CGTG129 and 











Figure 1.9 Regulation of HIF1α transcriptional activity 
 (a) Under normoxic conditions HIFα subunits are hydroxylated by PHD and FIH 
in an oxygen and 2-oxoglutarate dependent manner. Recruitment of VHL to 
hydroxylated HIFα results in ubiquitination and subsequent proteasomal 
degradation. (b) During periods of hypoxia in which oxygen is limited HIFα 
remains unhydroxylated and translocates to the nuclear. Nuclear HIFα forms 
heterodimers with HIFβ and recruits the co-activators CBP/p300 necessary for 










1.7 Prolyl hydroxylase domain proteins 
 
The prolyl hydroxylase domain proteins (PHDs), also known as HIF prolyl 
hydroxylases, form part of a wider family of 2-oxoglutarate (2-OG) dependent 
dioxygenases107, 132, 133. PHD enzymes require the co-substrates oxygen and  2-
OG in order to hydroxylate target proteins. In addition the enzyme requires both 
iron and ascorbate as co-factors120, 134. The dependence of PHD enzymes on 
molecular oxygen provides a novel mechanism for cellular oxygen sensing. In 
humans and mice three PHD isozymes have been identified (PHD-1-3)135. 
 
The domain architecture of the PHD isozymes has yet to be fully characterised. 
The highly conserved C-terminus has a double stranded beta helix (DSBH) 
motif, which is likely to confer enzymatic activity136. The function of the divergent 
N-terminus has yet to be elucidated, but may contribute to isoform 
conformation, localisation or target selectivity135. The crystal structure of PHD2 
complexed with the HIFα ODDD has afforded considerable insight into the 
hydroxylation mechanism137. It has been hypothesised that binding of 2-OG and 
molecular oxygen to conjugated Fe2+, resulting in the formation of Fe3+ or Fe4+, 
primes the active site for target hydroxylation137. Additionally, hydroxylation of 
proline within the HIFα ODDD may alter residue conformation so as to allow 
binding of VHL and recruitment of the ubiquitin ligase complex68. 
 
Measurements of PHD enzyme kinetics are consistent with a role for these 
enzymes in oxygen sensing. All three isozymes have a high Km for oxygen in 
the range of 230-250µM138. PHD enzyme Km values exceed intracellular 
oxygen concentrations ensuring that activity is oxygen sensitive. PHD enzymes 
hydroxylate proline residues 402 and 564 of HIF1α (Fig 1.10)120, 139. The C-
terminal residue, Pro564, was found to be hydroxylated efficiently by all 
isozymes whereas the N-terminal residue, Pro402, was less readily 
hydroxylated by PHD1 and PHD2 and not was not detected with PHD3138. More 
recently, an additional member of the PHD family has been identified, PHD-
transmembrane (PHD-TM), which also hydroxylates prolines present inHIF1α 
with a preference for the C terminal residue140. Under normoxic conditions both 
proline residues are likely to be hydroxylated. A comparison of residue 
hydroxylation has proposed that loss of hydroxylation is dependent on the 
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severity of hypoxia141. Under decreasing levels of hypoxia hydroxylation of 
Pro402 was found to be lost first, followed by Pro564141.  
 
Analysis of PHD isozyme expression at the gene level reveals that all three 
isoforms are fairly ubiquitously expressed with high levels of Phd1 in the testis, 
with Phd2 and Phd3 greatest in heart and skeletal muscle142. At the protein 
level PHD1 has been detected in the testis, skeletal muscle and spleen, while 
PHD2 and PHD3 expression was observed in the liver, spleen, kidney, skeletal 
muscle and heart143-145. Subcellular localisation of PHD isoforms has been 
examined in cells transfected with PHD-GFP constructs146, 147. PHD1 protein 
was localised exclusively in the nucleus whereas PHD2 and PHD3 protein 
expression was located in both the nucleus and cytoplasm. Cells expressing a 
PHD2 mutant unable to translocate to the nucleus, demonstrate impaired HIF1
α degradation under normoxic conditions which suggests that translocation 
affects the activity of this isoform148. 
 
The factors that contribute to basal levels of PHD isozyme expression are not 
fully understood. Estrogen signalling and the HIF target gene Epo have been 
found to stimulate expression of Phd2149, 150.  Transcription of PHD isoforms 
may also be regulated by HIF as both Phd2 and Phd3 contain HREs within their 
respective promoters97, 98. This HIF regulated PHD expression may form part of 
a negative feedback loop, whereby increased expression of PHD isozymes 
under hypoxic conditions primes cells for reoxygenation, allowing rapid 
degradation of newly synthesised HIFα. As the posttranslational level PHD1 
and PHD3 protein may be subject to proteasomal degradation under hypoxic 






Figure 1.10 PHD mediated hydroxylation of HIFα 
Under normoxic conditions PHD enzymes hydroxylate target proline residues 
present in HIFα (HIF1α Pro402 and Pro564) targeting these subunits for 
proteasomal degradation. HIFα subunits are also subject to hydroxylation by 
FIH at a specific asparagine residue (HIF1α Asn803) that prevents recruitment 
of the transcriptional coactivator CBP/p300. Under hypoxic conditions PHD and 
FIH enzymes are inactive leaving HIFα subunits free to translocate to the 
nucleus. Adapted from152. 
 
 
Regulation of HIFα isoform degradation is considered a major role of PHD 
isozymes. Additional targets of PHDs have been identified by the presence of 
conserved prolyl hydroxylation consensus sites. Inhibitor of nuclear factor 
kappa-B kinase subunit beta (IKKB) contains a putative prolyl hydroxylation 
consensus sequence proximal to a phosphorylation site153. IKKB is a potent 
activator of NF-κB and could therefore mediate the transcription of numerous 
inflammatory genes, including chemotactic cytokines and growth factors that 
might influence thrombus resolution154. Hydroxylation at this site has yet to be 
confirmed, although Phd1 gene silencing results in an acute increase in IKKB 
activity153. 
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PHD1 is a 44kDa protein encoded by the Egln2 gene (referred to as Phd1) 
present on chromosome 19 in man. Constitutive homozygous Phd1 gene 
knockouts appear to develop normally155. However, PHD1 has been found to 
mediate a number of cellular processes in vitro and in vivo. PHD1 is an 
important regulator of cell cycle progression through hydroxylation of a novel 
target Cep192, a protein involved in centriole formation during metaphase156. 
PHD1 also acts as a key mediator of cellular metabolism, Phd1 gene deletion 
results in increased cellular glycolysis and tolerance to tissue hypoxia in a 
HIF2α dependent manner144. Interestingly, knockdown of PHD1 protein 
expression serves to limit oxidative stress-induced neuronal cell death157. Taken 
together these findings suggest that the loss of PHD1 may help limits oxidative 
damage through a shift towards anaerobic respiration. 
 
1.7.2 PHD2 
PHD2 is a 46kDa protein encoded by the Egln1 gene (referred to as Phd2) 
present on chromosome 1 in man. Post-transcriptional modification of Phd2 
mRNA results in the generation of a number of splice variants with loss of exon 
3 resulting in loss of catalytic activity138. Unlike PHD1, constitutive homozygous 
Phd2 gene knockouts demonstrate embryonic lethality dying at E12.5 as a 
result of severe heart and placental defects155. Lethality of mice deficient for 
PHD2 reaffirms the importance of this isoform in the regulation of HIFα subunit 
stability. However, abnormalities in myocardial development appear to take 
place in a HIF1α independent manner suggesting other regulatory activities for 
this isoform155. 
 
PHD2 is an important mediator of tissue oxygenation through regulation of 
angiogenesis. Knockdown of PHD2 protein expression alters a number of 
angiogenic processes including vessel formation and normalisation158, 159. In 
vitro studies suggest that increased angiogenesis after PHD2 knockdown is 
mediated by both HIF1α and NFkB158, 159. Heterozygous Phd2 gene knockouts 
did not demonstrated increase vessel formation, instead improving vessel 
structure through HIF1α dependent upregulation of sVEGFR1 and VE 
cadherin160.  
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PHD2 has also been found to protect the brain during periods of cerebral 
ischaemia. In a murine model of mid cerebral artery occlusion (MCAO), 
constitutive heterozygous Phd2 gene deletion, but not homozygous deletion of 
Phd1 and Phd3, significantly reduced infarct size and was associated with 
increased capillary density161. A study of cerebral ischaemia in neuron-specific 
homozygous Phd2 knockouts suggests that neuronal loss of PHD2 was strongly 
cerebroprotective independent of capillary density162. In conditions of hyperoxia, 
as opposed to hypoxia, inducible homozygous deletion of Phd2 was found to 
protect retinal microvasculature163. 
 
PHD2 also affects macrophage heterogeneity. Phd2 gene deletion in a murine 
model of critical limb ischemia results in increased numbers of alternatively 
activated (M2) macrophages, with pro-angiogenic potential, that accumulate in 
the ischaemic tissue164. Ang1 has been proposed as an endogenous inhibitor of 
Phd2 gene expression resulting in skewing of macrophages towards an M2 
phenotype165. Interestingly, no difference in macrophage skewing occurs in 
PHD2 deficient tumours, indicating that cell phenotype may be influenced by 
differences in the hypoxic micro-environment166. 
 
Abnormalities in PHD2 are strongly associated with familial erythrocytosis in 
which patients present with elevated erythrocyte counts and an increased 
haematocrit131. A number of loss in function mutations in Phd2 have been 
identified that induce erythrocytosis through elevated production of the HIFα 
target gene EPO105, 167, 168. In murine Phd2 gene knockouts complementary 
increases in EPO expression and haematocrit have been observed143, 169, 170. 
 
1.7.3 PHD3 
PHD3 is a 27kDa protein encoded by the Elgn3 gene (referred to as Phd3) 
present on chromosome 14 in man. Two splice variants of Phd3 have been 
identified with excision of exon 1 resulting in loss of catalytic activity138, 171. 





PHD3 expressed in macrophages has been found to contribute to phenotypic 
skewing of this cell type. Loss of PHD3 in peritoneal macrophages results in 
increased expression of proinflammatory markers, consistent with classical (M1) 
activation172. PHD3 deficient macrophages demonstrate enhanced migration 
and phagocytosis, mediated by both HIF1α and NFkB172. However, there is 
conflicting evidence as skewing of monocytes towards an M1 phenotype results 
in high levels of PHD3 protein expression, whereas PHD3 expression is almost 
completely absent in alternatively activated (M2) macrophages173. Macrophages 
deficient in PHD3 also demonstrate enhanced cell survival in vitro independent 
of HIF1α stabilisation174. 
 
PHD3 is also expressed in neutrophils and potently upregulated in response to 
hypoxia175. PHD3 deficient neutrophils demonstrated reduced survival in a 
model of inflammation, however migration and phagocytosis were preserved175. 
The anti-apoptotic activity of PHD3 is surprising given that HIF1α and HIF2α 
both promote neutrophil survival during inflammation111, 176. An additional role 
for PHD3 has recently been identified in regulating lipid and glucose handling. 
Phd3 gene deletion in the liver was found to confer improved insulin sensitivity 
and glucose homeostasis providing protection against diet induced diabetes177. 
1.7.4 Factor Inhibiting HIF 
Factor inhibiting HIF (FIH) is a highly related 2-OG dependent dioxygenase 
targeting HIFα subunits for hydroxylation at specific asparagine residues178, 179. 
FIH is a 40kDa protein encoded by the Hif1an gene present on chromosome 
10. Unlike PHD proteins, FIH mediated hydroxylation of HIF1α results in 
transcriptional inactivation as opposed to proteasomal degradation180, 181. FIH is 
expressed in a broad range of tissues and deletion during embryogenesis 
results in an elevated metabolism and resistance to diet induced weight gain182. 
 
As well as hydroxylating HIFα subunits FIH also targets a number of ankyrin 
repeat domain-containing proteins. As with PHD isoforms FIH activity has been 
found to modulate NFkB signalling through oxygen dependent hydroxylation of 
IKKB although the functional consequence of this modification remains 
unclear183. Additionally, FIH has been found to hydroxylate members of the 
Notch family of receptors184, 185. Hydroxylation by FIH at two sites in the Notch 
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intracellular domain significantly repressed activity of the receptor providing 
evidence of oxygen-dependent regulation in Notch signalling185. A further target 
of FIH, ankyrin repeat and SOCS box protein 4, undergoes poly-ubiquitination 
and proteolysis upon hydroxylation suggesting that FIH also has the capacity to 
target proteins for proteasomal degradation186. The extent of FIH mediated 
hydroxylation of target proteins other than HIF and the contribution of this to the 
observed FIH knockout phenotype has still to be determined. 
 
1.8 HIF1α gene therapy 
 
Developments in adenoviral mediated gene delivery have enabled the 
generation and delivery of degradation resistant HIF1α constructs in vivo. The 
CA5 construct is protected from hydroxylation and subsequent proteasomal 
degradation by deletion of residues 392-520 and two mis-sense mutations 
(Pro567Thr and Pro658Gln)187. Production of degradation resistant HIF1α by 
the CA5 construct enables transcription of HIF1α target genes in normoxic or 
marginally hypoxic tissues. The therapeutic effects of CA5 have been explored 
in a variety of disease models using multiple gene delivery mechanisms. In a 
rabbit model of hind limb ischaemia, adenoviral expression of CA5 (AdCA5) 
was found to improve angiogenesis and restore blood flow to the ischaemic limb 
inducing expression of pro-angiogenic factors including VEGF, PlGF and MCP-
1188. On further investigation AdCA5 transfection was found to mobilise 
angiogenic cells of leukocyte origin into the circulation in a HIF1α dependent 
manner189. Transfection of AdCA5 into the ischaemic limb of mice improved 
limb perfusion accompanied by a marked increase in vessel density consistent 
with the pro-angiogenic activity of HIF1α190 and was superior to transfection of 
adenoviral VEGF in restoration of limb perfusion191. 
 
An initial small-scale trial of AdCA5 injection into the limbs of patients with 
severe critical limb ischaemia has reported beneficial outcomes. In 14 out of 32 
patients rest pain resolved and 5 out of 18 patients had complete ulcer healing 
after treatment with AdCA5192. Empty vector controls were not used in this 
study, which was a significant limitation. While these studies demonstrate the 
therapeutic potential of increased HIF1α stabilization transfection of murine 
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venous thrombi with AdCA5 failed to improve resolution79. The therapeutic 
potential of a HIF2α constitutively active variant has yet to be investigated. 
 
1.9 Pharmacological PHD inhibition 
 
Inhibition of PHD enzymes using a range of pharmacological agents has proved 
effective in protecting tissues in a range of ischaemic disorders. PHD inhibitors, 
in general, fall into one of four main classes; (i) iron chelators, (ii) 2-OG 
mimetics or (iii) active site blockers. Some inhibitors may satisfy the 
requirements of multiple classes (Table 1.2). These inhibitors demonstrate 
varying degrees of enzyme specificity and efficacy and affect a range of 
biological processes, some of which may be highly pertinent to thrombus 
resolution. 
1.9.1 Angiogenesis 
HIF1α transcriptional targets include a number of pro-angiogenic factors 
including VEGFA, VEGFR1, eNOS and iNOS. The ability of PHD inhibition to 
stimulate therapeutic angiogenesis has been is of considerable interest. A 
number of PHD inhibitors, including deferoxamine (DFO), TM6008 and 
TM6089, have been found to increase endothelial cell tubule formation in vitro 
193-195. In vivo hydralazine, TM6008 and TM6089 treatments enhanced 
formation of neovascular channels in a sponge model of angiogenesis194, 196. In 
addition the PHD inhibitor hydralazine was also found to increase circulating 
levels of VEGF measured in the plasma196. Dimethyloxalylglycine (DMOG) 
treatment in a murine model of critical limb ischaemia significantly increased 
capillary fibre ratio, a measure of angiogenesis, and expression of VEGFA and 
VEGFR1197. 
 
Recruitment of bone marrow-derived angiogenic cells (BMDAC) to the 
ischaemic limb is thought to be an important component of angiogenesis198. 
Injection of DMOG treated BMDACs into the ischaemic limb has proven 
insufficient to promote angiogenesis199; whereas injection of DMOG treated 
BMDAC in conjunction with adenoviral overexpression of constitutively active 
HIF1α in the ischaemic limb increases functional recovery and limb salvage 
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when compared to HIF1α transfection alone199. Increased β2 integrin 
expression was observed after treatment of BMDAC with DMOG in vitro199, 
which suggests BMDACs may have a role in angiogenesis through increased 
endothelial cell adhesion. 
1.9.2 Ischaemia protection 
The ability of PHD inhibitors to precondition tissues in advance of an ischaemic 
insult has also been investigated. Pharmacological preconditioning with the 
PHD inhibitor DMOG in a rabbit model of myocardial infarction significantly 
reduced infarct size200. Both in vivo and in vitro studies found DMOG 
pretreatment results in increased HIF1α stabilisation, induction of IL-10 protein 
expresssion and reduced production of IL-8, suggesting that HIF1α may be an 
important modulator of the inflammatory response within the ischaemic 
myocardium200, 201.  
 
Similar protective effects of increased HIF1α stabilisation were observed in a 
murine model of myocardial infarction after treatment with DMOG alone or in 
conjunction with Phd2 gene knockdown202. Gene silencing identified PHD2 as 
the main isoform involved in HIF1α stabilisation within the ischaemic 
myocardium202. Preconditioning via either approach was ablated when 
combined with gene silencing of HIF1α suggesting that the protective effects of 
DMOG are dependent on HIF1α stabilisation. DFO also significantly reduced 
infarct size in a murine model of myocardial infarction203. Increased oxygen 
radical accumulation was observed in the myocardium pre-treated with DFO 
indicating that PHD inhibition may promote oxidative stress. Recently a novel 
PHD inhibitor, GSK360A, that acts as a competitive inhibitor of 2-OG at the 
PHD active site was found to be cardioprotective in rat models of both 
myocardial infarction and ischemia reperfusion injury204, 205. 
 
Pre-treatment with the PHD inhibitor, FG-4487 in a murine model of renal 
ischaemia reperfusion injury was found to preserve kidney function206, 
suggesting that PHD inhibition protects against reperfusion injury. The inhibitors 
l-mimosine and DMOG have also been used in the same model and provide 
similar levels of protection207. Further examination of the protective mechanism 
provided by DMOG pretreatment identified iNOS as a key mediator with 
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pharmacological blockade of iNOS ameliorating the observed renal 
protection208. 
 
A wide range of PHD inhibitors have also been found to confer protection 
against cerebral ischaemia. DMOG, DFO, Compound A and Ethyl 3,4- 
dimethylbenzoate (3,4-DHB) have all been found to limit infarct size in rat 
models of cerebral ischaemia, accompanied by consistently increased HIF1α 
stabilization and induction of target genes including Vegf, Enos and Epo209-212.  
Table 1.2 Small molecule PHD inhibitors 
Inhibitor Mechanism Specificity (IC50) Application Refs 
Dimethyloxalylgly




















FG-0041 Active Site, Fe2+ Chelator 
PHDs, FIH*, 




FG-2216 Not described PHD, CPH Anemia 222, 223 
FG-2229  Active Site, Fe2+ Chelator 
PHDs, FIH*, 




FG-4383 2-OG Mimetic PHD2 (2.6µM) FIH* Anemia 
225 
FG-4497 Active Site PHDs, FIH* Kidney Failure 
226 


















JNJ-42041935 2-OG Mimetic PHDs, PHD2 (100-117nM) Anemia 
227, 228 









AKB-4924 Fe2+ Chelator PHDs, PHD2 (14 µM) Inflammation 
231-234 
*Inferred activity, adapted from152  
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1.9.3 Inflammation 
There is an increasing body of evidence to suggest that PHD inhibition may be 
effective in limiting the cellular response to inflammation. In murine models of 
drug induced colitis treatment with DMOG, FG4497 and AKB-4924 markedly 
reduced inflammatory damage to the bowel215, 233-236. The reduced severity of 
colitis after PHD inhibitor treatment is probably a result of increased epithelial 
cell survival and reduced production of pro-inflammatory cytokines including IL6 
and IL8233, 236. 
1.9.4 Erythrocytosis 
Numerous PHD inhibitors including; DMOG, FG-2216, FG-4497, GSK360A and 
JNJ42041935, have been found to potently increase measurements of 
haematocrit202, 204, 227, 237, 238. Corresponding with PHD knockout studies this is 
accompanied by sustained induction of EPO expression105, 167, 168. Increased 
haemoglobin concentrations and erythrocyte counts further supports the 
erythrocytosis-inducing properties of these agents. Sustained treatment with 
DFO in patients with erythropoiesis significantly improved haematocrit levels 





The early venous thrombus has been identified as an acute source of tissue 
hypoxia, correlating with stabilisation of the pro-angiogenic transcription factor 
HIF1α57. Increasing nuclear accumulation of HIF1α in the thrombus by 
treatment with the broad activity PHD inhibitor l-mimosine accelerated 
resolution and was accompanied by increased neovascular channel formation 
and macrophage recruitment57. The generation of PHD specific gene knockouts 
has enabled the contribution of individual isoforms to be assessed in vivo. 
PHD2 has been identified as a critical regulator of HIF1α stability241 with gene 
deletion resulting in increased angiogenesis and recruitment of myeloid cells158. 
A number of new PHD inhibitors have been developed that offer improved 
target specificity. 
 
1.11 Hypothesis and aims 
 
It was hypothesised that PHD enzyme expression in the resolving thrombus 
limits HIF1α stability and that inactivation of PHD enzyme activity would 
accelerate venous thrombus resolution in a HIF1α dependent manner. 
 
This study sought to determine:  
(i) the expression of PHD1, PHD2 and PHD3 at the gene and protein 
level during natural thrombus resolution  
 
(ii) the effect of gene specific deletion of Phd2 on thrombus resolution 
 
 
(iii) the effect of pharmacological pan-PHD inhibition on thrombus 
resolution 
 




Chapter 2 Characterisation of venous 




A number of murine model have been developed to study venous thrombus 
resolution in vivo242. The development of these models have been necessitated 
by ethical barriers to studying thrombus resolution in man and the failure of in 
vitro models to sufficiently recapitulate the complexity of this disease. Murine 
models of venous thrombosis are primarily induced by the manipulation of a 
Virchow’s triad.  
 
Ferric chloride induced endothelial dysfunction has proven an effective method 
in the induction of venous thrombi in both the femoral veins and IVC243-245. 
Application of ferric chloride was initially thought to cause localised endothelial 
denudation246, however, in a recent study endothelial integrity was preserved in 
the presence of thrombus247. An electrolytic IVC model (EIM) that passes direct 
current across the vessel wall also results in efficient thrombus formation248, 249. 
The EIM model stimulates thrombogenesis by inducing endothelial dysfunction 
and localised endothelial denudation. Consistent thrombus weights have been 
reported, however, this model is hindered by the relatively small thrombi 
produced and a lack of detailed characterisation. 
 
Ligation of the inferior vena cava (IVC) is another commonly used model of 
venous thrombosis42, 250, 251. Formation using this model, while highly efficient, 
takes place in the absence of flow that is likely to affect structure and cellular 
composition. Alternatively, a number of studies have used stenosis of the IVC, 
which permits residual blood flow through the vessel, to induce thrombosis250, 
252-254.However, the major limitation of this surgical technique is the highly 




The St Thomas’ model of IVC thrombosis is highly efficient resulting in 
thrombus formation in over 90% of surgeries. This model satisfies two tenants 
of Virchow’s triad, namely reduced blood flow and endothelial dysfunction, 
which may account for the high efficiency of thrombus induction. Thrombi 
formed are lamina in structure, with layers of erythrocytes and leukocytes (lines 
of Zahn), which closely resembles thrombi found in man256. 
 
This chapter was intended to provide further data on the dynamics of thrombus 
resolution in the St Thomas’ model and inform the selection of time-points for 
interventional studies. Additionally, it provided the opportunity to quantify 
changes in the composition of the thrombus. 
 
2.2 Aim 
To characterise changes in thrombus size, vein recanalisation, and thrombus 
organisation (fibrin, collagen and red cell content) during venous thrombus 




2.3.1 The St Thomas’ model of venous thrombosis 
All animal work was carried out in accordance with the Animal (Scientific 
Procedures) Act 1986. BALB/c mice 8-10 weeks in age were anaesthetised with 
isoflourane (5%, 1.0 l/min O2) in an induction chamber (VetTech, UK). The 
abdomen was shaved, disinfected (0.05% w/v chlorhexidine gluconate, Medlock 
Medical, UK) and draped (Kruuse, Denmark) in preparation for surgery. A 
midline laparotomy was made, extending anteriorly until the xiphoid process. 
The intestines were externalised and wrapped in wetted gauze. Blunt dissection 
with cotton swabs was used to reveal the retroperitoneal structures. Under 
microscopic visualisation (S6D, Leica, Germany) the inferior vena cava (IVC) 
was mobilised and separated from the aorta by blunt dissection. A length of 4-0 
silk suture material (Ethicon, UK) was passed behind the IVC inferior to the left 
renal vein (Fig 2.1A). A length of 5-0 prolene suture material (Ethicon, UK) was 
placed on the IVC longitudinally prior to constriction of the IVC by tying of the 
silk suture (Fig 2.1B). The prolene was removed to generate the required level 
of stenosis (~90%). A neurovascular surgical clip (Fine Scientific Tools, 
Germany) was applied to the IVC inferior at two locations distal to the site of 
stenosis for 20secs. The bowels were internalised and perioperative 
buprenorphine (Vetergesic, Alstoe, UK) administered to the wound edge and 
peritoneal cavity. Layered closure of the laparotomy with 4-0 polydiaxanone 
suture material (Ethicon, UK) was achieved using continuous sutures for the 
peritoneal and skin layer. Postoperatively animals were housed in a warmed 
recovery chamber (25°C) overnight. 
 
2.3.2 Tissue processing 
Thrombi were excised in situ with the surrounding inferior vena cava and fixed 
in 10% formyl saline overnight (VWR, UK) for histological analyses. Samples 
were processed (TP1020 tissue processor, Leica, Germany) and embedded in 
paraffin wax (TES99 tissue embedder, Medite, Germany). Transverse sections 
(5µm) were cut at 500µm intervals throughout the entire length of the thrombus 
for subsequent histological staining and analysis. 
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Figure 2.1 Surgical induction of venous thrombosis 
(A) Dissection between the IVC and aorta distal to the right renal vein allows 
passage of the silk suture (S) between the vessels. The silk suture is tied onto a 
piece of prolene suture (P) placed alongside the IVC which once removed 
generates a stenosis. (B) Endothelial dysfunction is induced by application of a 
neurovascular clip to regions of IVC distal to the site of stenosis (indicated by 
black arrows). 
 
2.3.3 Martius scarlet blue (MSB) staining 
I would like to acknowledge Mr Prakash Saha for assistance with MSB staining. 
The composition of the thrombus was assessed by MSB. Sections were 
warmed for 30mins at 60oC and were then dewaxed by 2x 5min xylene washes. 
Sections were rehydrated through graduated alcohol washes (100%, 75% and 
50%) and rinsed in tap water for 5mins. Sections were pretreated with Bouin’s 
solution (5% v/v acetic acid, 9% w/v formaldehyde, 0.9% v/v picric acid, Sigma, 
UK) at 60°C for 1hr. All staining was conducted at room temperature unless 
otherwise stated. Nuclei were counterstained with Mayer’s haematoxylin 
(Clintech, UK) for 5mins and washed in distilled water for 5mins. Sections were 
stained in martius yellow (2% w/v phosphotungstic acid, 0.5% w/v Martius 
yellow in 95% v/v ethanol, Sigma, UK) for 2mins and washed in distilled water. 
Sections were stained with brilliant crystal scarlet (1% w/v crystal ponceau 6R in 
2% v/v acetic acid, Sigma, UK) for 10mins and washed in distilled water. 
Staining was differentiated in a solution of 1% w/v phosphotungstic acid (Sigma, 
UK) for 10mins and washed in distilled water. Sections were then stained in 









in distilled water. Sections were rapidly dehydrated through graded alcohols 
(50%, 75% and 100%) to avoid loss in stain intensity. Slides were cleared in 
xylene and mounted with coverslips in DPX medium. 
 
2.3.4 Haematoxylin and eosin staining 
Sections were dewaxed and rehydrated as described in section 2.2.3. Sections 
were then stained in Mayers haematoxylin (Clin-Tech, UK) for 5mins followed 
by 5mins washing in running tap water. Staining was differentiated in 1% v/v 
acetic acid (Sigma, UK) in 100% alcohol (Sigma, UK) for 3secs, followed by a 
further 5min wash in running tap water. Sections were stained in eosin (Clin-
Tech, UK) for 2mins and washed in running tap water for 30secs. Sections were 
dehydrated, cleared and mounted as described in Chapter 2.2.3. 
 
2.3.5 Image analysis 
Images were captured at either 50x or 200x magnification with a Leica light 
microscope (DMRB, Leica, Germany) using a microscope mounted digital 
camera (Micropublisher 3.3, QImaging, Canada) on a motorised stage 
(ProScan, Datacell, UK). Histogram-based thresholding with Image Pro Plus 
software (Media Cybernetics, UK) was used to select areas of staining257. 
Measurements of thrombus cross-sectional area were obtained using Image 
Pro Premier software (Media Cybernetics, UK) from which thrombus volume 
were reconstructed. 
 
2.3.6 Statistical analysis 
Normality of data was assessed by Kolmogorov-Smirnoff tests to inform 
selection of appropriate parametric and non-parametric tests. Differences in 
measurements of thrombus volume and vein lumen were assessed by one-way 
analysis of variance (1-way ANOVA) and post-hoc Bonferroni. Differences in 
measurements of thrombus cross-sectional area and composition were 
assessed by Kruskal-Wallis. In all cases P<0.05 was considered statistically 
significant. Statistical analyses were conducted using Prism Software (v5, 
Graphpad, USA). Parametric data represented as mean ± SE and non-




To evaluate the dynamics of thrombus resolution histological measurements of 
thrombus volume and vein lumen recanalisation were made at days 1, 7, 14 
and 21 post-induction. Thrombus volume decreased significantly over time 
(P<0.0001, 1-way ANOVA, Fig 2.2A) with thrombus volume significantly less at 
days 14 and 21 than at days 1 and 7 (P<0.05, post-hoc Bonferonni). Vein lumen 
recanalisation increased significantly over time (P<0.0001, 1-way ANOVA, Fig 
2.2B) with vein lumen recanalization significantly greater at days 14 and 21 than 




Figure 2.2 Changes in thrombus volume and vein lumen recanalisation 
Histological measurements of (A) thrombus volume and (B) vein lumen 
recanalisation at days 1, 7, 14 and 21 post-induction (n=5 /group /time-point). 
Thrombus volume decreased and vein lumen increased significantly over time 
(P<0.0001, 1-way ANOVA). Data represented as mean ± SE. *P<0.05 day1 vs 

















































A marked degree of heterogeneity in thrombus cross-sectional area was 
apparent when analysing sections taken throughout the length of the thrombus. 
To appreciate the scale of this heterogeneity measurement of thrombus cross-
sectional areas were made at days 1, 7, 14 and 21 post-induction. Median 
thrombus cross-sectional area was found to decrease significantly with time 
(P<0.0001, Kruskal-Wallis, Fig 2.3-2.4). MSB staining revealed the changing 
composition of the resolving venous thrombus with significant changes in the 
erythrocyte, fibrin and collagen content during resolution (P<0.0001, Kruskal-



















Figure 2.3 Heterogeneity in thrombus cross-sectional area 
Thrombus cross-sectional area (n=32-37 /time-point) at days 1, 7, 14 and 21 
post-induction was found to decrease significantly over time (P<0.0001, 
Kruskal-Wallis), data represented by box-and-whisker plots (median, 
interquartile range, range).  






















Figure 2.4 Representative H&E stained thrombus micrographs 
Representative H&E stained micrographs of thrombus at days 1, 7, 14 and 21 
post-induction demonstrating the degree of thrombus heterogeneity. 

































Figure 2.5 Thrombus red cell, fibrin and collagen content 
Thrombus sections (n=12-42 per time-point) at days 1, 7, 14 and 21 post-
induction stained with MSB were segmented and their respective (A) red cell, 
(B) fibrin and (C) collagen content calculated as a percentage of thrombus area. 
The content of the thrombus was found to change significantly over time 
(P<0.0001, Kruskal-Wallis), data represented by box-and-whisker plots 
(median, interquartile range, range). Adapted from 257. 
























































Figure 2.6 Representative MSB stained thrombus micrographs 
Representative MSB stained thrombus micrographs at days 1, 7, 14 and 21 
post-induction (yellow = erythrocytes, red = fibrin, blue = collagen). Micrographs 
taken at an original magnification of 50x and 200x with error bars of 200µm and 




Measurements of thrombus volume are consistent with those of previous 
studies, with thrombus resolution taking in excess of 21 days32, 257. The rate of 
thrombus resolution was most pronounced between days 7 and 14 post-
induction (~70%), identifying this as an important time-point for future studies. A 
notable absence in thrombus resolution was evident between days 1 and 7 
post-induction. This could be explained by an initial lag phase in the thrombus 
resolution. Alternatively, thrombus propagation, reported in both mice and man, 
may occur post-formation with thrombus volume peaking between these two 
time-points254. However, given observed reductions in erythrocyte content, that 
would likely form the majority of the propagating thrombus, this is unlikely. A 
consistent increase in vein lumen recanalisation was also measured. 
Recanalisation of the lumen, occurring as a result of contraction of the thrombus 
from the vein wall and possibly some contribution from the coalescence of 
neovascular channels that appear during organisation of the thrombus, is 
important for restoration of blood flow through the thrombosed vessel51, 258.  
 
A number of previous studies of venous thrombus resolution have relied on 
single representative measures of thrombus cross-sectional area32, 51. In this 
study, it was clear, from the measurement of thrombus cross-sectional area at 
various points throughout the length of the thrombus, that there is a marked 
degree of heterogeneity in thrombus area throughout its length. This highlights 
the difficulty in obtaining reproducible estimates of thrombus resolution by from 
single measurements of cross-sectional area. Estimate of thrombus volume by 
measuring cross-sectional area at defined lengths throughout the whole 
thrombus, provides a more reproducible and accurate measure of thrombus 
burden54, 57. 
 
In addition to changes in size the venous thrombus also undergoes extensive 
remodeling of the extracellular matrix. Quantification of erythrocyte, fibrin and 
collagen content of the thrombus was achieved by segmentation of MSB 
stained sections. The acute thrombus was comprised mainly of erythrocytes 
that were rapidly cleared from the thrombus and were largely absent by day 14. 
The percentage area of the thrombus stained positively for fibrin peaked 
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between days 7 and 14 post-induction suggesting fibrin may be deposited or 
matures after initial thrombus formation. Finally, deposition of collagen within 
the thrombus increased with time rising from undetectable levels in the day 1 
thrombus to cover roughly 50% of the mean thrombus area by day 21. The 
increasing levels of collagen observed within the resolving thrombus suggest 
that this process may serve as a useful marker of thrombus organisation. 
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Chapter 3 PHD gene and protein expression 




High levels of HIF1α nuclear accumulation and transcriptional activity have 
been measured in the acute venous thrombus. The scale of HIF1α stabilisation 
observed has been attributed to poor oxygenation of the early thrombus that 
results in a marked degree of tissue hypoxia57. Reduced thrombus oxygenation 
is likely to limit the oxygen dependent hydroxylation of HIF1α by PHD enzymes 
that is required for degradation. As the thrombus resolves and tissue 
oxygenation improves decreasing levels of HIF1α nuclear accumulation are 
observed. Improved oxygenation is likely to restore PHD enzyme activity and 
allow resumption of HIF1α proteasomal degradation.  
 
Three prototypical members of the PHD family of enzymes have been identified 
encoded by three separate genes; Egln1, Egln2 and Egln3 (according to 
accepted convention these genes will be referred to as Phd2, Phd1 and Phd3 
respectively). The expression of Phd1, Phd2 and Phd3 appears to be fairly 
ubiquitous142. However, expression of their respective protein products; PHD1, 
PHD2 and PHD3 demonstrates a degree of tissue specificity143. At the cellular 
level PHD protein expression has been observed in a number of cell types 
present in the resolving venous thrombus in particular, neutrophils and 
macrophages173, 176.While HIF1α protein expression has been measured in the 
resolving venous thrombus, by both enzyme linked-immunosorbent assay 
(ELISA) and immunohistochemistry, the temporal and spatial expression 









3.3.1 Thrombus induction 
Thrombus induction was performed as described in Chapter 2.2.1. Thrombi 
were harvested at days 1, 3, 7 and 11 post-induction (n=5 mice/time point) for 
analysis by qPCR. Thrombi were harvested at days 1, 3, 7 and 14 post-
induction for immunohistochemical (IHC) analysis (n=5 mice/time point). Murine 
kidney was also collected for use as positive control tissue. For IHC, tissue was 
processed as described in Chapter 2.3.2. Thrombi separated found surrounding 
vein wall were harvested at days 1, 3, 7 and 14 post-induction for biochemical 
analysis by western blotting. Murine kidney, heart, liver, spleen and lung were 
collected for optimisation of western blotting. For biochemical analysis tissues 
were snap frozen in liquid nitrogen. 
 
3.3.2 RNA extraction 
Thrombi were separated from the IVC and immersed in RNase Zap (Ambion, 
UK) prior to snap freezing in liquid nitrogen and storage at -80°C. Frozen 
samples were homogenised in 800µl of Trizol (Invitrogen, UK) using an RNase 
free microcentrifuge tube homogenisation kit (Anachem, UK) and incubated at 
room temperature for 10mins.  Chloroform (160µl) was added and the sample 
shaken vigorously for 20secs to achieve phase separation. Samples were 
incubated on ice for 10mins followed by centrifugation at 10,000g for 15mins at 
4°C. The upper aqueous phase was collected into an RNAse free 
microcentrifuge tube and diluted with one volume of 70% ethanol.  
 
RNA extraction was performed using the RNeasy mini kit (Qiagen, UK) 
according to the manufacturers instructions. Samples were added to an RNeasy 
mini-column and centrifuged at 10,000g for 15secs. The eluate was re-applied 
and the mini-column centrifuged at 10,000g for 15secs. The mini-column was 
washed with 350µl of RW1 buffer and centrifuged at 10,000g for 15secs. An 
DNA cleavage step was performed by incubation with 10µl of DNAase (Qiagen, 
UK) for 15mins at room temperature. The mini-column was washed with 350µl 
of kit RW1 buffer and centrifuged at 10,000g for 15secs, transferred to a fresh 
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2ml collection. The column was washed twice with 500µl of kit RPE buffer with 
a 15sec, 10,000g centrifugation step in between. Eluates were discarded and 
the silica membrane in the column dried by centrifugation at 10,000g for 1min. 
RNase free water (33µl, Qiagen, UK) was applied to the mini-column and 
incubated for 10mins at room temperature. RNA was eluted from the mini-
column into an RNase free microcentrifuge tube, by centrifugation at 10,000g 
for 1min. On extraction RNA was immediately stored at -80°C. 
3.3.3 RNA quantification and integrity 
The concentration of RNA in the processed samples was measured 
spectrophotometrically using a NanoDrop 1000 (Thermo Fisher Scientific, 
USA). The absorbance spectrum of RNA has a single peak with a maximum of 
260nm. This spectrum also provides a measure of RNA purity with an 
absorbance ratio (260nm/280nm) of less 1.8 indicating such as of contaminants 
including DNA and phenol. RNA integrity was also assessed using a 
microfluidics chip (RNA 6000 Nano assay, Agilent, Germany) run on a 2100 
Bioanalyser (Agilent, Germany) according to the manufacturers instructions, 
representative RIN analyses provided in Appendix A1. RNA samples with an 
RNA integrity number (RIN) of greater than 7 were considered suitable for 
subsequent qPCR analysis. 
 
3.3.4 RNA ethanol precipitation 
RNA samples with low purity as determined by analysis of absorbance spectra 
underwent ethanol precipitation. RNA sample volumes were normalised to 
100µl by the addition of RNase free water and placed on ice, 10µl of 3M sodium 
acetate (pH 5.2) added and the sample mixed by vortexing. This was followed 
by addition of 220µl of ice-cold 100% ethanol (Sigma, UK) with thorough mixing 
and incubation at -80°C for 2hrs. RNA was pelleted by centrifugation at 14,000g 
for 10mins at 4°C. The supernatant was decanted and 500µl of ice cold 70% 
ethanol wash added to the pellet. Samples were centrifuged at 14,000g for 
5mins at 4°C. The supernatant was decanted and the RNA pellet air-dried prior 
to dissolution in the required volume of RNase free water (Qiagen, UK). 
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3.3.5 Thrombus micro-array 
The expression of PHD and HIFα subunits was analysed in a pre-existing 
murine micro-array dataset conducted by Dr Julia Humphries. In this dataset 
thrombus gene expression was analysed at days 1, 3, 7 and 11 post-induction 
(n=3 per group) on a murine gene 1.0 sense target (ST) arrays (Affymetrix, 
USA) used according to the manufacturers instructions. A complete 
methodology for the generation of microarray data can be found in Appendix 
A2. Subsequent expression data was normalised by the robust multi-array 
analysis (RMA) algorithm using Expression Console Software (Affymetrix, 
USA).  
3.3.6 cDNA synthesis 
Reverse transcription of RNA was performed using a high capacity RNA-to-
cDNA kit (Applied Biosystems, USA) according to the manufacturers 
instructions. The reaction mixture comprised of 4µl of master mix and up to 16µl 
of RNA template with the addition of nuclease free water to give a total reaction 
volume of 20µl containing 400ng of RNA. Non-reverse transcribed controls 
were generated by substitution with a master mix lacking reverse transcriptase. 
The reaction was conducted using a PTC 200 thermocycler (MJ Research, UK) 
under the following conditions; 5mins at 25°C, 30mins at 42°C and 5mins at 
85°C. The cDNA was stored at -80°C. 
3.3.7 qPCR confirmation  
(i) Primer pair design Design of primer pairs was conducted using 
ProbeFinder software (Roche, USA) derived from the primer3 algorithm259 using 
Ensembl ID inputs (Table 3.1). The use of probe based amplification detection 
required selection of primer pairs that encompassed a universal probe library 
(UPL, Roche, USA) binding sequence. Where possible intron spanning primers 
were selected. Site specificity was confirmed by crosschecking with a murine 
genome library (blastn, NCBI). Standard de-salted primers were purchased 
(Integrated DNA technologies, UK) and resuspended in nuclease free water 
(Amplicon, UK) to a stock concentration of 200µM. Aliquots of a working stock 
of 20µM were prepared by further dilution with nuclease free water. Appropriate 
reaction specific UPL fluorescent DNA probes were selected using the 
ProbeFinder software (Roche, USA). 
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Table 3.1 PCR primer sequences 
Primer Sequence Probe 
Hif1a Left tcccctctcctgtaagcaag #53 
Hif1a Right tcgacgttcagaactcatcct  
Hif2a Left ggagctcaaaaggtgtcagg #3 
Hif2a Right caggtaaggctcgaacgatg  
Hif3a Left ctgcccagaaaaacaagacc #94 
Hif3a Right ctccaagtccagagtgtcagg  
Phd1 Left ggaacccacatgaggtgaa #71 
Phd1 Right aacacctttctgtcccgatg  
Phd2 Left cgtctctcagtgattccaacc #108 
Phd2 Right actgttaggtcggtcgaagc  
Phd3 Left tgtctggtacttcgatgctga #29 
Phd3 Right agcaagagcagattcagtttttc  
Vegfa Left gtacctccaccatgccaagt #64 
Vegfa Right tgggacttctgctctccttc  
Gapdh Left gggttcctataaatacggactgc #52 
Gapdh Right ccattttgtctacgggacga  
Actb Left ctaaggccaaccgtgaaaag #64 
Actb Right accagaggcatacagggaca  
Gak Left cggacaccaaccactttctt #47 
Gak Right aacccagtctctggttctttttc  
Hif1a (2) Left ttacgtgtgagaaaacttctggat #98 
Hif1a (2) Right gccatctagggctttcagataa  
 
(ii) Validation of primer pairs by end-point PCR analysis    
Pooled thrombus cDNA was subject to end-point PCR using the HotStar DNA 
polymerase master mix (Qiagen, UK) according to the manufacturer’s 
instructions. A reaction mix for each gene of interest was prepared by addition 
of 10µl master mix, 2µl of coral load, 0.5µl of the forward and reverse primers 
(20uM), 1ul of template cDNA and 6ul of DNAse free water. Amplification was 
performed in a thermocycler (MJ Mini Thermocycler, Biorad, UK) under the 
following conditions; an initial 5mins at 95°C, 40 cycles of 1min at 94°C, 1 
minute at 60°C, 30secs at 72°C with a final 10mins at 72°C. For subsequent 
qPCR cDNA was diluted 10 fold in nuclease free water. The PCR product was 
stored at -80°C.  
 
PCR products were separated by agarose gel electrophoresis. A 5% agarose 
gel was prepared by dissolving 5g of agarose (Sigma, UK) in 100ml of TAE 
buffer (Ambion, UK) by heating in a microwave. The gel was allowed to cool 
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and 10µl of SYBRsafe (Invitrogen, UK) intercalating agent was added prior to 
casting. The agarose gel was poured into a casting tray (Flowgen, UK) with 
both ends sealed and a comb inserted. After solidifying the comb was removed 
and the tray positioned in the electrophoresis tank (Flowgen, UK). The agarose 
gel was immersed in 1xTAE buffer. Samples were loaded into the wells 
accompanied by an ultra low range DNA ladder (Fermentas, UK). Samples 
were electrophoresed at 20V for 20mins followed by 60mins at 100V. Bands 
were visualised using the ChemiDoc MP gel documentation system (Biorad, 
UK). Band size was estimated using ImageLab software (Biorad, UK). 
 
(iii) Primer efficiency    
Primer efficiency was calculated by generating a 5-point dilution series of 
pooled cDNA samples. Plots of Ct versus log [cDNA] were generated in SDS2.4 
(Applied Biosystems, USA) and gradient values obtained. Efficiencies were 
calculated using the equation E=10 (-1/slope)-1 and values are provided in 
Appendix A3. 
 
 (iv) qPCR   
The qPCR reaction mix for each gene of interest was prepared as follows. 
 Volume Final Concentration 
TaqMan Universal PCR master mix 
(2x, Roche, USA)  
25µl 1x 
Forward Primer (20µM) 0.5µl 200nM 
Reverse Primer (20µM) 0.5µl 200nM 
UPL Probe 0.5µl 100nM 
Nuclease free water 3.5µl  
cDNA 20µl  
 
Robotic dispensing (Biomek/FX, Beckman Coulter, UK) was used to aliquot 
20µl of cDNA template followed by 30µl of gene specific master mix into a 96-
well plate. Reaction volumes of 10µl were dispensed in quadruplicate into a 
384-well plate. The plate was sealed, vortexed and centrifuged prior to loading. 
The plate was run on a Real-Time PCR thermal cycler (ABI 7900HT, Roche 
Applied Biosystems, USA) under the following conditions; an initial 2mins at 
50°C was followed by 10mins at 95°C before 40 cycles of 15secs at 95°C and 
1min at 60°C. Representative standard curve and uknown amplification curves 
are provided in Appendix A4. 
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(v) Quantification of gene expression     
A standard curve approach was used to quantify gene expression. Serial 
dilutions of pooled cDNA were subject to qPCR alongside unknowns used to 
generate a standard curve for each gene of interest. Standard curves were 
generated by plotting CT values against log [cDNA] using SDS software (Roche 
Applied Biosystems, USA). Interpolation of the standard curve enabled 
quantification of genes of interest. Normalisation of data was achieved using the 
housekeeping genes Actb and Gak. 
3.3.8 Western blotting	  
Snap frozen kidney and thrombus tissue samples were processed using either 
radioimmunoprecipitation buffer (RIPA, Pierce Thermo Scientific, USA; 5mM 
Tris-HCl, 30mM NaCl, 0.2% NP-40, 0.2% sodium deoxycholate, 0.02% SDS) or 
a nuclear-cytoplasmic extraction kit (NE-PER, Thermo Pierce, UK) for 
subsequent biochemical analysis. For total protein extraction tissue was cut into 
5mm pieces washed with PBS, homogenised in RIPA buffer (10µl per 1mg) 
supplemented with protease inhibitors (Halt protease inhibitor, Pierce Thermo 
Scientific, USA) and incubated on ice for 10mins. The lysate was clarified by 
centrifugation at 16,000xg for 10mins, the supernatant was then transferred to 
microcentrifuge tubes for storage at -80oC. For the nuclear-cytoplasmic 
extraction tissue was cut into 5mm pieces washed with PBS and homogenised 
in 400µl of CER I buffer (based on 40mg of tissue) supplemented with protease 
inhibitors, vortexed thoroughly and incubated on ice for 10mins. Ice-cold CER II 
buffer was added (22µl), the sample vortexed and incubated on ice for 1min. 
The sample was vortexed and then centrifuged at 16,000xg for 5mins. The 
supernatant containing cytoplasmic proteins was removed and stored at -80oC. 
The pellet was resuspended in 200µl of ice-cold NER, vortexed for 10secs 
every 10mins for a total of 40mins. The sample was again centrifuged at 
16,000xg for 5mins, the supernatant containing the nuclear fraction was 
transferred to a microcentrifuge tube and stored at -80oC. 
 
Total soluble protein of tissue nuclear and cellular extracts was quantified using 
a bicinchoninic acid assay kit (Thermo Pierce, UK). Serial dilutions of bovine 
serum albumin (BSA) were prepared from a 2mg/ml stock to generate a 
standard curve (1.0, 0.5, 0.25, 0.125, 0.063, 0.031, 0.00mg/ml). BSA standard 
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or unknowns (10µl) were added to a 96-well plate in triplicate. After addition of 
200µl of assay reagent to each well the plate was sealed and incubated at 37°C 
for 30mins. Absorbance was measured at 562nm using a spectrophotometer 
(SpectraMax 340, Molecular Devices, USA). The BSA standard curve was 
plotted using a 4-perameter fit, from which concentrations of unknown were 
interpolated. 
 
Sample concentration was normalised by addition of RIPA, CERI or NER buffer. 
Protein samples were prepared for electrophoresis by addition of 5x Laemmli 
buffer; 60mM Tris-HCl pH 6.8, 2% (w/v) SDS, 10%(v/v) glycerol, 5% (v/v) β-
mercaptoethanol, 0.01% (w/v) bromophenol blue and heat denatured at 95°C 
for 5mins. Samples were loaded into precast 4-20% gradient polyacrylamide 
gels (Bio-Rad, UK) alongside pre-stained molecular weight standards (SeeBlue 
Plus2, Invitrogen, UK) at 120V for approximately 45 minutes in running buffer; 
25mM Tris, 192mM Glycine, 0.1% (w/v) SDS pH 8.3. Proteins were transferred 
to PVDF membranes electrophoretically at 2.5A (~25V) for 7 minutes using a 
Trans Blot Turbo system (Bio-Rad, UK) and Trans Blot Turbo PVDF packs (Bio-
Rad, UK) containing proprietary transfer buffer. 
 
Membranes were washed in tris buffered saline (TBS, 25mM Tris, 0.15M NaCl, 
pH7.2) supplemented with 0.1% Tween 20 (TBST, Sigma, UK). Membranes 
were blocked in 5% non-fat dried milk (NFDM, Marvel, UK) dissolved in TBST 
for 1hr at room temperature. Primary antibodies were prepared at the required 
concentration (Table 3.2) by dilution in 5% BSA and incubated with membranes 
overnight at 4°C. Membranes were washed in TBST (3x 5mins) prior to 
incubation with streptavidin HRP conjugated secondary antibody diluted in 5% 
NFDM (Table 3.2) for 1hr at room temperature. Membranes were again washed 
in TBST (3x 5mins) prior to detection of specific antibody antigen complexes by 
addition of a chemi-luminescent substrate (Western C, Bio-Rad, UK) visualised 
using a gel documentation system (Chemi Doc MP, Bio-Rad, UK). The 
molecular weights of specific antigen antibody complexes were estimated from 
the relative position of the prestained molecular weight marker using ImageLab 





Table 3.2 Antibodies used for western blotting 






PHD1 1.0 1/2500 ab108980 Abcam, UK 
PHD2 0.5 1/5000 ab109088 Abcam, UK 
PHD3 0.9 1/2500 ab30782 Abcam, UK 
α-Tubulin 1.0 1/1000 NB600-506 Novus Bio, UK 
Histone H3 1.0 1/1000 9715 Cell Signaling, USA 
Anti-Rabbit Unknown 1/100,000 A0545 Sigma, UK 
Anti-Rat Unknown 1/10,000 A5795 Sigma, UK 
 
 
3.3.9 IHC localisation of PHD protein	  
To localise PHD protein expression in the resolving venous thrombus an IHC 
technique was used. In order to optimise PHD antigen retrieval staining was 
assessed after treatment in both citrate and tris based buffers at a number of 
temperatures in kidney tissue acting as a positive control (Fig 3.1). Antibody 
staining was optimised under a number of primary antibody concentrations and 
incubation times (Fig 3.1). In tissues where poor staining was evident signal 




Figure 3.1 Optimisation of PHD immunohistochemistry 
To optimise the staining of PHD proteins by immunohistochemistry a number of 





Paraffin wax sections were warmed for 30mins at 60°C to soften the wax. 
Sections were deparaffinised in two 5min xylene washes. Endogenous 
peroxidase activity was quenched by incubation of sections in 1%(v/v) hydrogen 
peroxide in 100% ethanol for 30mins. Sections were rehydrated through 
gradated alcohol washes and rinsed in tap water for 5mins. Heat mediated 
antigen retrieval was carried out using an antigen access unit (Menarini 
Diagnostics, UK) at 125°C for 1min with citrate (pH6) or Tris-HCL (pH9) 
buffered retrieval solutions (Menarini Diagnostics, UK). Sections were washed 
in two changes of phosphate buffered saline (PBS, Sigma, UK), ringed using a 
wax pen (Dako), blocked for 10mins using a serum free protein block (Dako) 
and incubated with primary antibodies raised against PHD1 (5µg/ml, Abcam, 
UK), PHD2 (5µg/ml, Abcam, UK) and PHD3 (5µg/ml, Abcam, UK) diluted in 
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PBS for 1hr at room temperature in a humid chamber. Sequential sections were 
incubated with rabbit IgG as a control. Slides were washed three times in PBS 
for 10mins, incubated with biotinylated goat anti rabbit antibody for 45mins at 
room temperature and washed in 3x10min PBS washes. Sections were 
incubated with extravidin peroxidase (Sigma, UK) for 1hr at room temperature. 
Specific antigen antibody complexes were visualised colourimetrically using a 
chromogenic substrate (Vector SG, Vector laboratories, UK). Sections were 
washed in 3x10min PBS washes and counterstained in nuclear fast red (Vector 
laboratories, UK) for 7mins. Sections were rinsed in running tap water for 
30secs prior to dehydration through graded alcohol solutions. Sections were 
cleared in 2x5min xylene washes, mounted with cover slips in DPX medium and 
allowed to dry overnight. 
3.3.10 Polymer based amplification	  
An HRP polymer amplification kit (Menarini Diagnostics, UK) was used 
according to the manufacturers instructions. Sections were dewaxed, 
rehydrated and quenched for endogenous peroxidase activity as previously 
described (4.2.2). Sections were washed in 2 changes of PBS. Sections were 
ringed using a wax pen, blocked for 10mins with serum free protein block 
(Dako) and incubated with primary antibodies raised against PHD1 (5µg/ml, 
Abcam, UK), PHD2 (5µg/ml, Abcam, UK) and PHD3 (5µg/ml, Abcam, UK) 
diluted in PBS for 1hr at room temperature in a humid chamber. Slides were 
washed in 3x10min PBS washes and incubated with HRP polymer for 30mins at 
room temperature. Slides were washed in 3x10mins PBS washes and specific 
antigen antibody complexes were visualised colourimetrically using a 
chromogenic substrate (Vector SG, Vector laboratories, UK). Sections were 
washed in 3x10min PBS washes and counterstained in nuclear fast red (Vector 
laboratories, UK) for 7mins. Sections were rinsed in running tap water for 
30secs prior to dehydration through graded alcohol solutions. Sections were 
cleared in 2x5min xylene washes, mounted with cover slips in DPX medium and 
allowed to dry overnight. 
3.3.11 Biotinyl tyramide amplification	  
A biotinyl tyramide kit (Perkin Elmer, UK) was used according to the 
manufacturers instructions. Sections were dewaxed, rehydrated and quenched 
for endogenous peroxidase activity as previously described (4.2.2). Sections 
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were washed in 2 changes of 0.1M Tris-HCl, 0.15M NaCl and 0.05% (v/v) 
tween20 (TBS). Sections were ringed using a wax pen (Dako, UK) and 
incubated with the supplied blocking reagent for 30mins at room temperature. 
Sections were incubated with primary antibodies raised against PHD1 (5µg/ml, 
Abcam, UK), PHD2 (5µg/ml, Abcam, UK) and PHD3 (5µg/ml, Abcam, UK) 
diluted in blocking reagent for 1hr at room temperature in a humid chamber. 
Sequential sections were incubated with control rabbit IgG. Slides were washed 
three times in TBS for 10mins. Sections were incubated with biotinylated goat 
anti-rabbit antibody (4µg/ml, Sigma, UK) diluted in blocking reagent for 45mins 
at room temperature. Slides were washed three times in TBS for 10mins. 
Sections were incubated with supplied SA-HRP (1:100) diluted in blocking 
reagent for 30mins. Slides were subjected to 3x10min TBS washes. Sections 
were incubated with biotinyl tyramide (1:50) diluted in amplification diluent for 
10mins. Slides were washed three times in TBS for 10mins. Sections were 
incubated with supplied SA-HRP (1:100) diluted in blocking reagent for 30mins. 
Slides were washed four times in TBS for 10mins. Specific antigen antibody 
complexes were visualised colourmetrically using a chromogenic substrate 
(Vector SG, Vector labs, UK). Sections were washed in 3xPBS for 10mins. 
Sections were counterstained in nuclear fast red (Vector labs, UK) for 7mins. 
Sections were washed in tap water for 30secs prior to dehydration through 
gradiated alcohol, followed by clearing in 2x5mins xylene washes. Slides were 
mounted with cover slips in DPX medium (Sigma, UK) and allowed to dry 
overnight. 
3.3.12 Statistical analysis 
Normality of data was assessed using Kolmogorov-Smirnoff tests to inform 
selection of appropriate parametric and non-parametric tests. Differences in 
measurements of gene expression were assessed by 1-way ANOVA and post-
hoc Bonferroni. In all cases P<0.05 was considered statistically significant. 
Statistical analyses were conducted using Prism Software (v5, Graphpad, 
USA). Data represented as mean ± SE.   
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3.4 Results 
3.4.1 Thrombus micro-array analysis 
Phd1-3 gene expression was detected in a murine micro-array at days 1, 3, 7 
and 11 after thrombus induction. No significant change in Phd1 gene 
expression was observed (P>0.05, 1-way ANOVA, Fig3.2A). Phd2 gene 
expression changed significantly over time (P<0.01, 1-way ANOVA, Fig3.2B) 
with expression significantly reduced at days 3 and 7 compared to day 1 
(P<0.05, post-hoc Bonferonni). Similarly Phd3 gene expression changed 
significantly over time (P<0.05, 1-way ANOVA, Fig3.2C) with expression 



















Figure 3.2 Thrombus Phd1, 2 and 3 microarray gene expression  
Microarray data of (A) Phd1 (B) Phd2 and (C) Phd3 gene expression, 
expressed as normalised fluorescence intensity, was analysed (1-way ANOVA) 
Data represented as mean ± SE (n=3 per group). Phd2 *P<0.05 day1 vs day3, 
day1 vs day7. Phd3 *P<0.05 day1 vs day 7. 
Phd1







































































Hif1-3α gene expression was detected in a murine micro-array at days 1, 3, 7, 
11 after thrombus induction. Hif1α gene expression changed significantly over 
the time-course of the experiment (P<0.001, 1-way ANOVA, Fig 3.3A) with 
gene expression significantly reduced at days 7 and 11 as compared to days 1 
and 3. Gene expression of Hif2α also varied significantly over the time-course 
of the experiment (P<0.001, 1-way ANOVA, Fig 3.3B) gene expression was 
significantly higher at days 7 and 11 compared to day 1 (post-hoc Bonferroni). 
Hif3α gene expression was subject to significant changes with time (P<0.05, 1-
way ANOVA, Fig 3.3C) with gene expression significantly lower at day 7 and 11 


















Figure 3.3 Thrombus Hif1a, 2a and 3a microarray gene expression  
Microarray data of (A) Hif1a (B) Hif2a and (C) Hif3a gene expression, 
expressed as normalised fluorescence intensity, was analysed (1-way ANOVA). 
Data represented as mean ± SE (n=3 per group). Hif1a *P<0.05 day1 vs day7, 
day3 vs day7, day1 vs day11, day3 vs day11. Hif2a *P<0.05 day1 vs day 7, 
day3 vs day7, day3 vs day11. Hif3a *P<0.05 day1 vs day7, day1 vs day11. 
Hif3a





































































3.4.2 Primer validation 
Primer pair design was validated by endpoint PCR of pooled thrombus cDNA. 
Single amplicons were generated for Phd1, Phd2, Phd3, Hif1α, Hif2α, Hif3α, 
Vegfa, Actb, Gapdh and Gak. Observed amplicon sizes closely matched (within 
10%) the predicted values (Fig 3.4, Table 3.4). 
3.4.3 Thrombus quantitative PCR 
Expression of Phd1, 2 and 3 genes was detected in murine thrombus at days 1, 
3, 7 and 11 post-induction by qPCR. Phd1 gene expression was not 
significantly altered over-time (P>0.05, 1-way ANOVA, Fig 3.5A). Phd2 gene 
was significantly different over the time-course of the experiment (P<0.05, 1-
way ANOVA, Fig 3.5B). Significant changes in Phd3 gene expression were 
evident (P<0.05, 1-way ANOVA, Fig 3.5C) however, post-hoc tests failed to 
identify the source of this difference.  
 
Hif1a and Hif3a gene expression was not detected by qPCR. Hif2a gene 
expression changed significantly over the time-course of the experiment 
(P<0.05, 1-way ANOVA, Fig 3.6). However, post-hoc tests failed to identify the 


















Figure 3.4 Primer validation 
Agarose gel electrophoresis of end-point PCR product was used to validate 
genes of interest. Single discrete bands were observed for all target genes. 
 
 
Table 3.3 End-point PCR amplicon sizes 
Primer Pair Expected (bp) Observed (bp) 
Hif1a 104 109 
Hif2a 63 66 
Hif3a 71 75 
Phd1 125 130 
Phd2 62 65 
Phd3 85 88 
Vegfa 63 77 
Gapdh 112 116 
Actb 104 108 
Gak 64 66 













































































Figure 3.5 Thrombus Phd1, 2 and 3 qPCR gene expression 
Gene expression of (A) Phd1, (B) Phd2, and (C) Phd3 was quantified by qPCR 
(1-way ANOVA, n=5 per group) and expressed as normalised fluorescence 










Figure 3.6 Thrombus Hif2a qPCR gene expression 
Gene expression of Hif2a was quantified by qPCR (1-way ANOVA, n=5 per 
group) and expressed as mean normalized fluorescence intensity, data 
represented as mean ± SE. 


























































































3.4.4 Immunoblotting   
An immunoblotting approach was used to visualise PHD1, 2 and 3 protein 
expression within thrombus. Immunoblotting was first optimised in total lysates 
of control tissues: heart, lung, kidney, liver and spleen (Fig 3.7). It was not 
possible to visualize PHD1 protein expression in any of the positive control 
tissues by immunoblotting. Immunoblots for PHD2 visualised a discrete band at 
53kDa present in kidney and liver tissue lysates . PHD3 immunoblots identified 
a major band in kidney lysates with estimated molecular weight of 36kDa, a 
feint band with a lower molecular weight was also detected in heart tissue 
lysate. Expression of αTubulin, with an estimated molecular weight of 55kDa 
was expressed in all of the tissue lysates, although to varying degrees. 
 
To investigate the expression of PHD isoforms in the thrombus total tissue 
lysates from samples harvested at days 1, 3, 7 and 14 post-induction were 
analysed alongside kidney tissue lysates serving as a positive control (Fig 3.8). 
As before PHD2 and PHD3 expression was present in kidney lysates. 
Expression of PHD1, PHD2 and PHD3 was not detectable in thrombus tissue 
lysates at any of the time-points studied. Expression of the loading control 
αTubulin in thrombus lysates, while markedly less than in kidney lysates, was 
detected at all time-points and remained relatively invariant. 
 
The subcellular localisation of PHD isoforms was investigated in nuclear and 
cytoplasmic extracts of kidney tissue samples (Fig 3.9). PHD1 immunoblotting 
provided a discrete band of 51kDa present exclusively in the nuclear extracts. 
PHD2 and PHD3 protein expression was present mainly in cytoplasmic extracts 
with small amounts detectable in nuclear extracts. The cytoplasmic marker 
αTubulin was enriched in the cytoplasmic fraction with detectable levels also 
present in the nuclear compartment. Conversely the nuclear marker Histone H3 
was enriched in the nuclear fraction with some protein also present in the 
cytoplasmic fraction. Representative whole-membrane images are provided in 
Appendix A5. Fresh and snap-frozen tissue samples were also assayed to 
determine whether the extraction protocol used remained robust in frozen tissue 
samples (Appendix A6). Nuclear and cytoplasmic components were well 













Figure 3.7 PHD1-3 protein expression in murine tissues 
Representative immunoblots of PHD1-3 expression in murine heart (H), lung 
(Lu), kidney (K), spleen (S) and liver (Li) total tissue lysates. PHD1 protein was 
not detectable by immunoblotting in any of the tissue samples investigated. 
Immunoblotting revealed a discrete band for PHD2 at 53kDa in kidney and liver 
lysates. PHD3 protein expression was detected in kidney tissue lysate with a 
band at 36kDa, a lower molecular weight band was also detected in heart 
lysate. Expression of the loading control αTubulin was present in all samples 










Figure 3.8 PHD1-3 protein expression in the resolving venous thrombus 
Expression of PHD1-3 was not detectable in thrombus total tissue lysates at 
days 1, 3, 7 and 14 post-induction by immunoblotting. Expression of αTubulin 














Figure 3.9 PHD 1-3 protein compartmentalisation in kidney tissue 
The PHD protein content of kidney total, cytoplasmic and nuclear preparations 
was determined by immunoblotting. PHD1 protein was expressed specifically in 
nuclear extracts, with a discrete band at 51kDa, while remaining undetectable in 
total extracts. PHD2 and PHD3 proteins were present in cytoplasmic extracts 
and, to a lesser extent, nuclear extracts. The quality of protein separation was 
assessed by segregation of α-tubulin and histone h3 to the cytoplasmic and 
nuclear compartments respectively. A degree of cross contamination of nuclear 
components into the cytoplasmic compartment, and vice versa, was noted. 
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3.4.5 IHC  
Localisation of PHD1-3 protein by immunohistochemistry was optimised using 
in formalin fixed paraffin embedded (FFPE) murine kidney sections. Using 
standard extravidin peroxidase signal amplification failed to localize PHD 
protein expression to the kidney. Additional amplification using an HRP polymer 
successfully localised protein expression of PHD1-3 in the kidney medulla (Fig 
3.10). Localisation of PHD1-3 protein expression in FFPE of thrombus required 
additional signal amplification using a biotinyl tyramide based system. PHD1-3 
protein expression was observed in the thrombus at days 1, 3 7 and 14 post-
induction. PHD1 expression (Fig 3.11) at days 1 and 3 was associated with a 
polymorphonuclear cell infiltrate, although not all the cells were found to 
express this enzyme. PHD1 protein expression was markedly reduced at day 7 
with positive staining localised to the thrombus periphery. At day 14 PHD1 
protein was localised throughout the thrombus.  
 
Similarly, positive staining for PHD2 was observed at all time-points (Fig 3.12). 
PHD2 protein expression at days 1 and 3 was again associated with 
polymorphononuclear cells. At day 7 a large number of cells continued to 
express PHD2 both within the thrombus core and periphery. At day 14 PHD2 
protein was present in highly cellular regions of the organising thrombus, 
however, cellular staining for PHD2 appeared heterogeneous. Larger 
representative images for PHD2 localisation in the resolving thrombus are 
included in Appendix A7. 
 
PHD3 protein expression was observed at all time-points of thrombus resolution 
investigated. PHD3 protein at days 1 and 3 was present in cells distributed 
throughout the thrombus (Fig 3.13). At day 7 PHD3 protein expression was 
largely restricted to the thrombus periphery. PHD3 protein expression at day 14 
was associated with mononuclear cells the morphology of which was consistent 
with that of macrophages. PHD3 protein expression was again restricted to cell 








PHD1-3 protein was quantified by calculating the percentage area stained 
positively for each of the isoforms throughout the length of the thrombus (Fig 
3.14). The percentage of the thrombus stained positively for PHD1, PHD2 and 
PHD3 changed significantly with time (P<0.0001, 1-way ANOVA). Expression of 
all three PHD isoforms was significantly higher at day 14 vs days 1,3 and 7 





Figure 3.10 PHD1-3 kidney immunohistochemistry 
FFPE kidney sections were used as positive controls for the optimisation of 
PHD1-3 immunohistochemistry. Positive staining for (A) PHD1, (B) PHD2 and 













Figure 3.11 PHD1 immunohistochemistry in the resolving thrombus 
Nucleated cells in the resolving thrombus stained positively for PHD1. 
Sequential sections were incubated with appropriate IgG as control. Images 
















Figure 3.12 PHD2 immunohistochemistry in the resolving thrombus 
Nucleated cells in the resolving thrombus stained positively for PHD2. 
Sequential sections were incubated with appropriate IgG as control. Images 
















Figure 3.13 PHD3 immunohistochemistry in the resolving thrombus 
Nucleated cells in the resolving thrombus stained positively for PHD3. 
Sequential sections were incubated with appropriate IgG as control. Images 










































































































Figure 3.14 Quantification of PHD1-3 immunohistochemistry 
Percentage area of thrombus stained positively for PHD1-3 (A-C) protein at 
days 1, 3, 7 and 14 post-induction (1-way ANOVA, n=5 per group). *P<0.05 








Nuclear accumulation of HIF1α occurs early after thrombus formation (within 
24hours)57. PHD isozymes play a critical role in the regulation of HIF1α stability 
with hydroxylation targeting this protein for polyibiquitination and proteasomal 
degradation. To further understand the molecular processes that regulate 
HIF1α accumulation in the thrombus it was considered important to characterise 
the expression of individual PHD isoforms. 
 
PHD isoform expression was measured at the gene level by microarray and 
qPCR. Phd1 gene expression remained relatively constant during thrombus 
resolution as measured by the micro-array and subsequently confirmed by 
qPCR. Phd2 gene expression was significantly altered with time, as measured 
by both microarray and qPCR. Whilst time-point significant differences varied a 
similar reductions in Phd2 expression at mid time-points were evident. Similarly, 
with Phd3 significant temporal changes were observed by both techniques. A 
consistent trend towards decreased Phd3 expression at later time-points was 
apparent.  
 
Expression of Phd2 and Phd3 genes at early time-points after thrombus 
induction may be attributed to the high proportion of neutrophils found in the 
acute thrombus25. Human peripheral neutrophils express both Phd2 and Phd3 
and, importantly, the expression of these genes is rapidly upregulated by either 
hypoxia or an inflammatory insult176. Both Phd2 and Phd3 genes contain HREs 
in their respective promoters97, 98. The upregulation of Phd2 and Phd3 under 
hypoxic conditions maybe a result of increased HIF1α transcriptional activity 
present in the acute venous thrombus57, 260. An HRE has yet to be identified in 
the promoter of Phd1 and that may account, to some extent, for the observed 
invariance. 
 
Attempts to quantify Hif1a and Hif3a by qPCR proved unsuccessful. The Hif1a 
primer pair was successfully validated by endpoint PCR using a pooled 
thrombus cDNA sample. However, no amplification was observed during the 
qPCR run. This suggests either that Hif1a gene is too weakly expressed for 
detection or that the fluorescent probe was not successfully incorporated. A 
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second primer pair with a different probe was also designed and successfully 
validated by endpoint PCR but again no amplification was observed. This would 
suggest that, surprisingly, despite high levels of nuclear HIF1α protein 
expression, Hif1a gene expression is not detectable by qPCR. Hif3a primer pair 
validation by endpoint PCR was also successful. However, during qPCR 
amplification of Hif3a was only observed after 38 cycles and did not allow for 
construction of a standard curve, precluding further analysis. Hif2a gene 
expression was readily detectable by both micro-array and qPCR and was 
found to increase significantly as the thrombus resolved. The finding is 
consistent with immunohistochemical analysis of HIF2α protein expression in 
the thrombus where the proportion of the thrombus stained positively increased 
with time261. HIF2α protein is potently upregulated in hypoxic macrophages 
inducing expression of Vegfa and cell migration and this cell type could 
contribute to the levels observed in the thrombus262. 
 
When designing of the qPCR experiment the use of three reference genes was 
originally intended. Actb and Gapdh are both standard reference genes 
whereas Gak was selected due to invariance in the microarray dataset. After 
optimisation Gapdh was excluded for use as a reference gene due to concerns 
over hypoxia-inducibility. Gapdh contains a promoter resident HRE and there 
have been numerous reports of hypoxia-mediated induction in neutrophils, 
macrophages and endothelial cells176, 263, 264. 
 
While expression of Phd1, Phd2 and Phd3 mRNA was observed in the 
thrombus it was necessary to confirm expression at the protein level. Western 
blotting for PHD1-3 isoforms in thrombus tissue lysates was optimised. Initial 
success was achieved in the detection of PHD isoforms in positive control 
tissues. Molecular weight estimations correlate well with predicted values and 
with the exception of PHD3 antibodies provided single discrete bands. It is 
possible that the lower molecular weight band corresponds to alternate splice 
variants of PHD3 that have been described in the literature138, 171. Alternatively 
as the antibody used to detect PHD3 protein was polyclonal this additional band 




Attempts to detect PHD1-3 protein expression in the resolving venous thrombus 
by immunoblotting were unsuccessful. It is possible that PHD protein 
expression in the thrombus is relatively low. Immunohistochemical data 
supports this explanation as localisation required the maximum available level 
of signal amplification. Alternatively, there are a number of factors that may 
have led to the dilution of intracellular proteins in total tissue lysates. Carry over 
of blood when excising the thrombus may have diluted the samples with plasma 
proteins. The acute thrombus is also predominately composed of erythrocytes 
that may have further diluted out PHD protein expression in nucleated cells. The 
reduced intensity of αTubulin bands in thrombus lysates compared to those of 
kidney would support dilution of intracellular proteins. 
 
Kidney FFPE sections were used to successfully optimise immunohistochemical 
localisation of PHD1-3 protein. The expression pattern of PHD1-3 correlated 
well with previous immunohistochemical studies in the rat and human kidney 
samples265-267. However, in contrast to the nuclear segregation observed by 
immunoblotting PHD1 localised to the cytoplasm and nucleus of the kidney 
medulla. Although PHD2 localisation did not require amplification, both PHD1 
and PHD3 could only be localised clearly through the use of polymer-based 
amplification. Localisation of PHD1, 2 and 3 in the resolving thrombus 
represented a greater challenge because of the comparatively low levels of 
expression indicated by western blotting. A biotinyl tyramide amplification 
system, reported to provide approximately one thousand times greater 
sensitivity268, was optimized and specific staining with low levels of background 
was achieved for all three isoforms. 
 
For all three PHD isoforms protein expression was localized to the cellular 
component of the thrombus and was detectable at all time-points analysed. At 
early time-points PHD1-3 was expressed in cells morphologically consistent 
with neutrophils. This is consistent with previous reports in which expression of 
PHD1-3 was identified in circulating neutrophils by immunoblotting175. Only a 
proportion of cells present in the day 14 thrombus stained positively for PHD1, 
PHD2 or PHD3. It is possible that these cells are macrophages as this cell type 
is recruited in increasing numbers to the resolving venous thrombus. PHD3 
protein is strongly expressed in classically activated (M1) macrophages but not 
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in alternatively activated (M2) cells that may explain the pattern of 
localisation173. It is unclear whether skewing of macrophages has a similar 
effect on the expression of PHD1 and PHD2, however deletion of Phd2 has 
been found to skew macrophages towards an M2 phenotype164.  
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Chapter 4 The effect of constitutive 





Constitutive Phd gene knockouts have been generated for each of the three 
PHD isoforms. Homozygous deletion of Phd1 and Phd3 is well tolerated, with 
no observed impairment in development155. However, homozygous deletion of 
Phd2 results in severe placental and cardiac defects and embryonic death at 
mid to late gestation (E12.5-13.5)155. Ablation of PHD2, but not PHD1 or PHD3, 
expression is associated with a marked stabilisation of HIF1α and up-regulation 
of hypoxia responsive genes such as Vegfa; revealing the importance of this 
isoform in the regulation of HIF1α and associated transcriptional activity in the 
development of the embryo155. 
 
In contrast to homozygous Phd2 gene deletion, mice heterozygous for Phd2 
develop with no apparent embryonic defects.  PHD2 has an important role in 
regulating angiogenesis in vivo. Heterozygosity for Phd2 results in reduced 
tumour metastasis, potentially mediated by endothelial normalisation and 
improved tumour oxygenation269. Heterozygous deficiency for Phd2 also 
improves restoration of limb perfusion, through increased macrophage 
mediated collateralization, in a murine model of critical limb ischaemia and 
improved myocardial collateralisation after infarction164. Further studies have 
demonstrated that angiopoeitin 1, an important mediator of endothelial 
disruption during the initiating phase of angiogenesis, acts as an endogenous 
repressor of PHD2 required for skewing of macrophages towards a 
proangiogenic phenotype165. 
4.2 Aim 




4.3.1 Breeding strategy 
Male and female heterozygous Phd2 knockout mice (PHD2+/-) on a BALB/c 
background were crossed to obtain both heterozygous knockouts and wild-type 
littermate controls (PHD2+/+). 
4.3.2 Phd2 genotyping 
I would like to acknowledge Mr Jens Serneels and Mr Yannick Jonsson for 
genotyping of Phd2 knockout mice. DNA was extracted from tail snips using the 
hot sodium hydroxide and Tris (HotSHOT) method. Tail snips placed into 
individual PCR tubes containing 75µl of 25mM NaOH, 0.2mM disodium EDTA 
(pH12) and heated in a thermocycler at 94°C for 30mins to digest tissue and 
extract DNA. The extraction solution was neutralised with 75µl of 40mM Tris-
HCl (pH 5). 
 
Tail snip DNA was genotyped by PCR using a three-primer approach in which 
wild-type and knockout samples generate amplification products of differing 
sizes when resolved in agarose gels. The following primers (Integrated DNA 
technologies, UK) were used for Phd2 genotyping. 
 
Table 4.1 Genotyping primers 
Primer Sequence 
PHD2 common 5’ aaattctaatcgtagctgatgtgagc 3’ 
PHD2 wildtype 5’ acctatgatctcagcatttgggag 3’ 
PHD2 knockout 5’ tcaggacagtgaagcctagaaactct 3’ 
 
OneTaq DNA polymerase master mix (New England Biosystems, USA) was 
used according to the manufacturers instructions. A reaction mix was prepared 
for each gene of interest containing 12.5µl of master mix, 1µl of each primer 
(10µM), 1µl of template DNA and 6.5µl of DNAse free water. Amplification was 
performed in a thermocycler (PTC-100, Biorad, UK) under the following 
conditions: an initial 2mins at 94°C, 40 cycles of 30secs at 94°C, 30secs at 
59°C, 30secs at 72°C with a final 10mins at 72°C. 
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PCR products were resolved on a 1% agarose gel, prepared by dissolving 1g of 
agarose (Sigma, UK) in 100ml of TAE buffer (Ambion, UK) by heating in a 
microwave. The gel was allowed to cool and 10µl of SYBRsafe (Invitrogen, UK) 
intercalating agent added prior to casting. The agarose gel was poured into a 
casting tray (Flowgen, UK) with both ends sealed and a comb inserted. After 
solidifying the comb was removed and the tray positioned in the electrophoresis 
tank (Flowgen, UK). The agarose gel was immersed in 1xTAE buffer. Samples 
were loaded into the wells accompanied by GeneRuler low range DNA ladder 
(Fermentas, UK). Samples were electrophoresed at 20V for 20mins followed by 
60mins at 100V. Bands were visualised using the ChemiDoc MP gel 
documentation system (Biorad, UK). 
 
This three-primer approach results in the formation of two DNA products 
corresponding to the wildtype allele (340bp) and the knockout allele (380bp). In 
heterozygous knockouts bands for both products will be present whereas 
wildtype controls will present as a single band and allows for easy differentiation 
between genotypes. 
4.3.3 Thrombus induction 
Prior to thrombus induction mice were weighed and measurements of mass 
recorded for subsequent analysis. Thrombi were induced in the inferior vena 
cava of 6-12 week old PHD2+/- mice and wild-type littermate controls, as 
previously described in Chapter 2.3.1, in an operator-blinded manner. Thrombi 
were harvested at days 1, 14 and 21 post-induction for analysis by histology 
(Fig 4.1). Kidneys were also excised and snap frozen in liquid nitrogen for PHD 
western blot analysis.  
4.3.4 Tissue processing 
Thrombi were processed as described in Chapter 2.3.2. Snap frozen kidney 
samples were separated into cytosolic and nuclear fractions as described in 
Chapter 3.3.8. 
4.3.5 H&E staining 






Figure 4.1 Study design 
Thrombus was induced in 6-12wk old PHD2+/- and PHD2+/+ mice on a Balb/c 
background. Thrombi were harvested at days 1, 14 and 21 post-induction for 
analysis by histology. 
 
4.3.6 Immunohistochemical localisation of Mac-2 
Sections were dewaxed, rehydrated through gradated alcohol washes and 
rinsed in tap water for 5mins. Endogenous peroxidase activity was quenched by 
incubating sections in 1%(v/v) hydrogen peroxide in PBS for 30mins. Heat-
mediated antigen retrieval was carried out using an antigen access unit 
(Menarini Diagnostics, UK) at 110°C for 1min with citrate buffer (pH6, Menarini 
Diagnostics, UK). Sections were washed in two changes of PBS, ringed using a 
wax pen (Dako), blocked for 10mins using a serum free protein block (Dako) 
and incubated with primary antibody raised against Mac-2 (0.5µg/ml final 
concentration, clone M3/38, Biolegend, UK) diluted in PBS for 1hr and 2hrs 
respectively, at room temperature in a humidity chamber. Sequential sections 
were incubated with rat IgG at the appropriate primary antibody concentration to 
serve as negative controls. Slides were washed in PBS (3x10mins), incubated 
with biotinylated rabbit anti rat antibody (Dako, UK) for 45mins at room 
temperature and washed in PBS (3x10min). Sections were incubated with an 
extravidin peroxidase conjugate (Sigma, UK) for 1hr at room temperature. 
Specific antigen antibody complexes were visualised colourimetrically using a 
chromogenic substrate (Vector SG, Vector laboratories, UK). Sections were 
Thrombus  
Induction 
0 14 21 
PHD2 +/- 
Thrombus harvest and analysis 
1 
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washed in 3x10min PBS washes and counterstained in nuclear fast red (Vector 
laboratories, UK) for 7mins. Sections were rinsed in running tap water for 
30secs prior to dehydration through graded alcohol solutions. Sections were 
cleared in 2x5min xylene washes, mounted with cover slips in DPX medium 
(Sigma, UK) and allowed to dry overnight. 
4.3.7 Immunohistochemical localisation of CD31 
Sections were dewaxed, rehydrated, quenched for endogenous peroxidase 
activity and antigen retrieved as previously described (4.3.4), followed by 3x2 
min washes in PBS. Slides were carefully wiped dry around each section and 
the sections ringed using a wax pen. Care was taken not to allow sections to 
dry out before application of serum free protein block (Dako, 10mins at room 
temperature) to block non-specific antibody binding. Sections were incubated 
with primary antibodies raised against CD31 (0.2 µg/ml, Abcam, UK) for 2hrs at 
room temperature in a humid chamber. Sequential sections were incubated with 
rabbit IgG at the appropriate primary antibody concentration to serve as 
negative controls. Slides were washed in 3x10min PBS washes and incubated 
with HRP polymer for 30mins at room temperature. Slides were washed in 
3x10mins PBS and specific antibody antigen complexes identified as described 
in Chapter 4.3.6. Sections were dehydrated through graded alcohol solutions, 
cleared in 2x5min xylene washes and mounted in DPX medium. 
4.3.8 Localisation of collagen by picrosirius red staining 
Sections were dewaxed and rehydrated, (4.3.4) and stained for collagen using a 
picrosirius red staining kit (Polysciences, UK). In brief, sections were incubated 
with a 0.2% (w/v) solution of phosphomolybdic acid for 2mins followed by a brief 
was in distilled water. Sections were then incubated in a 0.1% (w/v) solution of 
picrosirius red dissolved in a saturated solution of picric acid (3%, w/v), followed 
by a 2min incubation in 0.1N hydrochloric acid. Finally, sections were rapidly 
dehydrated through graded alcohols, cleared in 2x5min xylene washes and 
mounted in DPX. 
4.3.9 Image analysis 
Images were captured at either 50x or 200x magnification with a Leica light 
microscope (DMRB, Leica, Germany) using a microscope mounted digital 
camera (Micropublisher 3.3, QImaging, Canada) on a motorised stage 
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(ProScan, Datacell, UK). Thrombus was demarked using an region of interest 
(ROI) tool at each level using Image Pro Plus software (Media Cybernetics, UK) 
to provide cross sectional area, this was multiplied by the distance between 
levels and finally summated to provide quantitative data on thrombus volume 
(mm3). Thrombus recanalisation was estimated by demarking the thrombus and 
the surrounding IVC using the ROI tool, recanalisation was expressed as a 
percentage of the total IVC lumen volume. Histogram-based thresh-holding with 
Image Pro Plus software (Media Cybernetics, UK) was used to select areas of 
Mac-2, Gr1 and picrosirius red staining. 
Thrombus neovascularisation was quantified by counting of CD31 positive 
channels. The percentage area of staining in all thrombus levels was assessed 
and the data represented as a mean percentage area or mean channel number. 
4.3.10 Western blotting 
Nuclear HIF1α and cytoplasmic PHD2 and PHD3 protein expression was 
determined by western blotting as described in Chapter 3.3.8. Nuclear HIF1α  
was detected using a rabbit anti-mouse antibody (NB100-479, Novus 
Biologicals, UK) at a concentration of 1µg/ml as previously reported79. Protein 
band intensity was quantified densitometrically using Image Lab software 
(Biorad, UK). Protein expression of cytoplasmic and nuclear extracts were 
normalised to αtubulin and Histone H3 respectively. 
4.3.11 Statistical analysis 
Kolmogorov-Smirnov tests were used to assess normality of data and 
parametric or non-parametric tests were used as appropriate. For data of 
mouse age, weight and parameters of thrombus resolution 2-way ANOVA was 
used. Chi-squared analysis was used to compare thrombus formation efficiency 
between knockouts and littermate controls. Densitometric values of PHD2, 
PHD3 and HIF1α protein expression on western blots were compared using 
Mann-Whitney U tests. In all cases P<0.05 was considered statistically 
significant. Statistical analyses were conducted using Prism Software (v5, 
Graphpad, USA). Parametric data represented as mean ± SE and non-
parametric data represented as individual data points with median. 
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4.4 Results 
4.4.1 Demographics of heterozygous Phd2 knockout mice 
Weight or age of heterozygous Phd2 knockouts was not significantly different 
from their wild-type littermate controls at the time of thrombus induction 
(P>0.05, 2-way ANOVA, Table 4.2, Fig 4.2). Neither was there any significant 
difference between the proportions of each sex analysed at each time interval 
analysed. The efficiency of thrombus formation was not significantly different in 
Phd2 knockout mice, 85% (21/25), when compared with wild-type littermate 




Figure 4.2 Demographics of heterozygous Phd2 knockout and control 
mice 
Measurements of mouse (A) weight (B) age and for PHD2+/+ and PHD2+/- at the 
time of thrombus induction. No significant difference was observed in baseline 
characteristics (ns= P>0.05, 1-way ANOVA, n=5-9 per group). Data 



















































4.4.2 Thrombus resolution in heterozygous Phd2 knockout mice 
Heterozygous deletion of Phd2 did not have a significant effect on measures of 
thrombus resolution. There was also no significant difference in thrombus 
resolution (thrombus volume or vein recanalisation) or measures of thrombus 
organisation (recanalisation, collagen or macrophage content) between PHD2+/- 
mice and PHD2+/+ littermate controls (1-way ANOVA, P>0.05, Table 4.3, Fig 4.3 
A-C). Data of individual replicates is provided in Appendix B1. 
 









Data represented as mean ± SE 
 
Table 4.3 The effect of heterozygous PHD2 on thrombus resolution 
Measure Day PHD2+/+ PHD2+/- 
Volume (mm3) 1 5.49 ± 0.7 5.92 ± 0.4 
 14 2.13 ± 0.4 2.64 ± 0.3 
 21 1.11 ± 0.2 0.58 ± 0.1 
Recanalisation (%) 1 7.94 ± 1.1 5.97 ± 1.1 
 14 24.0 ± 1.7 21.9 ± 1.2 
 21 28.5 ± 3.2 37.2 ± 4.8 
Neovascularisation  1 0.00 ± 0.0 0.00 ± 0.0  
(channels/level) 14 13.5 ± 0.8 8.59 ± 0.6 
 21 5.30 ± 0.9 7.27 ± 1.2 
Macrophage 1 0.00 ± 0.0 0.00 ± 0.0 
content (%) 14 7.89 ± 0.7 7.19 ± 0.7 
 21 10.0 ± 0.6 9.14 ± 0.0 
Collagen 1 0.55 ± 0.1 0.43 ± 0.1 
content (%) 14 15.7 ± 0.8 14.4 ± 0.9 
 21 33.5 ± 5.1 44.6 ± 4.3 
Data represented as mean ± SE 
 
 
Measure Day PHD2+/+ PHD2 +/- 
Weight (g) 1 20.7 ± 0.6 21.7 ± 1.7 
 14 25.1 ± 1.4 24.0 ± 0.9 
 21 23.9 ± 1.4 21.7 ± 0.9 
Age (weeks) 1 8.94 ± 0.8 8.71 ± 0.7 
 14 10.2 ± 0.5 11.3 ± 0.3 
  21 8.60 ± 0.7 8.33 ± 0.6 
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Figure 4.3 The effect of heterozygous Phd2 gene deletion on thrombus 
resolution 
(A) Representative haematoxylin and eosin stained micrographs of thrombi from 
PHD2+/+ and PHD2+/- at days 1, 14 and 21 post-induction taken at an original 
magnification of x50. Histological measurements of (B) thrombus volume and 
(C) vein lumen percentage recanalisation demonstrating no significant 
difference between knockout and respective littermate controls (ns=P>0.05, 2-













































































Figure 4.4 The effect of heterozygous Phd2 gene deletion on thrombus 
neovascularisation 
(A) Representative micrographs of CD31 positive neovascular channels in  
thrombi from PHD2+/+ and PHD2+/- at days 1, 14 and 21 post-induction taken at 
an original magnification of x400. (B) Histological measurement of the 
percentage area of the thrombus stained postively for Mac-2 (ns= P>0.05, 2-























































Figure 4.5 The effect of heterozygous Phd2 gene deletion on thrombus 
macrophage content 
(A) Representative Mac-2 stained micrographs of thrombi from PHD2+/+ and 
PHD2+/- at days 1, 14 and 21 post-induction taken at an original magnification of 
x50. (B) Histological measurement of the percentage area of the thrombus 
stained postively for Mac-2 (ns= P>0.05, 2way ANOVA, n=5-9 per group). Data 
























































Figure 4.6 The effect of Phd2 gene deletion on collagen deposition in the 
thrombus 
(A)  Representative picrosirius red staining of PHD2+/+ and PHD2+/- thrombi at 1, 
14 and 21days post-induction (mag x50). (B) Histological measurement of the 
percentage area of the thrombus stained postively for picrosirius red (ns= 
































4.4.3 Efficacy of Phd2 gene deletion 
Heterozygous Phd2 gene deletion resulted in lower protein levels of PHD2 and 
PHD3 compared with wild-type littermate controls, but this did not reach 
statistical significance (P>0.05 Mann-Whitney U test, Fig 4.7). Nuclear HIF1α 
protein levels in these samples were similar in PHD2+/- and littermate controls 











Figure 4.7 Immunoblot of cytoplasmic PHD2 and PHD3 in Phd2 
heterozygous knockout kidney 
(A) Representative immunoblot of PHD2 and PHD3 protein expression in kidney 
cytoplasmic extracts from PHD2 heterozygous (+/-) knockouts and wild-type 
(+/+) littermate controls. Densitometric analysis of (B) PHD2 and (C) PHD3 
protein expression normalised to αTubulin (ns= P>0.05, Mann-Whitney). Data 


































































Figure 4.8 Immunoblot of nuclear HIF1α in Phd2 heterozygous knockout 
kidney 
(A) Representative immunblot of HIF1α protein expression in kidney nuclear 
extracts from PHD2 heterozygous knockouts and wild-type littermate controls. 
(B) Densitometric analysis of HIF1α protein expression normalised to Histone 







































Heterozygous deletion of the Phd2 gene had no effect on any measure of 
thrombus resolution examined in this study that included; thrombus volume, 
vein recanalisation, thrombus neovascularisation, collagen and macrophage 
content. Measures of thrombus formation between wild-type and knockout were 
not signficantly different, suggesting that heterozygosity for Phd2 does no affect 
thrombus formation. In agreement with this finding thrombus volumes 24hrs 
post induction were comparable between wild-type and Phd2 heterozygous 
knockouts. 
 
It was hypothesised that under situations of increased HIF1α stabilisation, such 
as that predicted after heterozygous Phd2 gene deletion, increased 
neovascular channel formation and macrophage infiltration would be observed 
complementing previous observations in the thrombus after PHD inhibition57. 
The lack of significant difference in these markers of thrombus organisation is, 
however, consistent with previous findings in the same constitutive 
heterozygous knockout system where, during tumour development, 
vascularisation and leukocyte infiltration remained broadly unchanged160. 
Instead, heterozygous deletion of Phd2 was associated with increased tumour 
vessel normalisation as demonstrated by improved vessel maturation and 
reduced vessel leakage160. Additionally recruitment of macrophages to sites of 
tissue hypoxia, such as the ischaemic hindlimb, does not appear to be altered 
by heterozygosity for Phd2 instead resulting in skewing of this cell type towards 
an alternately activated phenotype164. These findings go some way to 
explaining the observed phenotypes with respect to venous thrombus 
resolution. 
 
Kidney samples were analysed by western blotting in order to examine the 
effect of heterozygous Phd2 gene deletion on PHD protein expression and 
HIF1α stabilisation as this technique was not sensitive enough to detect 
thrombus levels of PHDs. Despite marked reductions in the expression of PHD2 
and PHD3 in the cytoplasmic fraction of PHD2+/- kidney extracts, this difference 
was not significant. The lack of significance with this degree of difference and a 
small sample number could have been the result of a Type-II error.  This finding 
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is, however, similar to a study of tissue lysates from embryonic tissues, in which 
PHD2+/- mice were found to retain a large degree of PHD2 protein 
expression155.  The reduction in PHD3 expression, if genuine would be 
surprising as the Phd3 gene contains a promoter-resident HRE98. It would 
therefore be expected for Phd3 gene expression to be upregulated in response 
to HIF1α stabilisation270. 
 
Heterozygous deletion of Phd2 should have lead to increased nuclear 
accumulation of HIF1α.  However, in the present study HIF1α stablisation was 
not increased in nuclear extracts from the kidneys of PHD2+/- mice. Whilst 
surprising this is in keeping with the previous data that showed efficient HIF1α  
degredation in PHD2+/- embryonic hearts155. Together, these data suggest that, 
at the tissue level, remaining expression of PHD2 in heterozygous knockouts is 
capable of hydroxylating the HIF1α and preventing stabilisation. Post-
translational compensation in constitutive heterozygous gene deletents has 
been reported in the literature, occuring either as a result of reduced protein 
turnover or increased utilisation of the remaining mRNA271. It is possible that 
PHD1 and PHD3 expressed in the resolving venous thrombus may have 
compensated for the loss in PHD2 expression since both of these isozymes 
have been shown to hydroxylate HIF1α in vitro272. 
 
Quantification of protein expression by western blotting was associated with a 
large degree of variability. Kidney tissue samples were taken from the same 
region and were of equal mass for subsequent processing. Tissue samples 
were processed in batches containing equal numbers of knockout and control 
tissues to limit the potential of batch variability affecting protein extraction 
efficiency. One advantage of this immunoblotting approach, over alternative 
techniques such as ELISA, is that it allowed for normalisation of protein 
expression to house keeping genes, such as αTubulin and Histone H3.  
 
The majority of studies investigating venous thrombus resolution selectively use 
8-10 week old mice. This strategy is designed to avoid variability in thrombus 
induction that has, in part, been attributed to age. Age has been found to 
modulate thrombus formation with both propensity and speed of thrombosis 
increasing in models of accelerated aging273, 274. Mice over a broader age range 
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(7-12 weeks) were included in this study because of the limited supply of 
PHD2+/- mice. Relaxation of the study inclusion criteria could introduce 
additional biological variability into the experiment. In the present study mouse 
demographics were well controlled with no significant differences in either 
mouse age or mass at the time of thrombus induction. This suggests that 








































Chapter 5 The effect of inducible Phd2 gene 




No significant difference in thrombus resolution was observed after 
heterozygous gene deletion of Phd2 (Chapter 4). Only a modest loss in 
cytoplasmic PHD2 protein expression was observed in Phd2 heterozygous 
knockouts compared with wild type littermate controls and it is, therefore, 
possible that residual PHD2 protein expression may have been sufficient to limit 
the nuclear accumulation of HIF1α. It is not possible to study the effects of 
constitutive homozygous Phd2 gene deletion as this genotype demonstrates 
embryonic lethality that precludes studies in adulthood155. An inducible cre 
recombinase loxP based Phd2 knockout system has been developed allowing 
for deletion of PHD2 protein expression during adulthood169. 
 
The cre recombinase LoxP system, first identified as part of the replicative 
machinery of the P1 bactriophage, is a powerful tool for the manipulation of the 
murine genome275. The LoxP construct is a 34bp sequence containing an 8bp 
core flanked by two 13bp inverted repeats276. When LoxP constructs are 
inserted in the same orientation flanking a gene of interest this region can be 
excised upon expression of cre recombinase (Fig 5.1)275. Induction of cre 
recombinase expression can be controlled through use of tamoxifen inducible 
elements277. In addition gene deletion can be limited to selected tissues or cells 


















Figure 5.1 Schematic of LoxP cre mediated recombination 
LoxP sites flanking a gene of interest allows for excision on expression of cre 
recombinase. 
 
Initial observations of inducible all-cell homozygous Phd2 knockout mice 
revealed significantly increased serum EPO, erythrocyte count and 
haematocrit143, 169. These hemodynamic changes, consistent with polycythemia, 
are associated with reduced survival thought to be a result of venous 
obstruction and cardiac hypertrophy169. Deletion of Phd2 in CD68-expressing 
cells was also found to induce polycythemia with further evidence to suggest 
that this takes place in a HIF2α dependent manner170. 
 
Inducible gene deletion of Phd2 has been studied in a number of pathologies 
relevant to venous thrombus resolution. In an orthotopic model of cancer global 
Phd2 gene deletion increased markers of angiogenesis such as vessel 
coverage and perfusion, although not absolute vessel number269. These 
alterations in angiogenesis were not associated with changes in tumour volume 
in all-cell, endothelial, fibroblast or macrophage specific Phd2 gene 
knockouts269. In a model of hypertension-induced cardiac remodelling 
macrophage specific Phd2 gene deletion significantly reduced myocardial 
collagen gene expression and interstitial cardiomyocyte fibrosis278. 
 
5.2 Aim 
To investigate the effect of all-cell inducible Phd2 gene deletion on venous 




5.3.1 Breeding strategy 
Breeding was carried out in the Mazzone laboratory (Katholieke Universiteit 
Leuven, Belgium). Breeding pairs with the following genotypes were crossed; 
 
PHD2fl/fl; Rosa26creERT2+/- x  PHD2fl/+; Rosa26creERT2+/+ 
PHD2fl/fl; Rosa26creERT2+/+ x  PHD2fl/+; Rosa26creERT2+/- 
 
This enables generation of homozygous and heterozygous floxed PHD2 alleles 
in mice either with or without alleles for the conditional expression of cre 
recombinase. From these crossings the following genotypes were obtained with 
the following effective genotypes; 
 
Table 5.1 Actual and effective genotypes of conditional PHD2 knockouts 
Actual Effective 
PHD2fl/fl; Rosa26creERT2+/+ Wild-type 
PHD2fl/+; Rosa26creERT2+/+ Wild-type 
PHD2fl/+; Rosa26creERT2+/- Heterozygous 
PHD2fl/fl; Rosa26creERT2+/- Homozygous 
 
5.3.2 Genotyping 
DNA was extracted as described in Chapter 4.3.2. Tail snip DNA was 
genotyped for both cre recombinase and Phd2 floxed alleles. The following 
primers (Integrated DNA technologies, UK) were used. 
Table 5.2 Genotyping primers  
Primer Sequence 
CRE1 5’ cgccgtaaatcaatcgatgagttgcttc 3’ 
CRE2 5' gatgccggtgaacgtgcaaaacaggctc 3' 
PHD2CKO1 5’ ccttccatgttggctcattccatt 3’ 
PHD2CKO1 5' tgctga-attgagttgcataccttg 3' 
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Separate reactions were prepared for genotyping of cre recombinase and phd2 
floxed alleles. OneTaq DNA polymerase master mix (New England Biosystems, 
USA) was used according to the manufacturers instructions. A reaction mix was 
prepared for each gene of interest containing 12.5µl of master mix, 1µl of each 
primer (10µM), 1µl of template DNA and 7.5µl of DNAse free water. 
Amplification was performed in a thermocycler (PTC-100, Biorad, UK) under the 
following conditions: an initial 2mins at 94°C, 40 cycles of 30secs at 94°C, 
30secs at 62°C (Cre) or 53°C (Phd2), 30secs at 72°C with a final 10mins at 
72°C. PCR products were resolved as described in Chapter 4.3.2. 
 
5.3.3 Thrombus induction 
Tamoxifen was administered at a dose of 1mg/mouse/day as previously 
reported269 in mice 5 days before thrombus induction. This results in effective 
excision of Phd2 alleles in floxed cre recombinase positive mice with cre 
recombinase negative mice serving as controls for both the presence of floxed 
alleles and tamoxifen treatment. 
 
Mice received daily intraperitoneal injections of tamoxifen (1mg) for 5 days prior 
to induction of thrombosis. Thrombus was induced in 7-17 week old mice on a 
C57B/6 background with effective wild-type, heterozygous and homozygous 
genotypes. Mice received longitudinal 3D high frequency ultrasound scans of 














Figure 5.2 Study Design 
Mice received daily 1mg injections of tamoxifen for five days preceeding 
thrombus induction. Thrombus was imaged at days 1, 7 and 14 post-induction 
by 3D-HFUS and by histology at day 14 post-induction. 
 
5.3.4 3D High frequency ultrasound 
Thrombus was visualised by 3D high frequency ultrasound (3D-HFUS) of the 
abdomen using a 40MHz ultrasound probe connected to a Vevo2100 imaging 
unit (Visual Sonics, Canada, Figure 5.3). Anaesthesia was induced by 
inhalation of isofluorane (5%, 1.0 l/min O2) and maintained at 3.0-3.5% for the 
duration of the procedure. Hair was removed from the abdomen of the mouse 
by application of depilating cream. The mouse was secured to the imaging 
stage in the supine position and connected to the physiological monitoring unit 
to enable respiration gating during image acquisition. Ultrasound transmission 
gel was placed on the abdomen and the ultrasound probe secured to the 
stepper motor. The infra-renal IVC was located by traversal of the probe in the 
transverse orientation. A 12mm segment of the IVC, containing the thrombus, 
was imaged with data acquired at 108µm intervals at a maximum depth of 
8mm. Image stacks were exported as DICOM files to allow for analysis using 
Osirix software (v5.5). Thrombus was manually segmented from surrounding 
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tissue using the closed polygon tool and the segments reconstructed as a 3D 
volume render from which measurements of thrombus volume were obtained, 
representative images of the segmentation process are provided in Appendix 
C1. I would like to acknowledge Stéphanie De Vleeschauwer and Melissa 






Figure 5.3 3D High frequency ultrasound 
(A) The Vevo 2100 HFUS and (B) mounting of 3D stepper motor on integrated 








5.3.5 Tissue processing 
Tissues were harvested and processed as described in Chapter 4, Section 
4.3.4. 
5.3.6 Histology and immunohistochemistry 
Thrombus sections were stained with H&E, CD31, Mac-2 and picrosirius red at 
described in Chapter 4, Sections 4.3.5-4.3.9. 
5.3.7 Western blotting 
Kidney samples were blotted for PHD2, PHD3, αTubulin, HIF1α and Histone H3 
at detailed in Chapter 4, Section 4.3.10. 
5.3.8 Haematocrit measurements 
Blood was sampled by cardiac puncture, collected into graduated EDTA anti-
coagulated tubes (Greiner Bio-One, UK) and centrifuged for 10mins at 
10,0000xg. The total volume (TV) of blood collected and the mean corpuscular 
volume (MCV) were recorded and haematocrit reported as a percentage. 
5.3.9 VEGF ELISA 
The concentration of VEGF in murine plasma samples was quantified using a 
commercially available ELISA assay (Quantikine, R&D systems, USA) 
according to the manufacturers instructions. VEGF standard was serially diluted 
to provide a seven-point standard curve (500, 250,125, 52, 21, 16 and 8pg/ml) 
and calibrator diluent was used as a blank zero standard. Plasma samples were 
diluted 1 in 5 by addition of calibrator diluent. The microplate was prepared by 
addition of 50µl of assay diluent. Standards and samples were then added 
(50µl) in triplicate and incubated for 2hrs at room temperature. Samples were 
removed and wells washed 5 times by addition of 400µl of wash buffer using an 
automated washer (Multiwash III, TriContinent, USA). VEGF conjugate (100µl) 
was added to the wells and incubated for 2hrs at room temperature. Wash 
steps were repeated and 100µl of TMB peroxidase substrate solution added 
followed by a 30min incubation protected from light. Stop solution (100µl) was 
added and absorbance recorded at 450nm using a spectrophotometer 
(SpectraMax 340, Molecular Devices, USA). VEGF plasma concentrations were 




5.3.10 Statistical analysis 
Normality of data was assessed by Kolmogrov-Smirnov tests with parametric or 
non-parametric tests used as appropriate. Differences in thrombus volume and 
rate of resolution as determined by 3D-HFUS were interrogated by repeated-
measure 2-way ANOVA with post-hoc Bonferroni. Mouse demographics and 
histological measurements of thrombus volume were assessed by 1-way 
ANOVA with post-hoc Bonferroni. Measurements of protein expression (PHD 
and HIF1 α) and blood haematocrit were interrogated by Kruskal-Wallis with 
Dunn’s post-hoc tests. Measurements of plasma VEGF were analysed using a 
student’s t-test. In all cases P<0.05 was considered statistically significant. 
Statistical analyses were conducted using Prism Software (v5, Graphpad, 
USA). Parametric data represented as mean ± SE and non-parametric data 




5.4.1 Visualisation and quantification of thrombus resolution by 3D HFUS 
Thrombus was hyperechoic compared with blood (Fig 5.4). Segmentation of the 
thrombosed IVC at days 1, 7 and 14 post-induction enables reconstruction of 
3D renders from which estimates of thrombus volume can be made (Fig 5.5). A 
3D image stack of a representative day 1 thrombus visualised by 3D-HFUS is 






Figure 5.4 HFUS of the thrombosed IVC 
Transverse HFUS sections of the IVC in (A) sham-operated and (B) operated 
mice in which a hyperechoic thrombus (T) is present, scale bar represents 







Figure 5.5 3D HFUS and volumetric reconstruction of venous thrombi 
(A) Representative transverse HFUS slices of the intraluminal thrombus (white 
arrowhead) at days 1, 7 and 14 days post-induction, scale bar represents 
500µm. (B) Representative 3D volume renders of thrombus at 1, 7 and 14 days 





Mass or age of wild-type, heterozygous and homozygous inducible all-cell 
PHD2 knockout mice was not significantly different between groups (P>0.05, 1-
way ANOVA, Table 5.3, Fig 5.6).  
Table 5.3 Demographics of inducible Phd2 knockout mice  
Genotype +/+ (n=7) +/- (n=5) -/- (n=6) 
Mass (g) 22.3 ± 0.6 23.3 ± 1.1 25.4 ± 1.5 
Age (weeks) 10.9 ± 1.7 10.8 ± 1.8 13.1 ± 1.7 














Figure 5.6 Demographics of inducible Phd2 knockout mice 
Measurements of mouse (A) mass and (B) age in inducible Phd2 knockouts at 
the time of thrombus induction (n=5-7 per group). No significant difference was 
observed in baseline characteristics (ns= P>0.05, 1-way ANOVA), data 



































5.4.3 Thrombus resolution in Phd2 inducible knockout measured by 3D 
HFUS  
No significant difference between genotypes was observed in either thrombus 
volume (P>0.05, 2-way ANOVA, Table 5.4, Fig 5.7A/C) or the rate of thrombus 
resolution expressed as the percentage decrease in volume between days 1 
and day 7 or day 7 and day 14 (P>0.05, 2-way ANOVA, Table 5.5, Fig 5.7B). 




Table 5.4 The effect of inducible Phd2 gene deletion on thrombus volume 
Day Phd2 genotype Volume (mm3) 
1 +/+ 13.4 ± 0.8 
 +/- 13.3 ± 0.6 
 -/- 11.5 ± 1.0 
7 +/+ 6.50 ± 0.5 
 +/- 6.25 ± 0.5 
 -/- 6.23 ± 0.7 
14 +/+ 3.35 ± 0.5 
 +/- 3.47 ± 0.3 
 -/- 3.29 ± 0.2 
Data represented as mean ± SE 
 
Table 5.5 The effect of inducible Phd2 gene deletion on the rate of 
thrombus resolution 
Data represented as mean ± SE 
 
 
Time Period Phd2 genotype Percentage change (%) 
1-7 +/+ 50.1 ± 4.9 
 +/- 52.9 ± 3.5 
 -/- 45.7 ± 4.1 
7-14 +/+ 49.4 ± 5.2 
 +/- 43.6 ± 5.5 


















Figure 5.7 Thrombus resolution in inducible Phd2 knockouts 
(A) Representative transverse HFUS sections of thrombus at days 1, 7 and 14 
post-induction in wild-type (+/+), heterozygous (+/-) and homozygous (-/-) 
inducible Phd2 knockouts, white arrow indicates position of the thrombus and 
scale bars represent 500µm. Corresponding (B) longitudinal 3D-HFUS derived 
measurements of thrombus volume and (C) rate of thrombus resolution (n=5-7 
per group) were not significantly different between groups (ns= 2-way ANOVA, 



















































5.4.4 Thrombus resolution in Phd2 inducible knockout measured by 
histology   
Endpoint analysis of thrombus resolution was also investigated by histology at 
day 14 post-induction. No significant difference in thrombus volume, vein lumen 
recanalization neovascular channel formation, macrophage recruitment, or 
collagen deposition was observed between genotypes (P>0.05, 1-way ANOVA, 
Table 5.6, Fig 5.8-5.11). Data of individual replicates is provided in Appendix 
C3. 
 












Measure Genotype  Result   (mean ± SE) 
Volume (mm3) +/+ 0.67 ± 0.3 
 +/- 1.11 ± 0.4 
 -/- 0.71 ± 0.3 
Recanalisation (%) +/+ 40.3 ± 7.3 
 +/- 23.5 ± 2.8 
 -/- 33.2 ± 3.0 
Neovascularisation +/+ 8.36 ± 2.9 
(channels/level) +/- 12.9 ± 2.1 
 -/- 9.48 ± 1.3 
Macrophage content (%) +/+ 6.84 ± 1.4 
 +/- 6.69 ± 1.1 
 -/- 6.10 ± 1.6 
Collagen content (%) +/+ 21.4 ± 3.6 
 +/- 17.1 ± 1.7 






Figure 5.8 Histological analysis of the effect of inducible Phd2 gene 
deletion on thrombus volume and vein lumen recanalisation 
(A) Representative haematoxylin and eosin stained micrographs of thrombi from 
inducible Phd2 knockout mice with effective wild-type (+/+), heterozygous (+/-) 
and homozygous (-/-) genotypes, images taken at an original magnification of 
50x. Quantification of (B) thrombus volume and (C) vein lumen recanalisation 
(n=5-7 per group) demonstrating no significant difference between genotypes 

















































Figure 5.9 Histological analysis of the effect of inducible Phd2 gene 
deletion on endpoint thrombus neovascularisation 
(A) Representative CD31 stained micrographs of thrombi from inducible Phd2 
knockout mice with effective wild-type (+/+), heterozygous(+/-) and homozygous 
(-/-) genotypes (n=5-7 per group), images taken at an original magnification of 
400x. (B) Quantification of neovascular channels in which no significant 
difference between genotypes was observed (ns= P>0.05, 1-way ANOVA). 

































Figure 5.10 Histological analysis of the effect of inducible Phd2 gene 
deletion on endpoint thrombus macrophage content 
(A) Representative Mac-2 stained micrographs of thrombi from inducible Phd2 
knockout mice with effective wild-type (+/+), heterozygous(+/-) and homozygous 
(-/-) genotypes (n=5-7 per group), images taken at an original magnification of 
50x. (B) Quantification of thrombus macrophage content in which no significant 
difference between genotypes was observed (ns= P>0.05, 1-way ANOVA,). 




































Figure 5.11 Histological analysis of the effect of inducible Phd2 gene 
deletion on endpoint thrombus collagen content 
(A) Representative picrosirius red stained micrographs of thrombi from inducible 
Phd2 knockout mice with effective wild-type (+/+), heterozygous(+/-) and 
homozygous (-/-) genotypes (n=5-7 per group), images taken at an original 
magnification of 50x. (B) Quantification of thrombus collagen content in which 
no significant difference between genotypes was observed (ns= P>0.05, 1-way 





















5.4.5 Functional assessment of inducible PHD2 deletion  
Kidney samples were taken from all thrombosed mice for analysis of PHD2, 
PHD3 and HIF1α protein expression in wild-type, heterozygous and 
homozygous inducible Phd2 gene knockouts (Fig 5.12-5.13). Protein 
expression of PHD2 was significantly altered by inducible deletion of PHD2 
(P<0.05, Kruskal-Wallis,). Homozygous Phd2 gene deletion significantly 
lowered expression of PHD2 protein compared to littermate controls (P<0.05, 
Dunn’s post-hoc) but not in heterozygous knockouts. PHD3 protein expression 
was not significantly altered after inducible deletion of Phd2 (P>0.05, Kruskal-
Wallis). Nuclear accumulation of HIF1α was significantly altered after inducible 
Phd2 gene deletion (P<0.05, Kruskal-Wallis). Nuclear HIF1α was significantly 
increased in Phd2 homozygous knockouts compared to both wild-type and 
heterozygous knockouts (P<0.05, Dunn’s post-hoc). 
 
The effect of Phd2 gene deletion on haematocrit was also investigated. Blood 
haematocrit was significantly altered by inducible Phd2 gene deletion (P<0.001, 
Kruskal-Wallis, Fig 5.14). Haematocrit was significantly higher in homozygous 
PHD2 gene knockouts than wild-type or heterozygous Phd2 gene knockouts 
(P<0.05, Dunn’s post-hoc). The concentration of VEGF in plasma was not 
significantly altered in inducible homozygous Phd2 gene knockouts (63.1 ± 



























Figure 5.12 Immunoblot of kidney cytoplasmic PHD2 and PHD3 in 
inducible Phd2 gene knockout mice 
(A) Representative immunoblots of PHD2 and PHD3 protein expression in 
kidney cytoplasmic extracts from wild-type (+/+), heterozygous (+/-) and 
homozygous (-/-) inducible Phd2 gene knockouts. Densitometric analysis of (B) 
PHD2 and (C) PHD3 expression normalised to αTubulin (Kruskal-Wallis with 









































































Figure 5.13 Immunoblot of kidney nuclear HIF1α in inducible Phd2 gene 
knockout mice 
(A) Representative immunoblot of HIF1α protein expression in kidney nuclear 
extracts from wild-type (+/+), heterozygous (+/-) and homozygous (-/-) inducible 
Phd2 gene knockouts. (B) Densitometric analysis of HIF1α expression 
normalised to Histone H3 (Kruskal-Wallis with Dunn’s post-hoc, *P<0.05 -/- vs 









































Figure 5.14 The effect of inducible Phd2 gene deletion on haematocrit 
Haematocrit was significantly altered by inducible deletion of Phd2 (Kruskal-
Wallis, P<0.001). Haematocrit was significantly increased in homozygous Phd2 
knockouts (-/-) compared to wild-type (+/+) and heterozygous (+/-) Phd2 
knockouts (Dunn’s post-hoc, *P<0.05 -/- vs +/+ and +/-). Data represented as 










Figure 5.15 Effect of inducible Phd2 gene deletion on plasma VEGF  
Plasma VEGF levels were not significantly different in homozygous Phd2 gene 
knockouts (-/-, n=7) compared to wild-type (+/+, n=6) littermate controls (ns= 




































Homozygous inducible Phd2 deletion was effective in reducing expression of 
this isoform at the protein level compared to wild-type littermate controls. This 
was accompanied by a significant increase in the nuclear accumulation of 
HIF1α. A comparable study has also observed increases in HIF1α nuclear 
accumulation in inducible homozygous Phd2 knockouts; however, this effect 
was not quantified169. As with the constitutive Phd2 heterozygous knockouts no 
significant differences in PHD2 expression or HIF1α stabilisation were observed 
in respective inducible heterozygous Phd2 knockouts.  
 
Assessment of the efficacy of Phd2 gene deletion did not rely solely on western 
blot measurements of nuclear HIF1α accumulation. Previous observations have 
demonstrated a sustained increase in haematocrit after inducible homozygous 
deletion of Phd2169, 170. In the present study, complementary increases in 
haematocrit were observed in inducible homozygous Phd2 knockouts. This 
increase, measured 14 days after completion of tamoxifen treatment, is slightly 
greater in magnitude than previous reports169, 170.  
 
Inducible Phd2 gene deletion did not significantly alter thrombus resolution as 
determined by either 3D-HFUS or histology. Measurements of thrombus 
neovascularisation, macrophage content and collagen content were similarly 
unaffected. The lack of phenotype in inducible homozygous Phd2 knockouts 
indicates that PHD2 activity may be dispensable for venous thrombus 
resolution. This is in stark contrast to the regulation of erythropoiesis that 
appears to be strongly dependent on PHD2 activity. 
 
Homozygous deletion of Phd2, but not Phd1 or Phd3, has previously been 
found to enhance vessel density in a number of tissues at baseline, 
accompanied by markedly increased HIF1α stabilisation and VEGFA 
production145. Conversely, selective deletion of endothelial Hif1a in a murine 
model of cancer impaired pathological angiogenesis and reduced tumour 
growth279. Taken together these findings would suggest that PHD2 mediated 
HIF1α degradation serves as a critical negative regulator of angiogenesis. 
However, this is not uniformly supported by the literature as others have found 
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that deletion of Phd2, in a range of cell types including those of the endothelial 
and myeloid lineage, did not significantly alter the absolute quantity of vascular 
channels during tumour growth but instead selectively improved vessel 
normalisation160, 269. This later finding is consistent with a more limited 
contribution of PHD2 to angiogenesis in hypoxic tissues and might explain the 
lack of significant difference in neovascularisation in Phd2 deficient thrombi. 
 
Phd2 knockdown, specifically in tumours, has been shown to significantly 
increase infiltration of leukocytes, however, the exact cellular composition of this 
infiltrate has yet to be determined158. Consistent with involvement of the PHD-
HIF axis deletion of Hif1a and Hif2a resulted in corresponding reductions in 
leukocyte accumulation in inflamed tissues74, 262. In contrast, macrophages 
deficient in Phd2 after gene deletion, that stabilise significantly increased levels 
of HIF1α and HIF2α, demonstrate moderate reductions in their migratory 
capacity towards the chemokine MCP1278. These potentially opposing 
observations would appear to largely nullify one another in global Phd2 
knockouts where heterozygous deletion resulted in similar levels of 
macrophages in the ischaemic hindlimb164. Instead loss of Phd2 expression was 
associated with increased skewing of tissue resident macrophages towards an 
alternately activated (M2) phenotype164. The phenotypic shift of PHD2 deficient 
macrophages is complicated by observed increased expression of the M2 
marker CD206 in HIF1α deficient macrophages280. Further studies are required 
to determine the effect of Phd2 gene deletion on thrombus macrophage 
skewing.  
 
Thrombus resolution was quantified in a longitudinal manner using HFUS in the 
range of 40-60MHz, which facilitates high-resolution imaging of the mouse 
abdomen whilst maintaining adequate tissue penetration. HFUS has previously 
been used to image acute IVC thrombi in vivo with transverse and sagittal 
planes providing measures of thrombus cross-sectional area and length, 
however, this did not extend beyond the first few hours post-induction281. In the 
present study, the thrombosed IVC could readily be identified at acute time-
points as it was hyperechoic compared with the non-thrombosed vessel. 
Hyperechoicity of the thrombus appeared to increase with time, consistent with 
organisation of the thrombus. Integration of a motorised stage with HFUS 
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facilitates the generation of 3D volume renders of the thrombus282. This 3D-
HFUS protocol allowed for longitudinal assessment of thrombus volume that 
may provide a more representative measure of overall thrombus burden. One 
limitation of non-contrast HFUS is the relatively low levels of tissue contrast 
particularly at early time-points. This could be overcome by the use of 
transpulmonary microbubble contrast agents such as Sonovue283. In some 
instances segmentation of the thrombus was hampered by scar tissue at the 
site of the laparotomy that casts a shadow over regions of the IVC. This 
problem was largely negated by rotation of the probe (5-15%). 
 
It may be useful to consider instances in other pathologies where deletion of 
Phd2 was not associated with an altered phenotype. In a study of tumour 
biology global Phd2 deletion or cell-specific Phd2 deletion in macrophages, 
fibroblasts and endothelium did not significantly effect tumour development, 
despite significantly increasing nuclear stabilisation of both HIF1α and HIF2α269. 
This comparison is relevant as angiogenesis and macrophage recruitment are 
common processes shared by both tumour development and venous thrombus 
resolution. 
 
An important technical consideration in the design of the current study was the 
timing of gene deletion. Gene recombination was initiated prior to induction of 
thrombus by administration of tamoxifen (1mg/mouse/day) for 5 consecutive 
days, previously reported to be sufficient for excision of the Phd2 locus269. The 
deletion of Phd2 immediately prior to thrombus induction was aimed at limiting 
any potential effects of longer-term Phd2 gene deletion on thrombus formation. 
Long term deletion of Vegfr2 in the endothelium initiated 3 weeks prior to 
thrombus induction significantly affected acute measurements of thrombus 
volume that were likely to have confounded subsequent analysis of thrombus 
resolution54. A drawback to this approach is that residual PHD2 protein present 
in cells that constitute the thrombus may have persisted after thrombus 
induction. 
 
The initiation of Phd2 gene deletion prior to induction of thrombosis may have 
affected the efficiency of thrombus formation. As such measurements of 
thrombus formation efficiency were made. No significant differences between 
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wild-type (7/8, 88%), heterozygous (5/9, 56%) and homozygous (6/9, 67%) 
inducible Phd2 knockout mice were observed (chi-square test, P>0.05). 
However, a trend towards reduced thrombus formation efficiency was evident 
and the contribution of PHD2 towards thrombus initiation cannot be discounted. 
Measurements of thrombus volume at day 1 post-induction were comparable 
suggesting that any contribution of PHD2 affects thrombus formation in a binary 
fashion. This study was originally designed with group sizes of between eight 
and nine but due to the reduced efficiency of thrombus induction, group sizes 
fell to between five and seven. The power of this study was, therefore, markedly 





Chapter 6 The effect of pharmacological 





Neither constitutive heterozygous Phd2 knockouts (Chapter 4) nor inducible 
Phd2 homozygous knockouts (Chapter 5) significantly altered venous thrombus 
resolution. The lack of a phenotype suggests that thrombus resolution may 
occur in a PHD2 independent manner. Alternatively, it is possible that residual 
PHD2 protein in heterozygous knockouts or PHD3 expression in homozygous 
knockouts may compensate for loss of PHD2. A broader approach using 
inhibitors of PHD enzyme activity as considered suitable for investigating the 
contribution of these enzymes as a whole and largely negate compensatory 
mechanisms. 
 
PHD inhibition using the iron-chelating agent l-mimosine results in accelerated 
venous thrombus resolution, as assessed by reduced thrombus weight and 
volume57. L-mimosine was also found to enhance thrombus 
neovascualarisation and macrophage recruitment. These effects were 
accompanied by increased thrombus nuclear HIF1α accumulation and 
corresponding increases in protein expression of HIF1α target genes including 
Vegfa and its receptor Vegfr157. However, given the mode of action of l-
mimosine as an iron chelator, a number of PHD-HIF1α independent effects may 
also have contributed to the observed phenotype, for example l-mimosine 
reduces the secretion of mature collagen through inhibition of a number of iron 
dependent prolyl 4-hydroxylases230. L-mimosine has also be found to inhibit a 
number of other enzymes by chelation of zinc and copper284, 285. 
 
A number of novel small molecule PHD inhibitors with increased specificity have 
recently been developed. One such inhibitor, AKB-4924, is a potent inhibitor of 
PHD enzyme activity with an inhibitory concentration (IC50) of 14µM for 
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PHD2231. AKB-4924 is a four-substituted 3-hydroxy-2-oxo-1, 2-dihydropyridine 
derivative, with an iron-binding α-hydroxycarbonyl group similar to that present 
in l-mimosine. In vitro characterization has demonstrated the capacity of AKB-
4924 to stabilize HIF1α and induce expression of the HIF1α transcriptional 
target Vegfa286. Treatment of neutrophils and macrophages with AKB-4924 
significantly increases phagocytosis233. This may be of particular interest in the 














Figure 6.1 Structure of AKB-4924 and JNJ-42041935 
The structure of (A) AKB-4924 a four-substituted 3-hydroxy-2-oxo-1,2-
dihydropyridine derivative (Z = halogen substituted phenyl, R4 = linear alkyl salt) 














An alternative small molecule, JNJ-42041935, has also been developed and 
unlike either AKB-4924 or l-mimosine inhibits PHD enzyme activity through 
displacement of the rate-limiting co-substrate 2-oxoglutarate227. JNJ-42041935 
is a highly selective PHD inhibitor with a low IC50 of 0.1µM for PHD2 compared 
to FIH (IC50 100µM)227. JNJ-42041935 is a potent inducer of HIF transcriptional 
activity as assessed by HIF-luciferase reporter mice227.  Mice treated with 
100µmol/kg JNJ-42041935 demonstrated significantly increased circulating 
protein levels of the HIF target gene epo and an increased haematocrit227. Both 
of these agents have been described as pan-PHD inhibitors through their 
capacity to increase stabilisation of both HIF1α and HIF2α. However, AKB-4924 
may demonstrate a degree of selectivity towards PHD2 as it preferentially 
stabilises HIF1α231. Direct data of isoform specificity of AKB-4924 is not 
currently available, with analysis to date focussing on HIFα subunit stabilisation. 
To confirm whether AKB-4924 selectively inhibits a single isoform IC50 
measurements for PHD1-3 would be required.  
6.2 Aim 






6.3.1 Contrast enhanced micro-computed tomography 
To visualise thrombus resolution in a longitudinal manner a contrast enhanced 
microCT imaging protocol was developed. Mice were anaesthetised under 3% 
isoflurane at an oxygen flow rate of 0.5l/min. The tail was warmed under an 
infra-red lamp to facilitate contrast injection. Aurovist 15nm nanogold (nAu) 
contrast agent (Nanoprobes, USA, 200mg/ml nAu) was diluted with sterile PBS, 
pH7.4 to a concentration of 50mg/ml nAu. A 200µl bolus (10mg nAu) of contrast 
agent was administered by intravenous injection into the tail vein. Contrast was 
allowed to circulate for 5mins prior to scanning. 
 
A fusion PET/CT scanner (Mediso, Hungary and Bioscan, USA) was used for 
contrast-enhanced microCT. The mouse was first placed on the scanner bed in 
the prone position. A pressure transducer was secured to the animals back for 
intra-scan monitoring of respiration allowing for adjustment of anaesthesia. An 
initial scout view was generated from which an area of interest was marked 
extending from the diaphragm to the lower abdomen. The following scan 
parameters were used for this study. I would like to acknowledge Dr Kavitha 
Sunassee and Mr Sobath Premeratne for assistance in developing the microCT 
imaging protocol. 
 
Table 6.1 MicroCT scanner settings 
Parameter Value 
Zoom Maximum 
Projections        360 
Pitch 1 
Tube Voltage 45kVP 
Exposure Time 1000ms 
Binning 4 to 1 
Scan Length ~20mins 
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6.3.2 Drug treatment 
Experimental venous thrombi were induced in the inferior vena cava (IVC) of 8-
10 week old male BALB/C mice as described in Chapter 2.3.1. AKB-4924 
(Akebia Therapeutics, USA) was prepared at a concentration of 2mg/ml in 40% 
(v/v) aqueous 2-hydroxypropyl-beta cyclodextrin (Sigma, UK), 60% (v/v) 50mM 
citrate buffer pH5. Mice were randomised to receive either AKB-4924 at a dose 
of 5mg/kg or 10mg/kg, or vehicle control by daily subcutaneous injection 
starting 24hrs after thrombus induction (Fig 6.3). 
 
Thrombus was induced in a second cohort of mice to investigate a second 
inhibitor, JNJ-42041935 (Johnson and Johnson, USA). JNJ-42041935 was 
prepared in 20% (w/v) 2-hydroxypropyl-beta cyclodextrin at a concentration of 
3mg/ml. Mice were randomised to receive either JNJ-42041935 at a dose of 
100umol/kg or vehicle control by daily intraperitoneal injection starting 24hrs 






Figure 6.2 AKB-4924 study design 
Schematic representation of the experiment time-course and treatment groups 
 
Time (days) 0 1 
5mg/kg AKB-4924  
Contrast enhanced microCT angiography 
7 14 
10mg/kg  AKB-4924 
Vehicle control 
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6.3.3 Image reconstruction and analysis 
Scans were reconstructed using VivoQuant software (v1.22 Invicro, USA) giving 
a voxel size of 65µm and exported as a metaimage file. Reconstructed scans 
were segmented and analysed using ITKsnap software (v2.4, Open Source) in 
an observer-blinded manner287. Image contrast was adjusted linearly to provide 
optimal parameters for subsequent analysis. Thrombi were reconstructed in 3D 
using a semi-automatic volumetric bubble propagation system. Using the snake 
ROI tool a region of interest, containing the thrombus, was marked. Pre-
processing of the image was used to delineate thrombosed tissue inside the 
IVC restricting sphere-based propagation to the thrombus. A series of spheres 
were then placed along the length of the thrombus. Spheres were propagated 
with a balloon expansion force of 1.00 and a curvature term of 0.20. The 
propagated region was extended until the majority of the thrombus was 
included. Corrections to the segmentation were made using the free-hand tool. 
When the segmentation was complete a 3D rendered mesh of the thrombus 
was generated and data on thrombus volume recorded, representative images 
of the segmentation process are provided in Appendix D1. The microCT bed 
was removed manually for representative images using Image J software (NIH, 
USA). 
6.3.4 Reproducibility of contrast-enhanced microCT segmentation 
To assess the reproducibility of thrombus volume measurements made by 
segmentation of contrast-enhanced microCT scans measures of both intra and 
inter observer variability were made. A single observer segmented the same set 
of scans (n=18) separated by a 2-week interval and two independent observers 
segmented the same set of scans (n=18) in order to assess intra and inter 
observer variability. 
6.3.5 Tissue processing 
Tissues were harvested and processed as described in Chapter 4.3.4. 
6.3.6 Histology and immunohistochemistry 
Thrombus sections were stained with H&E, CD31, Mac-2 and picrosirius red at 
described in Chapter 4.3.5-4.3.9. For quantification of Mac-2 Nova Red 




6.3.7 Western blotting 
Kidney samples were blotted for PHD2, PHD3, αTubulin, HIF1α and Histone H3 
at detailed in Chapter 4.3.10. 
 
6.3.8 Haematocrit measurements 
Measurements of blood haematocrit were determined as described in Chapter 
5.3.8. 
 
6.3.9 VEGF ELISA 
Plasma VEGF concentration was determined using a murine VEGF ELISA as 
described in Chapter 5.3.9.  
 
6.3.10 Statistical analysis 
Normality of data was assessed by Kolmogrov-Smirnov tests with parametric or 
non-parametric tests used as appropriate. Reproducibility of contrast-enhanced 
microCT based measurements of thrombus volume were assessed by Bland-
Altman and intra-class correlation (ICC). Differences in thrombus volume and 
rate of resolution as determined by contrast-enhanced microCT were 
interrogated by repeated-measure 2-way ANOVA with post-hoc Bonferroni. 
Histological measurements of thrombus volume after treatment with AKB-4924 
and JNJ-42041935 were assessed by 1-way ANOVA with post-hoc Bonferroni 
and student’s t-test respectively. Measurements of protein expression (PHD and 
HIF1 α) and blood haematocrit were interrogated by Kruskal-Wallis with Dunn’s 
post-hoc and Mann-Whitney U respectively. Measurements of plasma VEGF 
were analysed using student’s t-tests. In all cases P<0.05 was considered 
statistically significant. Statistical analyses were conducted using Prism 
Software (v5, Graphpad, USA) or for ICC analyses SPSS statistics (v22, IBM, 
USA). Parametric data represented as mean ± SE and non-parametric data 





6.4.1 Imaging of venous thrombus by contrast-enhanced microCT  
Using this protocol thrombus can effectively be discriminated from surrounding 
tissue as a result of a filling defect in the IVC lumen that can be observed in 
sagittal, coronal and transverse planes (Fig 6.3). A 3D image stack of a 




Figure 6.3 Contrast enhanced microCT of venous thrombus 1 day post-
induction 
Representative contrast enhanced microCT slices and corresponding schematic 
images of a day 1 thrombus in (A/D) sagittal, (B/E) coronal and (C/F) transverse 
planes. Images annotated with the location of the site of stenosis (S), the aorta 




Contrast enhanced microCT scan at days 1, 7 and 14 (Fig 6.4A) post-induction 
were reconstructed and 3D volume renders generated to provide 
measurements of thrombus volume and a visual representation of thrombus 
burden (Fig 6.4B). Volume renders revealed considerable heterogeneity in 






Figure 6.4 Contrast enhanced microCT and 3D volumetric reconstruction 
(A) Representative transverse slices of thrombus at days 1, 7 and 14 post-
induction, scale bars represent 4mm. (B) Representative 3D volumetric 








6.4.2 MicroCT variabilty 
Regression analyses comparing measurements of thrombus volume between 
observations (intra-observer) and between observers (inter-observer) 
suggested that measurements of thrombus volume by contrast-enhanced 
microCT were reliable and reproducible (Fig 6.5). The strength of the 
relationship of both comparisons was quantified by ICC. Intra-observer 
(ICC=0.99, P<0.001) and inter-observer (ICC=0.91, P<0.001) measurements of 
thrombus volume by contrast enhanced microCT demonstrated strong positive 
correlations.  
 
Bland-Altman plots were used to visually assess agreement in intra-observer 
and inter-observer measurements of thrombus volume (Fig 6.6). For 
measurement of intra-observer variability the limits of agreement were narrow 
and the mean difference was low suggesting that these measurements were 
close to equivalence. For measurements of inter-observer variability as 
thrombus volume increased the difference between measurements also found 
increased. When combined with a relatively large mean difference of 2mm3 this 
suggests that one observer may over estimate volumes of larger thrombi 














































Figure 6.5 Comparison of contrast enhanced microCT measurements of 
thrombus volume by regression analysis 
Regression analysis of (A) intra-observer and (B) inter-observer comparisons of 
thrombus volume determined by contrast enhanced microCT at days 1, 7 and 
14 post-induction (n=6 per time-point).  
 







































































Figure 6.6 Comparison of contrast enhanced microCT measurements of 
thrombus volume by Bland-Altman 
(A) Intra-observer and (B) inter-observer Bland-Altman plots to compare 
measurements of thrombus volume determined by contrast-enhanced microCT 
at days 1, 7 and 14 post-induction (n=18). Red lines represent the mean 
difference and dotted lines represent 1.96 standard deviations from the mean. 
 































6.4.3 Effect of AKB-4924 treatment on venous thrombus resolution 
Thrombus volume as measured by contrast enhanced microCT was not 
significantly different in mice treated with the PHD inhibitor AKB-4924 at either 
5mg/kg or 10mg/kg when compared with vehicle treated control (P>0.05, 2-way 
ANOVA, Fig 6.7A/B and Table 6.2). When thrombus resolution was represented 
as the percentage change from thrombus volume measured at day 1 post-
induction, again no significant difference between treatments was observed 
(P>0.05, 2-way ANOVA, Fig 6.7C and Table 6.3). Data of individual replicates is 
provided in Appendix D3. 
 










Data represented as mean ± SE 
 
 
Table 6.3 The effect of AKB-4924 on the rate of thrombus resolution 
 
Time Period AKB-4924 (mg/kg) Percentage Change (%) 
1-7 0 0.89 ± 7.2 
 
5 4.83 ± 7.2 
 
10 8.24 ± 3.4 
7-14 0 45.9 ± 6.4 
 
5 53.2 ± 5.3 
 
10 59.3 ± 4.8 








1 0 13.7 ± 0.3 
 
5 12.2 ± 1.2 
 
10 13.9 ± 0.9 
7 0 13.4 ± 0.7 
 
5 11.3 ± 0.6 
 
10 12.7 ± 0.6 
14 0 7.38 ± 0.9 
 
5 5.59 ± 0.7 
 
























Figure 6.7 Measurement of thrombus volume by microCT after treatment 
with AKB-4924 
Thrombosed mice (n=6 per group) were treated with the PHD inhibitor AKB-
4924 at either 5mg/kg or 10mg/kg and compared to vehicle control. (A) 
Representative transverse slices of IVC thrombi imaged by microCT, scale bars 
represent 4mm (B) Thrombus volume as measured by segmentation of 
contrast-enhanced microCT. (C) The rate of thrombus resolution measured as 
the percentage reduction in thrombus volume over the preceding 7 days. Data 

























































Complementary thrombus volume measurements were obtained when 
measured histologically at 14 days post-induction. Treatment with AKB-4924 (5 
or 10mg/kg) had no significant effect on thrombus resolution determined by 
either thrombus volume (P>0.05, 1-way ANOVA) or vein recanalisation (P>0.05, 
1-way ANOVA, Table 6.4, Fig 6.8A-C). Only one marker of thrombus 
organisation, thrombus neovascularisation, was significantly enhanced after 
treatment with AKB-4924 (P<0.001, 1-way ANOVA, Table 6.4, Fig 6.9). Post-
hoc tests revealed that neovascularisation was significantly increased only after 
treatment with 10mg/kg AKB-4924 (P>0.05, post-hoc Bonferroni). Thrombus 
macrophage and collagen content were not significantly altered by AKB-4924 
(P>0.05, 1-way ANOVA, Table 6.4, Fig 6.10 and 6.11). Data of individual 
replicates is provided in Appendix D3. 
 
Table 6.4 Histological measurements of thrombus resolution after 
treatment with AKB-4924 
  
Measure AKB-4924  
(mg/kg)  
Result  
(mean ± SE) 
Volume (mm3) 0 2.58 ± 0.3  
 5 1.93 ± 0.3 
 10 1.82 ± 0.4 
Recanalisation (%) 0 11.0 ± 1.5 
 5 13.8 ± 1.6 
 10 10.8 ± 1.9 
Neovascularisation 0 4.84 ± 0.3 
(channels/level) 5 5.85 ± 0.6 
 10 9.16 ± 0.9 
Macrophage content (%) 0 10.7 ± 1.1 
 5 13.3 ± 1.2 
 10 15.7 ± 2.1 
Collagen content (%) 0 10.1 ± 1.0 
 5 12.7 ± 2.4 





















Figure 6.8 The effect of AKB-4924 on thrombus resolution  
(A) Representative H&E stained sections of thrombi after treatment with either 
5mg/kg or 10mg/kg AKB-4924 compared with vehicle control at day 14 post-
induction (n=6 per group). (B) There were no significant differences in either 
thrombus volume (P>0.05,1-way ANOVA,). or vein lumen recanalisation 
































































Figure 6.9 The effect of AKB-4924 on thrombus neovascularisation  
 (A) Representative CD31 stained sections of thrombi after treatment with the 
PHD inhibitor AKB-4924 at either 5mg/kg or 10mg/kg compared with vehicle 
treated control at 14 days post-induction (n=6 per group). Neovascular channels 
are stained black and denoted with black arrows, images taken at an original 
magnification of 400x. (B) Thrombus neovascularization was found to differ 
significantly between groups (P<0.05, 1-way ANOVA) specifically in mice 
treated with 10mg/kg AKB-4924  compared to venicle control (*P<0.05 post-hoc 
























































Figure 6.10 The effect of AKB-4924 on thrombus macrophage content  
 (A) Representative Mac-2 stained sections of thrombi after treatment with the 
PHD inhibitor AKB-4924 at either 5mg/kg or 10mg/kg compared to vehicle 
treated control at day 14 post-induction (n=6 per group). Macrophages are 
stained brown, images taken at an original magnification of 50x. (B) There was 
no significant effect of treatment on macrophage content (P>0.05 1-way 
















































Figure 6.11 Thrombus collagen content after treatment with AKB-4924 
(A) Representative picrosirius red stained sections of thrombi after treatment 
with the PHD inhibitor AKB-4924 at either 5mg/kg or 10mg/kg compared with 
vehicle treated control at day 14 post-induction (n=6 per group). Collagen is 
stained red, images taken at an original magnification of 50x. (B) There was no 
significant difference in collagen content across treatment groups (P>0.05, 1-



























To directly compare measurements of thrombus obtained by microCT and 
histology paired data samples from thrombi at 14 days post induction were 
analysed. Regression analysis of thrombus volume determined by both 
techniques suggested that these measurements might agree (Fig 6.12A). 
Analysis by intra-class correlation revealed a moderately strong correlation 
between the two measures (ICC=0.75, P<0.01). A Bland-Altman plot revealed 
that as volume increased the difference between the two measurements also 
increased (Fig 6.12B). The mean difference between measurements was also 
high (4.2mm3) suggesting that the absolute values were markedly different. 
Comparing both measures, histological thrombus volume (1.99 ± 0.22mm3) was 
found to be significantly lower than respective contrast-enhanced microCT 
values (6.2 ± 0.5mm3, P<0.0001, paired t-test). 
 
 
Figure 6.12 Comparison of paired measurements of thrombus volume 
Paired measurements of thrombus volume by contrast-enhanced microCT and 
histology were compared in thrombi at day 14 post-induction (n=18) by (A) 
linear regression and (B) Bland-Altman where the red lines represents the mean 












































6.4.4 Efficacy of PHD inhibition by AKB-4924 
The effect of PHD inhibition on PHD2 and PHD3 protein expression was 
assessed by western blotting of kidney cytoplasmic extracts obtained from 
animals treated with AKB-4924 (Fig 6.13A). Densitometric quantification 
revealed a slight but insignificant increase in PHD2 expression (P>0.05, 1-way 
ANOVA, Fig 6.13B) with PHD3 expression remaining largely invariant (P>0.05, 
1-way ANOVA, Fig 6.13C). Western blotting of kidney nuclear extracts for 
HIF1α (Fig 6.14A) revealed significant differences after treatment with AKB-
4924 (P<0.001, 1-way ANOVA, Fig 6.14B). HIF1α accumulation was 
significantly increased after treatment with 10mg/kg AKB-4924 compared with 




Figure 6.13 PHD protein expression after treatment with AKB-4924  
(A) Representative western blots of PHD2, PHD3 and αTubulin expression. 
Densitometric quantification of (B) PHD2 and (C) PHD3 in kidney cytoplasmic 
extracts after treatment with AKB-4924 (Kruskal-Wallis, ns P>0.05), data 
































































Figure 6.14 HIF1α protein expression after treatment with AKB-4924  
(A) Representative western blots of HIF1α and histone H3 protein expression 
and (B) densitometric quantification of HIF1α in kidney nuclear extracts after 
treatment with AKB-4924 (Kruskal-Wallis with post-hoc Dunn’s), data 
represented as individual points with median. *P<0.05 0mg/kg vs 10mg/kg and 



































6.4.5 Effect of JNJ-42041935 treatment on venous thrombus resolution 
The effect of a second PHD inhibitor, JNJ-42041935, on thrombus resolution 
was investigated. Histological assessment of thrombus volume and vein lumen 
recanalisation at day 14 post-induction revealed no significant affect of JNJ-
42041935 on thrombus resolution as compared to vehicle control (P>0.05, 
student’s t-test, Fig 6.15 and Table 6.5). Thrombus neovascularization was 
significantly upregulated after treatment with JNJ-42041935 as compared to 
vehicle control (P<0.01, student’s t-test, Fig 6.16). Thrombus collagen and 
macrophage content remained unchanged after treatment with JNJ-42041935 
as compared to vehicle control (P>0.05, student’s t-test, Fig 6.17 and 6.18). 
Data of individual replicates is provided in Appendix D3. 
 
Table 6.5 Histological measurements of thrombus resolution after 
treatment with JNJ-42041935 
Measure Vehicle (n=9) JNJ-42041935 (n=9) 
Volume (mm3) 2.79 ± 0.2 2.57 ± 0.1 
Recanalisation (%) 13.7 ± 1.1 14.3 ± 1.2 
Neovascularisation (channels/level) 7.32 ± 0.8 11.0 ± 0.5 
Macrophage content (%) 7.86 ± 0.4 9.03 ± 0.6 
Collagen content (%) 15.7 ± 0.9 15.7 ± 1.2 



































Figure 6.15 The effect of JNJ-42041935 on venous thrombus resolution 
(A) Representative H&E stained sections of thrombi after treatment with JNJ-
42041935 compared with vehicle control at day 14 post-induction (n=9 per 
group). (B) No significant difference in thrombus volume was observed (P>0.05, 
student’s t-test). (C) Vein lumen recanalisation was not significantly altered 



























































Figure 6.16 The effect of JNJ-42041935 on thrombus neovascularisation 
(A) Representative CD31 stained sections of thrombi after treatment with JNJ-
42041935 compared with vehicle control at day 14 post-induction (n=9 per 
group). (B) Neovascularization was significantly increased in JNJ-42041935 
treated thrombi when compared to vehicle control (P<0.01, student’s t-test), 























































Figure 6.17 The effect of JNJ-42041935 on thrombus macrophage content 
(A) Representative Mac-2 stained sections of thrombi after treatment with JNJ-
42041935 compared with vehicle control at day 14 post-induction (n=9 per 
group). (B) No significant difference in thrombus macrophage content was 














































Figure 6.18 The effect of JNJ-42041935 on thrombus collagen content 
(A) Representative picrosirius red stained sections of thrombi after treatment 
with JNJ-42041935 compared with vehicle control at day 14 post-induction (n=9 
per group). (B) No significant difference in thrombus collagen content was 



























6.4.6 Efficacy of PHD inhibition by JNJ-42041935 
Haematocrit was significantly increased by treatment with JNJ-42041935 as 












Figure 6.19 Effect of JNJ-42041935 on haematocrit 
Haematocrit was significantly increased after treatment with JNJ-42041935 
compared to vehicle control (P<0.01, Mann-Whitney), data represented as 



































6.4.7 Effect of PHD inhibition on circulating levels of VEGF 
The plasma concentration of VEGF was not significantly altered by 10mg/kg 
AKB-4924 (72.3 ± 6.5pg/ml) when compared to vehicle control (75.0 ± 4.0pg/ml, 
P>0.05, student’s t-test, Fig 6.20A). Similarly plasma VEGF concentrations 
were not significantly different in JNJ-42041935 treated mice (69.0 ± 3.1pg/ml) 





Figure 6.20 The effect of AKB-4924 and JNJ-42041935 on plasma VEGF 
Plasma VEGF levels were determined by ELISA after treatment with (A) 
10mg/kg AKB-4924 or (B) JNJ-42041935 and compared to respective vehicle 
controls. No significant difference in plasma VEGF was observed after 





































A pharmacological approach was used to assess the contribution of PHD 
enzymatic activity towards venous thrombus resolution. The PHD inhibitor, 
AKB-4924 was administered at a dose of 5mg/kg and 10mg/kg, corresponding 
respectively to the recommended and maximal tolerated dose in mice. 
Thrombus resolution was quantified by a novel application of contrast-enhanced 
microCT and confirmed by end-point histological analysis. 
 
There was a dose dependent trend towards increased thrombus resolution in 
mice treated with AKB-4924, although this did not reach statistical significance. 
The failure of this trend to reach the significance is probably the result of the 
relatively small differences between treatment groups (<25%). This experiment 
was powered to observe drug effects of greater than 30%, and therefore, in 
order for significance to be attained, group sizes would need to be increased. 
End-point measures of thrombus volume obtained by histological analysis were 
well matched with the microCT analyses. 
 
Histological analysis revealed the novel finding that stabilisation of HIF1α using 
AKB-4924 was associated with increased thrombus neovascularisation. This 
finding complements previous studies of increased thrombus neovascularisation 
after treatment with the PHD inhibitor L-mimosine57. The lack of an effect by 
AKB-4924 on thrombus resolution (in contrast to L-mimosine), in the face of 
increased nuclear HIF stabilisation, suggests that HIF driven neovascularisation 
alone is not a major driver of thrombus resolution. This is consistent with work in 
which treatment of experimental venous thrombi with basic fibroblast growth 
factor, a downstream target for HIF1α, increased neovascularisation without 
increasing thrombus resolution 58.  
 
Other measures of thrombus organisation including collagen deposition and 
macrophage accumulation again showed trends towards enhanced 
organisation, but did not reach statistical significance. This is surprising given 
that HIF1α plays an important role in collagen deposition during embryological 
development288, and a number of collagen modifying genes including P4ha1, 
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P4ha2 and Plod2 are HIF1α transcriptional targets289. It was hypothesised that 
PHD inhibition would promote recruitment of macrophages to the resolving 
venous thrombus given that both HIF1α and HIF2α are critical for migration74, 
262. It is possible instead that PHD inhibition fine-tunes macrophage activation 
and skewing as has been previously reported164. 
 
Direct measurements of HIF1α nuclear accumulation were made in order to 
assess the efficacy of AKB-4924. This is in contrast to the majority of other 
studies using AKB-4924 that have relied on in vitro measurements of HIF1α or 
in vivo measurements of downstream HIF1α target genes231, 233, 234, 290. Mice 
treated with 10mg/kg of AKB-4924 showed significantly increased nuclear 
accumulation of HIF1α in kidney tissue. This demonstrates that AKB-4924 is an 
effective PHD inhibitor in vivo. It was also interesting to note the variable protein 
expression of histone H3 in western blots of kidney nuclear extracts, observed 
in previous experiments (Chapter 4 and Chapter 5). Studies of HIF1α target 
genes have not identified histone H3 nor was it possible to find any evidence in 
the literature to suggests that hypoxia induced expression of histone H3. It 
would appear more likely that variation in histone H3 protein expression occurs 
as a result of the tissue extraction protocol, although further experiments would 
be required to confirm this. Given the need for significant normalisation of these 
samples this precluded the use of potentially more sensitive HIF1α ELISA. 
 
JNJ-42041935 
A potential limitation of the experiments conducted with AKB-4924 was the 
relative small group sizes used. The study was initially powered to observe a 
30% change in thrombus volume by histology with an alpha of 0.05 which 
required a samples size of six per group. Changes in thrombus volume after 
treatment with AKB-4924 were less than 30% meaning that this study was not 
sufficiently powered for the scale of change observed. It was not possible to 
increase group sizes with AKB-4924 because of the limited supply of this drug. 
To address this limitation thrombus resolution was studied after treatment with a 
second PHD inhibitor JNJ-42041935 with a group size of nine per treatment. 
 
Treatment with JNJ-42041935 resulted in an increase in HIF1α transcriptional 
activity, as determined by significant increases in haematocrit similar in scale to 
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those previously described for this compound227. As with the other HIF 
stabilising agent, AKB-4924, thrombus resolution was not significantly altered 
after treatment with JNJ-42041935. Measures of thrombus collagen and 
macrophage content were similarly unchanged after treatment with this agent. 
However, treatment with JNJ-42041935 significantly enhanced thrombus 
neovascularisation (~50% increase), which is a novel finding with this agent that 
has been characterised with respect to its proerythropoietic activity227, but not 
angiogenic potential. 
 
The two PHD inhibitors, AKB-4924 and JNJ-42041935, demonstrate strong 
phenotypic agreement in terms of their effect on thrombus, resolution and 
organisation, suggesting that the major contribution of PHD enzyme inhibition to 
thrombus resolution is the formation of neovascular channels. The use of two 
inhibitors with differing modes of action and therefore non-overlapping off-target 
effects, AKB-4924 an iron chelator and JNJ-42041935 a 2-OG mimetic, further 
strengthens this finding227, 231. 
 
Contrast-enhanced microCT 
Advances in CT imaging technologies have enabled the development of high-
resolution microCT imaging platforms suitable for pre-clinical use291. MicroCT 
was selected as it provides improved spatial resolution (22-65µm) compared to 
3D-HFUS. It also benefits from greater technical simplicity, only requiring the 
relevant region of interest to be selected. Imaging of the vasculature by contrast 
enhanced microCT requires administration of blood-pool contrast agents292. 
Contrast-enhanced microCT has been used extensively in murine models of 
cardiovascular disease such as critical limb ischaemia, abdominal aortic 
aneurysms and myocardial infarction164, 293, 294.Contrast-enhanced microCT of 
experimental venous thrombi has been reported in the literature, but this has 
been limited to demonstrating the presence of thrombus or for co-registration 
with other imaging modalities254, 295.  
 
In the current study Aurovist, a nanogold based contrast agent, was selected as 
this offered superior x-ray attenuation, good retention in the vascular 
compartment and low toxicity compared with other ionidated or microparticle 
based agents296. Previous studies using Aurovist have provided excellent 
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vascular contrast when administered at a dose of 20mg nAu per mouse. Given 
the high cost of this agent a lower dose of Aurovist, that still provided sufficient 
contrast to allow for segmentation of the thrombus, was desirable. Aurovist 
administered at a dose of 10mg of Au, half that of previous studies, was 
sufficient to visualise thrombus present in the IVC.  
 
Contrast-enhanced microCT of thrombosed mice at 1, 7 and 14 days post-
induction was well tolerated with no adverse events observed. Sufficient 
vascular contrast was obtained to allow for segmentation of the thrombus at 
every time-point studied. Others have reported difficulties in repeated 
administration of Aurovist as a result of tissue leakage at the site of injection297. 
This was avoided in our study by utilisation of distal segments of the caudal 
vein, allowing subsequent injections to be located in increasingly proximal 
segments. Injection may have also been aided by the use of a smaller dose of 
contrast agent. 
 
To quantify thrombus volume, a method of image segmentation and 3D volume 
reconstruction was required. Using semi-automated propagation-based 
segmentation software it was possible to generate detailed 3D volume renders 
of the thrombus from which measurements of volume could be obtained. As the 
majority of scan segmentations required a degree of manual refinement, it was 
important to ensure that this component of the analysis was both reliable and 
reproducible. Encouragingly measures of both inter- and intra observer 
variability showed strong positive correlations. 
 
Paired analysis of thrombus volume determined by contrast-enhanced microCT 
and histology revealed a relatively strong correlation. This correlation could be 
further strengthened by the addition of further time-matched samples as the 
range of volume measured was relatively narrow. It was also interesting to note 
the large degree of bias (~4mm3) between measurements, suggesting that 
volumes determined by histology were markedly lower than those by contrast-
enhanced microCT. This can be explained by the effects of shrinkage observed 
during processing of tissues for paraffin embedding298. 
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Chapter 7 The effect of inhibition of vascular 
endothelial growth factor receptors 
(VEGFRs) on venous thrombus resolution 
 
7.1 Introduction 
Tissue hypoxia, like that present in the early venous thrombus57, is considered 
a key regulator of angiogenesis in a range of human pathologies including 
myocardial infarction and cancer299, 300. Hypoxia-induced angiogenesis is 
mediated by the expression of a number of HIF1α target genes including Vegfa, 
Plgf and Vegfr1301-303. VEGFA treated endothelial cells demonstrate enhanced 
migration and proliferation in vitro 304, 305. In vivo vessel formation appears to be 
highly sensitive to gradients of VEGFA that coordinate the migration of 
specialised tip cells and proliferation of stalk cells306. 
 
Angiogenesis and the development of neovascular channels during thrombus 
organisation is thought to be an important process in the resolution of venous 
thrombi. There is a distinct, temporal pattern of VEGFA expression within the 
thrombus48. Increasing the levels of VEGFA in the resolving thrombus, either 
through direct injection of recombinant protein, or gene-mediated (plasmid or 
adenoviral) overexpression, significantly enhances resolution. This is 
associated with increased lumen recanalisation and macrophage recruitment49-
51. 
 
VEGFA must bind to and activate cognate VEGF receptors (VEGFRs) present 
on the surface of a wide range of cell types, in order to promote 
angiogenesis307. The VEGFR family consists of three members (VEGFR1, 
VEGFR2 and VEGFR3) that bind to a variety of ligands (Fig 7.1). On ligand 
binding VEGFRs undergo auto-phosphorylation of tyrosine residues mediated 
by receptor tyrosine kinase domains present in cytoplasmic tail307. VEGFR auto-
phosphorylation triggers downstream signal transduction through activation of 




Figure 7.1 VEGFR signalling 
VEGFR ligands including VEGFA, VEGFB, VEGFC, VEGFD and PLGF bind to 
a series of VEGFR present as either hetero- or homo- dimers at the cell 
surface. Adapted from307. 
 
The VEGF family of heparin binding glycoproteins also includes a number of 
related factors produced by separate genes that include VEGFB, VEGFC, 
VEGFD and PlGF. Whereas VEGFA, VEGFB and PlGF are important 
promoters of angiogenesis308-310, VEGFC and VEGFD serve as critical 
regulators of lymphatic development311, 312. A large number of VEGFA splice 
variants have been identified; VEGFA 165, 189, 121, 206, 183, 145 and 111 (in 
reference to amino acid length)313. These splice variants vary in their capacity to 
bind to heparin and the extracellular matrix. Similar variants have also been 
described for VEGFB and PlGF314, 315. Comparatively recently an additional 
cohort of VEGFA splice variants has been identified (VEGFA 165b, 189b, 121b) 
with greatly reduced angiogenic activity313. 
 
Targeting of VEGF signalling through cognate VEGFRs has proven an effective 
strategy for the treatment of a range of cancers316. Drugs have been developed 
that target either the VEGF ligand, such as the monoclonal blocking antibody 


























that have been characterized 
as receptors for semaphorins in 
neuronal guidance and as 
co-receptors for VEGFs in 
angiogenesis.
Oedema
Abnormal and excessive 
accumulation of fluid in the 
tissue, which might be localized 
or generalised.
Structure and expression of VEGFs. Structurally, the 
VEGFs are related to the PDGF family of growth factors, 
with intrachain and interchain disulfide bonds between 
eight cysteine residues in conserved positions. The cry s-
tal structure of VEGFA revealed two monomers that are 
organized in an anti-parallel fashion to form a dimer, 
with the receptor-binding sites located at each pole of 
the dimer3. The VEGFs preferentially form homodimers, 
although VEGFA and PLGF heterodimers have been 
identified4 (FIG.1a).
Alternative splicing of several of the VEGF family 
members gives rise to isoforms with different biological 
activities. The human isoforms are denoted VEGFA121, 
VEGFA145, VEGFA165, VEGFA189 and VEGFA206 
(see Supplementary information S1 (figure)). The 
mouse isoforms are one amino-acid residue shorter 
than the corresponding human isoform, and they are 
denoted VEGFA120 and so forth. The activities of the 
VEGFA isoforms are dictated by their different abilities 
to interact with VEGFR co-receptors, such as neuropi-
lins and HSPGs (FIG. 1b,c). Another splice variant of 
VEGFA, known as VEGF165b, has been proposed to 
negatively regulate VEGFR activity5.
The bioactivity of VEGF family members is also 
regulated by proteolytic processing. This mechanism 
might enable specific interactions with different 
types of receptor. For example, in humans, processed 
VEGFC and D bind to VEGFR2, as well as to VEGFR3. 
Furthermore, proteolytic processing of VEGFA splice 
variants affects their ability to interact with the VEGF 
co-receptors HSPGs and neuropilins6.
Structure of VEGFRs. The VEGFRs are members 
of the RTK superfamily and they belong to the same 
subclass as receptors for PDGFs and fibroblast growth 
factors (FGFs). The VEGFRs are equipped with an 
approximately 750-amino-acid-residue extracellular 
domain, which is organized into seven immunoglobulin 
(Ig)-like folds. In VEGFR3, the fifth Ig domain is 
replaced by a disulfide bridge. The extracellular domain 
is followed by a single transmembrane region, a juxta-
membrane domain, a split tyrosine-kinase domain that 
is interrupted by a 70-amino-acid kinase insert, and a 
C-terminal tail (FIG. 2). Structural and functional studies 
have yielded insights into how the distinct domains 
contribute to VEGFR activity. The crystal structure of 
part of the extracellular domain of VEGFR1, alone and 
in complex with ligand, shows that the Ig domain-2 
constitutes the ligand-binding site on the receptor7. 
In addition, biochemical analyses showed that the 
Ig domain-3 in VEGFR2 is important for the determin-
ation of ligand-binding specificity8. Alternative splicing 
or proteolytic processing of VEGFRs give rise to secreted 
variants of VEGFR1 (REF. 9) and VEGFR2 (REF. 10), and in 
humans, to a C-terminal truncated VEGFR3 (REF. 11).
Although the VEGFRs are primarily expressed in the 
vascular system, more sensitive methodologies com-
bined with improved reagent quality have allowed the 
detection of VEGFR expression in non-endothelial cells 
(see Supplementary information S2 (table)). However, 
genetic models (TABLE 1) imply that the most important 
function of VEGF/VEGFRs is in the vascular system.
Regulation of VEGFR activity
The activity of RTKs is regulated by the availability of 
ligands. A particular feature of the VEGFA ligand is the 
dramatic upregulation of its expression levels under 
hypoxic conditions. Hypoxia allows the stabilization 
of hypoxia-inducible factors (HIFs) that bind to specific 
promoter elements that are present in the promoter 
region of VEGFA12. Similarly, expression of VEGFR1 
is directly regulated by HIFs13. VEGFR2 is also upregu-
lated during hypoxia, but the role of different HIFs 
in this regulation remains to be clarified. VEGFR3 
expression is upregulated in differentiating embryonic 
stem cells that are cultured in a hypoxic atmosphere14. 
However, the contribution of hypoxia to regulation of 
VEGFR3 expression in vivo is still unclear.
Figure 1 | VEGF receptor-binding properties and signalling complexes. 
a | Mammalian vascular endothelial growth factors (VEGFs) bind to the three VEGF 
recep or (VEGFR) tyrosine kinases, leading to the formation of VEGFR homodimers and
heterodimers. Proteolytic processing of VEGFC and D allows for binding to VEGFR2. 
b | VEGFR signalling is modulated by different co-receptors. VEGFs as well as VEGFRs 
bind  co-receptors such as heparan sulphate proteoglycans (HSPGs) nd neur pilins. 
These interactions can influence VEGFR-mediated responses, for example, affecting 
the half-life of the receptor complex. c | Mechanosensory complex formation. Blood 
flow might activate VEGFRs in a ligand-ind pendent manner, by the formation of 
mechanosensory complexes that consist of platelet-endothelial-cell adhesion 
molecule-1 (PECAM1), vascular endothelial (VE)–cadherin, VEGFRs and integrins. 
PLGF, placenta growth factor.
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sunitinib140, 186. Axitinib is a novel small molecule VEGFR inhibitor currently in 
phase I to III trials for multiple tumour types and approved for the treatment of 
metastatic renal cell carcinoma (Fig 7.2)317, 318.  
 
 
Figure 7.2 Axitinib structure 
The molecular structure of the small 




Axitinib inhibits angiogenesis by blocking ligand-induced VEGFR 
phosphorylation, significantly reducing tumour vascularisation in a number of 
murine disease models319-321. The anti-angiogenic effects of axitinib are likely to 
the result of dysregulation of numerous VEGF mediated pathways within the 
endothelium as treatment results in increased vascular permeability319, 
decreased tubule formation and decreased endothelial cell survival322. 
Pharmacokinetic studies show that axitinib is a pan-VEGFR inhibitor with IC50 
values in the range of 0.1-0.3 nmol/L and active against both human and 
murine VEGFR protein322. 
 
Given that a number of VEGF-VEGFR proteins are HIF1α transcriptional targets 
it is important to understand to what extent signalling through this pathway 
contributes to venous thrombus neovasculariastion and resolution. Unlike 
previous studies upregulating VEGF49-51 the use of a VEGFR antagonist allows 




To investigate the effect of VEGFR inhibition on venous thrombus resolution 




7.3.1 Thrombus induction and axitinib treatment 
Thrombi were induced in the inferior vena cava of 8-10 week old male BALB/c 
mice as described in Chapter 2.3.1. Axitinib (25mg/kg) or vehicle control was 
administered by intra-peritoneal injection twice daily (B.I.D). This dose and 
treatment schedule is commonly used in the literature and effective in inhibiting 
VEGFR activation319-321. Axitinib was prepared in 30% (v/v) polyethelene glycol 
400 (Sigma, UK) 70% (v/v) acidified water. Thrombi were harvested at days 3, 





Figure 7.3 Study Design 
Thrombus was induced in 8-10 week old male Balb/c mice. Mice were 
administered 25mg/kg axitinib or vehicle control twice daily by intraperitoneal 
injection started 24hrs post-induction. Thrombi were harvested at days 2, 10 
and 17days post-induction for analysis. 
 
7.3.2 Thrombus processing  
Thrombus tissue samples were processed as described in Chapter 4.3.5 
Thrombus  
Induction 
0 1 3 10 17 
25mg/kg Axitinib B.I.D  
Thrombus harvest and analysis 
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7.3.3 Thrombus immunohistochemistry 
Thrombus sections were stained with H&E, CD31, Mac-2 and picrosirius red 
and analysed as described in Chapter 4.3.6-4.3.9 
 
7.3.4 Statistical analysis 
Kolmogorov-Smirnov tests were used to assess normality of data and 
parametric or non-parametric tests were used as appropriate. The effect of 
axitinib treatment on thrombus resolution was assessed by 2-way ANOVA with 
post-hoc Bonferroni. In all cases P<0.05 was considered statistically significant. 
Statistical analyses were conducted using Prism Software (v5, Graphpad, 





Axitinib treatment resulted in impaired thrombus resolution shown by a greater 
thrombus size and reduced vein recanalisation compared with vehicle treated 
control (P<0.002, and P<0.001 respectively, 2-way ANOVA, Fig 7.4 and Table 
7.1). Thrombus volume was temporally increased at day 10 after treatment with 
axitinib while recanalization was increased at day 17 (P<0.01, post-hoc 
Bonferroni). Thrombus organisation was also significantly impaired after 
treatment as shown by reduced thrombus neovascularisation (P<0.0001, 2-way 
ANOVA, Fig 7.5), macrophage content (P<0.0001, 2-way ANOVA, Fig 7.6) and 
reduced fibrillar collagen content (P<0.0001, 2-way ANOVA, Fig 7.7) compared 
with vehicle control.  These markers were impaired at both days 10 and 17 after 
axitinib treatment (P<0.05, post-hoc Bonferroni). Data of individual replicates is 
provided in Appendix E1. 
 
Table 7.1 Thrombus volume, recanalisation and neovascularisation  
Measure Day Vehicle Axitinib 
Volume (mm3) 3 5.81 ± 0.3 6.38 ± 0.4 
 10 2.40 ± 0.2 4.10 ± 0.5 
 17 1.71 ± 0.3 2.47 ± 0.3 
Recanalisation (%) 3 6.59 ± 1.2 5.46 ± 1.3 
 10 10.2 ± 1.5 4.87 ± 1.2 
 17 19.0 ± 1.6 11.5 ± 2.0 
Data represented as mean ± SE 
Table 7.2 Thrombus macrophage and collagen content 
Measure Day Vehicle Axitinib 
Neovascularisation  3 0.33 ± 0.0 0.17 ± 0.0 
(channels/level) 10 2.86 ± 0.3 2.00 ± 0.3 
 17 5.29 ± 0.3 2.29 ± 0.3 
Collagen 3 1.41 ± 0.1 1.30 ± 0.1 
content (%) 10 4.46 ± 0.4 1.09 ± 0.1 
 17 19.5 ± 1.6 11.6 ± 1.3 
 
 
Macrophage 3 0.06 ± 0.0 0.05 ± 0.0 
content (%) 10 6.89 ± 0.3 2.91 ± 0.4 
 17 8.51 ± 0.7 5.23 ± 0.4 















Figure 7.4 Thrombus volume and vein lumen recanalisation after axitinib 
treatment 
(A) Representative H&E sections of thrombi at days 3, 10 and 17 post-induction 
treated with either axitinib or vehicle control (n=6-8 per group), images taken at 
an original magnification of x50. (B) Thrombus volume was significantly greater 
by axitinib treatment (2-way ANOVA). (C) Vein recanalisation expressed as a 
percentage of lumen area was significantly reduced (2-way ANOVA). Data 
























































Figure 7.5 Thrombus neovascularisation after axitinib treatment 
(A) Representative micrographs of CD31 positive channels at days 3, 10 and 17 
post-induction treated with axitinib or vehicle control, images taken at an original 
magnification of x400. (B) The mean number of CD31 positive channels per 
level was significantly reduced after axitinib treatment (2-way ANOVA). Data 
represents mean ± SE, n=6-8 per group. **P<0.05, ***P<0.001 Bonferroni post-












































Figure 7.6 Quantification of thrombus macrophage content after axitinib 
treatment 
(A) Representative Mac-2 stained micrographs of thrombi at days 3, 10 and 17 
post-induction treated with axitinib or vehicle control. (B) Macrophage content 
was significantly reduced in the thrombus of mice treated with axitinib compared 
with control (2-way ANOVA). Data represents mean ± SE, n=6-8 per group. 















































Figure 7.7 Quantification of thrombus collagen content after axitinib 
treatment 
(A) Representative picrosirius red stained micrographs of thrombi at days 3, 10 
and 17 post-induction treated with axitinib or vehicle control, images taken at an 
original magnification of x50. (B) Collagen content was significantly reduced in 
the thrombus of mice treated with axitinib compared with control (2-way 
ANOVA). Data represents mean ± SE, n=6-8 per group. *P<0.05 vs. control. 






























In this study, axitinib treatment significantly impaired thrombus resolution as 
assessed by measurements of thrombus volume and vein lumen 
recanalisation82. In axitinib treated mice thrombus burden remained high for an 
extended period of time. Thrombi were significantly (~60%) larger at day 10 in 
the axitinib treatment group when compared to vehicle control. However, at day 
17 no significant difference was observed despite axitinib treated thrombi 
remaining ~40% larger than respective controls. The increased proportional 
variability at the later time-point may have contributed to the lack of significance. 
It is also likely that venous thrombus resolution is mediated, in parallel, by a 
series of VEGFR independent mechanisms such as endogenous uPA mediated 
thrombolysis that enables a degree of phenotypic catch up32.  Alternatively, 
mice treated with axitinib for a prolonged period may have acquired a degree of 
drug resistance. Acquired drug resistance has been observed in cancer cell 
lines treated with either axitinib or sunitinib, however, this phenomenon has not 
been described in non-cancer derived cell lines323. 
 
The impairment of vein recanalisation observed after axitinib treatment is most 
likely a result of the increased thrombus volume in this group. Alternatively, it is 
possible that axitinib acts on the thrombosed vessel affecting either tone or 
pathological vein wall remodelling. Anti-angiogenic agents such as axitinib are 
thought to be vaso-active because of the high incidence of hypertension in 
patients treated with these drugs324. This is further supported by evidence that 
bevacizumab, targeting the same VEGF-VEGFR signalling pathway, 
significantly reduces endothelial-dependent vasodilatation in man325. 
 
To investigate whether axitinib treatment affected thrombus organisation, 
neovascularisation, collagen content and macrophage content were quantified. 
Axitinib treatment resulted in a sustained impairment in thrombus 
neovascularisation consistent with the role of axitinib as a potent inhibitor of 
tumour microvasculature development319-321. Sensing of VEGFA gradients by 
primarily VEGFR2 present on the surface of endothelial cells is critical to the 
formation of neovessels306. VEGFC is also an important promoter of 
angiogenesis, stimulating endothelial cell migration and proliferation in a 
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VEGFR2 and VEGFR3 dependent manner326. Inhibition of VEGFR2 and 
VEGFR3 signalling using monoclonal antibodies has been shown to reduce 
vascular network development and endothelial sprouting during 
embryogenesis306, 327.  
 
Axitinib also significantly reduce thrombus macrophage content. Macrophage 
accumulation is a hallmark of venous thrombus resolution25, 328. Inhibition of 
macrophage accumulation within the thrombus through deletion of the gene 
encoding CC chemokine receptor 2 (CCR2), or through inhibition of the CC 
chemokine system as a whole results in impaired thrombus resolution43, 329. 
Conversely, directly increasing macrophage numbers has been found to 
enhance thrombus resolution25. VEGFR1, present on the surface of primary 
human monocytes, stimulates their migration into tissues330, 331. Inhibition of 
VEGFR1 activity on macrophages by axitinib may therefore account for the 
reduced number of these cells accumulating in the thrombus. 
 
The very low levels of fibrillar collagen deposition observed in untreated 
thrombus at day 3 post induction are consistent with previous observations 
which show that fibrin predominates in the early thrombus257. Treatment with 
axitinib resulted in a ~75% reduction in thrombus collagen deposition by day 10 
and 50% at day 17 post-induction. There is conflicting evidence on the role of 
VEGF-VEGFR signalling in collagen-mediated fibrosis. Loss of VEGFA 
expression in myeloid cells enhances pulmonary fibrosis, suggesting that 
production of VEGFA in this cell type has important anti-fibrotic activity332. 
Blockade of VEGFR signalling by either sVEGFR1 transduction or 
pharmacological inhibition significantly reduces collagen deposition in a murine 
model of pulmonary fibrosis333, 334. In the present study the antifibrotic effects of 
VEGFR disruption may be secondary to impaired recruitment of collagen 
producing macrophages335.  Fibroblasts are the major cellular producers of 
collagen, but their role in the pathogenesis of venous thrombus resolution is 
currently not known and is worthy of investigation. 
 
Given that axitinib acts as a pan-VEGFR inhibitor it has not been possible to 
investigate the contribution of individual VEGFR isoforms to thrombus 
resolution. In a recent study endothelial specific deletion of VEGFR2 was found 
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to significantly impair thrombus resolution54. Measurements of thrombus volume 
and weight at day 1 post-induction reveal that the thrombus in VEGFR2 
deficient mice was, however, more than double the size of respective littermate 
controls. This initial difference in thrombus size is likely to confound subsequent 
studies of resolution. 
 
The observed impairment in venous thrombus resolution attributed to axitinib 
treatment may also have important implications for patients receiving this drug. 
Patients with cancer already possess an elevated risk of venous thrombosis 
than found in the general population336. There is evidence to suggest that 
treatment with anti-tumourigenic agents may increase the incidence of venous 
thrombosis further, possibly by reducing endothelial anti-thrombotic activity and 
increasing platelet pro-thrombotic activity337, 338. A meta-analysis of 
bevacizumab trials suggests that patients receiving this agent are at a higher 
risk of developing VTE339. However, the findings of this meta-analysis are 
strongly contested on the basis that the authors failed to correct for the length of 
time on treatment.  
 
Whilst only a few phase III trials of axitinib have reached completion in a 
landmark study comparing the effect of axitinib to sorafenib in patients with 
metastatic renal cell carcinoma (clinicaltrials.gov, NCT00835978) a marked 
increase in the incidence of venous thromboembolism (VTE) was noted317. 
Even when adjusted for the time on treatment the axitinib treatment arm had a 
significantly higher incidence of all grade VTE (7/359) than the sorafenib arm 
(1/359) as assessed by chi squared test (P<0.05, relative-risk 1.76, 95% 
confidence interval 1.34 – 2.30). It is interesting to note that in this trial patients 
with a recent history of VTE were excluded, but since being licensed axitinib is 
available to these patients. 
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Chapter 8 General discussion and future 
studies 
8.1 Discussion 
8.1.1 Expression of PHD isoforms in the thrombus 
PHD proteins serve as key molecular oxygen sensors regulating the cellular 
response to tissue hypoxia through the oxygen-dependent hydroxylation and of 
HIF1α leading to proteasomal degradation. Previous studies have 
demonstrated that the newly formed venous thrombus was acutely hypoxic, 
which lead to increased nuclear accumulation of HIF1α and expression of 
HIF1α target genes including Vegfa. During resolution oxygen tension in the 
thrombus increases, resulting in a loss of HIF1α nuclear accumulation 
presumably through the restoration of PHD enzymatic activity57. 
 
In the present study, quantification of PHD expression at the gene and protein 
levels revealed that all three isoforms (PHD1, PHD2 and PHD3) are expressed 
in the resolving thrombus. At the gene level different temporal patterns in 
expression of Phd1, Phd2 and Phd3 were observed. Expression of Phd1 
remained relatively constant across the time-course of the experiment. Hypoxia 
has not been found to induce expression of the Phd1 gene142 and expression of 
this gene can be down regulated by hypoxia in certain cell types340. The Phd1 
gene promoter lacks an HRE sequence instead possessing a HIFβ/Single 
Minded binding sequence340 that represses HIF1α transcriptional activity341. The 
expression of Phd2 and Phd3 was found to change significantly over time in the 
resolving venous thrombus. At early and late time-points phd2 gene expression 
was elevated compared to that at mid time-points. Expression of Phd2 has been 
observed in neutrophils, which predominate in the early thrombus, and 
macrophages, which accumulate as the thrombus resolves. PHD2 is an 
important regulator of monocyte/ macrophage cell function, regulating 
phenotypic skewing and angiogenic potential165. The expression of the Phd3 
gene was greatest in the acute thrombus before falling. Phd3 gene expression 
is likely maximal at this time-point as hypoxia potently upregulates expression of 
this isoform in neutrophils175. Expression of Phd3 has also been observed in a 
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pro-inflammatory subset of macrophages173. 
 
At the protein level PHD1, PHD2 and PHD3 expression was localised to the 
cellular component of the thrombus by immunohistochemistry. Based on 
morphological appearance, PHD expression was distributed amongst 
neutrophils and macrophages. It was interesting to note that not all cells present 
in thrombus at later time-points stained positively for PHDs. Differential 
expression of PHD3 protein has been observed in macrophages; with 
classically-activated macrophages expressing significantly higher levels than 
alternately activated cells173. It is unclear whether expression of PHD2 is 
regulated in a similar manner in macrophages. The differential expression of 
PHD isoforms in the thrombus could also be attributed to the presence of other 
cell types, such as fibroblasts.  
 
In order to determine the cellular origin of PHD expression in the resolving 
venous thrombus it would be necessary to carry out further flow cytometric 
analyses. Flow cytometry based cell sorting is a powerful technique that allows 
for more detailed phenotypic analysis and isolation of specific cell populations 
by examining the expression of multiple cell surface markers. Cells known to be 
present in the resolving venous thrombus including; neutrophils, monocytes, 
macrophages, and endothelial cells could be isolated using appropriate panels 
of antibodies (Table 8.1). Once isolated RT-PCR and western blotting of 
individual cell populations could be used to quantify PHD, HIFα and HIFα 
transcriptional targets expression at the gene and protein level. This approach 
would provide powerful cellular data, as opposed to whole tissue, and may 
overcome some of the challenges, such as protein dilution, highlighted during 
the present study. 
Table 8.1 Cell surface markers for flow cytometry 
 
Cell type Surface markers 
Neutrophil Ter199- NK1.1- CD3- CD9- Ly6C- CD45+ Ly6G+ 
Monocyte Ter199- NK1.1- CD3- CD9- Ly6G- F480- CD45+ Ly6C+ 
Macrophage Ter199- NK1.1- CD3- CD9- Ly6G- CD45+ Ly6C+ F480+  
Endothelial cell Ter199- NK1.1- CD3- CD9- Ly6G- CD45- VEGFR2+ CD31+ 
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8.1.2 The effect of Phd2 gene deletion on thrombus resolution 
It was unclear, whether a single, specific PHD isoform was responsible for 
regulation of HIF1α during thrombus resolution, as all isoforms have 
demonstrated the capacity to hydroxylate HIF1α272. However, gene knockdown 
studies suggested that under normoxic conditions PHD2 activity, but not PHD1 
or PHD3, was required for efficient degradation of HIF1α241. Combined with 
expression studies in the thrombus this highlighted PHD2 as an isoform of 
particular interest, leading to the investigation of thrombus resolution in Phd2 
gene specific knockouts. Somewhat surprisingly neither constitutive nor 
inducible all-cell Phd2 knockouts had any detectable effect on venous thrombus 
resolution or organisation. In Phd2 constitutive heterozygous knockouts this 
could be accounted for by the lack of significant up-regulation in HIF1α nuclear 
accumulation. However, in homozygous inducible Phd2 knockouts, in which 
HIF1α nuclear accumulation and transcriptional activity was significantly 
increased, no difference in thrombus resolution or organisation was observed. 
The confirmation of previously reported elevations in haematocrit makes it 
unlikely that loss of PHD2 is compensated for by other isoforms169. However, 
from the present study of Phd2 gene knockouts it is not possible to discount the 
contribution of other PHD isoforms or PHD enzyme activity as a whole.  
 
Non-overlapping functions for individual PHD isoforms have been described 
and may be attributed to: the HIFα subunit selectivity, the kinetics of HIFα 
hydroxylation or differential expression of PHD isoforms138, 272. Gene specific 
deletion of Phd3 results in impaired neutrophil cell survival and increased 
macrophage migration41, 172, cell types important to thrombus resolution. 
Relatively little is known about the specific contribution of PHD1 to the cellular 
response to hypoxia. Initial studies have shown this enzyme, but not PHD2 or 
PHD3, regulates changes in cellular metabolism in response to hypoxia144. 
Although the levels of Phd1 gene expression were invariant during thrombus 
resolution, this does not mean that this enzyme is redundant. Studying venous 
thrombus resolution in available Phd1 and Phd3 gene knockouts may improve 
understanding of the role that these specific isozymes play144, 176. Cooperation 
of PHD isoforms could similarly be investigated using a double knockout 
strategy as previously reported143. 
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8.1.3 The effect of PHD inhibition on thrombus resolution 
PHD inhibition using the iron chelating agent l-mimosine significantly increased 
venous thrombus resolution57. It is possible, however, that because of the broad 
activity of l-mimosine, other enzymes including the collagen-modifying prolyl-4-
hydroxylases may also have been inhibited230, 342. After studies on the effects of 
l-mimosine on thrombus resolution were completed, a new class of PHD 
inhibitors, with improved selectivity and specificity, were developed. It was 
possible to secure access to two of these PHD inhibitors, AKB-4924  (Akebia 
Therapeutics, USA) and JNJ-42041935 (Johnson and Johnson, USA)227, 231. 
This provided the opportunity to reassess the effect of pan-PHD inhibition on 
venous thrombus resolution. Importantly, AKB-4924 and JNJ-420241935 have 
distinct modes of action with the former inhibiting PHD activity through chelation 
of iron at the active site 231and the later competing with the co-factor 2-OG227. 
Use of these agents in the thrombosis model was aimed at identifying 
processes affected specifically by PHD inhibition. 
 
Treatment with either AKB-4924 or JNJ-42041935 did not alter thrombus 
resolution, despite significantly increasing HIF1α nuclear accumulation and 
haematocrit respectively. Both AKB-4924 and JNJ-42041935 had similar effects 
on thrombus organisation, with significantly increased thrombus 
neovascularisation, but no effect on macrophage and collagen content. This 
would suggest that pan-PHD inhibition selectively affects the formation of 
neovascular channels, a process that is akin to angiogenesis and occurs during 
natural resolution52. A number of studies have demonstrated that inhibition of 
PHD enzymes strongly upregulates angiogenesis in vivo194, 196, 197. PHD2 and 
PHD3 have also been found to cooperate in the induction of angiogenesis343. 
Cooperation of multiple PHD enzymes could explain why neovascularisation 
was increased in mice treated with PHD inhibitors but not in Phd2 gene 
knockouts. 
 
Having demonstrated that PHD inhibition resulted in a significant upregulation in 
neovascular channel formation further investigation of this pro-angiogenic effect 
would be advantageous. In vitro tubule formation assay could demonstrate 
whether PHD inhibition in endothelial cells directly affects angiogenesis. 
Alternatively, tubule formation could be observed in co-cultures of endothelial 
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cells and macrophages pretreated with PHD inhibitors as this cell type is known 
to aid co-ordination of neovessel formation344. The effect of PHD inhibition on 
endothelial proliferation could also be investigated using a bromodeoxyuridine-
based assay given that HIF1α is known to regulate apoptosis and proliferation 
of this cell type345. 
 
It is possible that deletion of Phd2 and PHD inhibition may affect skewing of 
macrophage populations present in the resolving venous thrombus164. Recent 
flow cytometric analysis of macrophage populations in the resolving venous 
thrombus has revealed accumulation of distinct subsets of macrophages, based 
on expression of MHC class II346. The effect of PHD inhibition on skewing of 
thrombus resident macrophages could be investigated using a similar flow 
cytometric technique. Alternatively in vitro analysis of monocyte skewing in 
response to macrophage colony-stimulating factor (MCSF) and granulocyte 
macrophage colony stimulating factor (GMCSF) could be studied in conjunction 
with PHD inhibition or Phd2 gene deletion. 
 
Increased haematocrit has been implicated as a causative factor in the 
formation of venous thrombi347. In the present study both PHD inhibition with 
JNJ-42041935 and inducible homozygous Phd2 gene deletion resulted in 
increase haematocrit levels measured at 14 days post thrombus induction that 
were consistent with previous reports143, 169, 227. It is possible that elevated 
haematocrit could affect thrombus propagation after initial induction. Thrombus 
volumes in inducible Phd2 knockouts were not significantly different from that of 
littermate controls when measured at days 1 and 7 post-induction suggesting 
that propagation was unaffected by increased haematocrit. It is unclear whether 
increased haematocrit affected thrombus resolution after treatment with JNJ-
42041935. It is also possible that haematocrit was not induced until thrombus 
resolution was well under way; further intermediate measurements of 
haematocrit would be needed to measure the rapidity of onset. 
 
Both Phd2 gene deletion and PHD inhibition have been associated with 
increasing circulating levels of VEGF145, 196, although others have failed to 
reconfirm these initial findings269. In the present study VEGF plasma 
concentrations determined by ELISA remained unchanged after inducible phd2 
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homozygous deletion and inhibition of PHD with either AKB-4924 or JNJ-
42041935. It is possible that PHD mediated changes in VEGF levels were 
masked by surgical injury and the presence of a thrombotic insult both of which 
contribute to elevated levels of circulating VEGF 48. 
 
8.1.4 Contribution of VEGFR signalling to thrombus resolution 
Previous studies have demonstrated the potential benefit of enhanced VEGFA 
expression, and presumably downstream VEGFR signalling activity, in 
accelerating venous thrombus resolution. The requirement of endogenous 
VEGFR signalling for venous thrombus resolution was much less clear. 
Gradients of VEGFA are required for organised migration of endothelial cells348 
whereas absolute levels of VEGFA regulate proliferation and the propensity to 
form tubules349, 350. VEGFA is also an important regulator of monocyte 
chemotaxis and transmigration330, 351. Given that numerous cell types present in 
the thrombus are regulated by VEGFR signalling activity, it was reasonable to 
suggest that this pathway might be required for venous thrombus resolution. To 
investigate the requirement of endogenous VEGFR signalling thrombus 
resolution was studied in mice treated with the small molecule pan-VEGFR 
inhibitor axitinib. 
 
Treatment with axitinib significantly delayed venous thrombus resolution, with 
thrombus volume approximately 60% greater than respective vehicle control at 
10 days post induction. Thrombus resolution at day 17 whilst still impaired by 
axitinib treatment (~40%) was not significantly different. The temporal 
impairment in venous thrombus resolution suggests that VEGFR signalling is 
required for the early phases of thrombus resolution (day 3-10) but is perhaps 
dispensable at later time-points (day 10-17). Reduced thrombus recanalisation 
after axitinib treatment may occur primarily as a consequence of reduced 
thrombus resolution. However, vessel tone may also be affected by axitinib 
treatment as VEGFA induced activation of eNOS results in generation of the 
potent vasoldilator NO352. The reduction in neovascular channel formation is 
most likely dependent on endothelial VEGFR2 activation306 as endothelial 
specific deletion of Vegfr2 has been found to impair neovascular channel 
formation in the resolving venous thrombus54. Loss of VEGFR1 activity could 
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account for the impaired recruitment of monocytes/macrophages to the 
thrombus after axitinib treatment as this receptor is the major VEGFR 
expressed on monocytes and is required for VEGFA and PlGF mediated 
monocyte migration330, 331. However, a subpopulation of monocytes, present in 
the thrombus, also express VEGFR2, and the contribution of this receptor to 
cellular function cannot be discounted56.  
Loss of HIF1α stabilisation and hence activity has also been studied in venous 
thrombus resolution. Treatment of thrombosed animals with 2-methoxy estradiol 
(2ME) a microtubule depolimerising agent that prevents the accumulation of 
HIF1α in the cell nucleus, was found to significantly impair thrombus resolution. 
It is interesting to note that the scale of impairment in thrombus resolution after 
2ME treatment was similar to that found with axitinib. The similarity between the 
phenotypes following treatment with axitinib or 2ME suggests that endogenous 
VEGFR activity could account for the majority of HIF1α biological activity in 
venous thrombus resolution. Consistent with this concept endothelium-specific 
hif1a gene deletion strongly inhibits angiogenesis in a VEGFA-VEGFR2 
dependent manner279. However, VEGFA independent processes have been 
attributed to HIF1α, specifically recruitment of myeloid cells to an inflammatory 
nidus74. 
 
8.1.5 Imaging of thrombus resolution 
The cost and availability of imaging techniques currently used to assess 
thrombus resolution represents a significant barrier to researchers. Application 
of new quantitative imaging modalities that enable longitudinal analysis of 
thrombi could be of considerable benefit. These techniques would not only 
provide powerful, paired data but also reduce the number of animals required 
for experimentation.  
 
High frequency ultrasonography (HFUS) is one such technique that is both 
affordable and readily available for imaging of small animals. Its applicability in 
imaging of IVC thrombi has already been demonstrated281, however, the two-
dimensional data so far reported using HFUS provides only qualitative, rather 
than quantitative, measures of thrombus burden. In the present study, use of a 
3D-HFUS imaging platform allowed quantitative measurements of thrombus 
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volume to be made. 3D-HFUS also allowed for segmentation of thrombus from 
surrounding tissue, however, the relatively low contrast of the early thrombus 
presented a technical challenge. The lack of contrast could be overcome by the 
use of a highly echogenic blood pool contrast agent283. Targeted contrast 
agents for both fibrin and platelets have been developed and these would 
enable imaging at the molecular and cellular level353, 354. Another limitation of 
3D-HFUS was the low resolution achieved in the z-axis (110µm); this was 
necessitated by the relatively small memory buffer of the ultrasound machine 
combined with a need to scan the entire thrombosed segment of the IVC. 
 
Contrast-enhanced microCT has been reported as an effective method of 
delineating the thrombus from surrounding tissue254. In the present study a 
method of contrast-enhanced microCT was developed using a low volume 
bolus injection of the blood pool contrast agent, Aurovist, which facilitated 
longitudinal imaging of thrombus resolution. Computational image segmentation 
and volumetric rendering allowed measurement of thrombus volume. Inter- and 
intra-observer analysis showed this technique to be robust and reliable. 
Thrombus volumes derived from microCT compared favourably to histological 
measurements which is the most common method of assessing thrombus size. 
A notable bias was, however, apparent when comparing the two measures, with 
histological measurements consistently smaller than those by microCT. This 
could be explained by shrinkage of histological samples during post-fixation 
processing and tissue sectioning298.  
 
In the present study contrast enhanced microCT scans were reconstructed at a 
resolution of 65µm, however, with the microCT datasets obtained it would have 
been possible to reconstruct images with a voxel size of 22µm, almost tripling 
the resolution. Initial attempts at analysis of high-resolution reconstructions 
proved challenging as files sizes were too large to be handled by the analysis 
software based on current computing capacity. Improved computing power or 
more restricted ROI placement would likely overcome this technical limitation 
and may improve fidelity of thrombus segmentation. It is also possible that high-
resolution reconstructions could be used to identify neovascular channels in the 
organised thrombus and this would merit further investigation. 
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Comparing these two modalities for imaging of the venous thrombus contrast-
enhanced microCT was considered technically superior to 3D-HFUS. Contrast-
enhanced microCT provided higher spatial resolution compared to 3D-HFUS, 
with potential for further such increases. Contrast between thrombus and 
surrounding tissue was not only greater by contrast-enhanced microCT than 
3D-HFUS but also more consistent across the thrombus aiding segmentation. 
Whereas a single scan was sufficient to image the thrombus by microCT, 3D-
HFUS often required multiple scans with adjustments to the positioning of the 
probe so as to capture the entire length of the thrombosed IVC while avoiding 
wound tissue that impaired ultrasound conductance. 
 
 
8.2 Limitations of the study 
 
8.2.1 PHD quantification 
It was not possible to measure the expression of PHD proteins in the resolving 
thrombus in a quantitative manner. Attempts to quantify PHD protein expression 
in the thrombus by western blotting proved unsuccessful as expression was 
below the detectable limits of this methodology. It may be possible to improve 
the sensitivity of the western blot technique using substrates with increased 
sensitivity or signal amplification techniques such as those afforded by biotinyl 
tyramide conjugates. However, at best, densitometric analysis of western blots 
can only be considered semi-quantitative. ELISA would provide the most 
sensitive and quantitative measure of thrombus PHD protein expression, but 
there are presently no robust commercially available kits for these proteins. 
Although IHC analysis of protein expression in the thrombus provides a highly 
amplified signal and hence very high sensitivity, this technique is not 
quantitative in its current state. Recent developments in this area, suggest that 
it may be possible to use IHC to quantify proteins in situ355. The main drawback 
to this procedure is the amount of time involved and the accuracy/reproducibility 
of the addition of the assay components. 
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8.2.2 HIF1α quantification 
Another potential limitation of the western blot technique used in the present 
study was observed when quantifying HIF1α in the nuclear extracts of kidney 
samples, where there was marked variability in expression of the nuclear 
loading control Histone H3. The use of frozen tissue samples could have 
reduced the reproducibility of nuclear protein extraction, in the future it would be 
advantageous to extract protein from fresh tissue samples. Extensive 
normalisation of samples was required to reveal significant differences in 
nuclear HIF1α accumulation. Had a commercially available HIF1α ELISA been 
used these differences would not have been detected and may have skewed 
quantification. 
 
Alternatively, it is possible that the lysis protocol used in the present study may 
have resulted in inefficient recovery of HIF1α protein. Considerable success has 
been achieved using stronger solubilising agents, in particular 8M urea, to 
generate total cell lysates. This method, whilst quantifying total HIF1α levels, is 
sensitive to changes in HIF1α stability as a result of gene knockdown of 
Phd2356. To further strengthen the observed phenotype of increased HIF1α 
stabilisation after both Phd2 gene deletion and pan-PHD inhibition it would be 
useful to quantify downstream transcriptional targets of HIF1α in kidney tissue 
lysates. Quantification of targets such as Glut1, VEGFA and carbonic 
anhydrase IX (CAIX) by western blotting would provide a measurement of 
HIF1α transcriptional activity357. 
8.2.3 PHD IHC specificity 
In this study, the specificity of IHC antibodies to the target PHD isoforms was 
assessed by comparison of patterns of staining in the kidney to those previously 
reported. It may have been possible to validate IHC staining of PHD2 in 
sections of thrombus from inducible homozygous phd2 knockouts. These 
knockout mice should have no PHD2 and therefore no staining. Any staining 
seen would therefore be non-specific. This would be expanded to both PHD1 
and PHD3 immunohistochemistry. However, it is important to note that 
conditional knockout may not result in complete loss of protein as some protein 
may be retained in the cell following deletion of the gene. 
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8.2.4 Factor inhibiting HIF 
When investigating the regulation of HIF1α stabilisation by PHD deletion and 
inhibition, the expression of a related enzyme factor inhibiting HIF (FIH) was not 
investigated. FIH has been proposed to regulate HIF transcriptional activity 
through hydroxylation of an asparagine residue present in the C-terminal 
activation domain of HIFα subunits181. The activity of FIH is of particular 
relevance to studies of PHD inhibition as it is also a 2-OG dependent 
dioxygenase that requires iron as a co-factor181. The increased haematocrit 
observed in homozygous inducible phd2 knockouts would suggest that FIH 
activity does not prevent transcription of HIF target genes. Commonly used 
PHD inhibitors such as DMOG and DFO are therefore effective antagonists of 
FIH enzyme activity181, 358. However, while JNJ-420241935 is a potent inhibitor 
of PHD2 activity, it is a much weaker inhibitor of FIH227. Little is known with 
regards to the selectivity of the agent AKB-4924 in the inhibition of FIH. 
 
8.2.5 VEGFR inhibition 
In mice treated with the VEGFR antagonist, axitinib, measurements of drug 
efficacy were not made. While widely reported as a potent and selective 
inhibitor of VEGFR the finding of this study would be further strengthened by 
direct measurements of VEGFR inhibition in the thrombus. VEGFR activation 
results in downstream phosphorylation of multiple kinases, in particular Akt and 
ERK, and this could also be quantified by conventional western blotting 
techniques or more sensitively by PhosFlow cytometry359. 
 
8.2.6 Imaging 
All imaging technologies involve a degree of subjective interpretation and 
therefore must be validated not only against a standard technique (e.g. 
histology) but also by a number of assessors. In this study this was carried out 
for the microCT analysis, but not for HFUS measurements. The lack of contrast, 
made HFUS analysis more subjective compared with contrast-enhanced 
MicroCT and potentially less reliable. More detailed validation of this technique 
for assessment of venous thrombus resolution is therefore required. 
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8.3 Future work 
 
An important finding of this study was the requirement of endogenous VEGFR 
signalling as a significant stimulus for venous thrombus resolution. While a 
detailed phenotypic characterisation of thrombus resolution after axitinib 
treatment was completed, further investigation into the cellular effects of 
VEGFR inhibition are warranted. Axitinib treatment may prevent 
monocyte/macrophage chemotaxis along VEGF gradients and thus explain 
reduced accumulation of macrophages into the thrombus. A Boyden chamber 
based assay could be used to determine the effect of axitinib treatment on 
monocyte and macrophage migration towards VEGF and PlGF330, 331. Short 
interfering RNA mediated gene knockdown of VEGFR1 and VEGFR2 in 
monocytes and macrophages could be used to determine whether an individual 
receptor drives VEGFR dependent cell migration.  
 
Axitinib is a broad acting VEGFR inhibitor preventing activation of all three 
receptors and did, therefore, not allow the contribution of individual VEGFRs to 
be assessed. The importance of VEGFR family members could be further 
investigated using conditional gene specific Vegfr1, Vegfr2 and Vegfr3 
knockouts360-362. Given the observed reductions in neovascular channel 
formation and macrophage recruitment after axitinib treatment it would be of 
particular interest to study specific gene deletion in these cell types. Studies of 
endothelial-specific Vegfr2 gene deletion have highlighted difficulties using this 
approach as deletion prior to induction of thrombosis can affect formation54. 
Alternatively, selective small molecule inhibitors of Vegfr2, such as vandetanib 
or apatanib, could be investigated in the context of venous thrombus 
resolution363, 364. The major benefit of pharmacological inhibition when studying 
thrombus resolution is that treatment can be initiated after induction, preventing 
confounding effects on thrombus formation.  
 
Increased HIF1α stability, as a result of either PHD inhibition of Phd2 gene 
deletion was not sufficient to accelerate thrombus resolution. This does not, 
however, discount the requirement of endogenous HIF1α transcriptional activity 
for natural thrombus resolution. Endogenous thrombus HIF1α transcriptional 
activity could be studied using ODD-luciferase reporter mice225. Whilst ODD-
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luciferase is most commonly used to determine the efficacy of HIF1α stabilising 
interventions it has also been used to study physiological HIF1α transcriptional 
activity in small subcutaneous tumours and may therefore be sufficiently 
sensitive to detect activity in the thrombus365. The contribution of endogenous 
HIF1α to thrombus resolution could be studied using tissue-specific gene 
knockouts366. Loss of HIF1α transcriptional activity is likely to lead to impaired 
myeloid cell recruitment and angiogenesis as has been previously reported74. 
Recently, expression of HIF2α has been localised to the venous thrombus, 
accumulating as resolution progresses261. Thrombus resolution in tissue-





The data from this study shows that PHD isoforms are expressed in the 
resolving venous thrombus at both the gene and protein level. Specific loss of 
Phd2 expression, whether by constitutive heterozygous or inducible 
homozygous deletion, was not found to affect any measure of venous thrombus 
resolution. Pharmacological inhibition of PHD enzyme activity selectively 
enhanced the formation of neovascular channels in the thrombus, without 
affecting thrombus resolution or other markers of organisation. This finding 
challenges the notion that the formation of neovascular channels in the 
thrombus contributes significantly to resolution. Pharmacological blockade of 
VEGFR signalling, in which a number of HIF1α transcriptional targets are 
involved, significantly impaired thrombus resolution and organisation. It is not 










Figure A1 Analysis of RNA integrity 
RNA integrity was assessed using a Nano 6100 microfluidic chip. (A) 
Representative electrophoretic traces of RNA samples. (B) Graphical 
representation of traces from which algorithm based RNA integrity values (RIN) 
values were calculated.  
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A2. Murine thrombus micro-array method 
 
i) Target Preparation 
Total RNA (400ng) was concentrated to 3µl using a Gyrovap vacuum (Howe 
and co, UK)system at 2,800g (20ºC). RNA obtained from HeLa cells (1mg/ml) 
was used as a positive control. Samples were spiked with synthetic 
polyadenylated RNA (Poly A RNA) transcripts of B. subtilis genes to monitor 
amplification and labeling. 
 
ii) cDNA Synthesis 
First strand master mix (FSM, 4µl 1st strand buffer, 1µl transcriptase) was added 
to each RNA sample containing T7-Oligo(dT) primer mix and incubated for 1hr 
at 25ºC, 1hr at 42ºC and 2mins at 4ºC. Second strand master mix (SSM, 12.5µl 
2nd strand buffer, 32.5µl RNase-free water, 5µl polymerase) was added to each 
sample and incubated for 1hr at 16ºC, 10mins at 65ºC and 2mins at 4ºC. IVT 
master mix, 24µl IVT buffer, 6µl IVT enzyme) was added to each sample 
followed by incubation for 16hr at 40ºC. cRNA was purified using nucleic acid 
binding beads (10µl beads, 50µl buffer, Applied Biosystems, USA) and 60µl of 
isopropanol were added to each sample followed by a 2min incubation. Nucleic 
acid binding beads were isolated using a magnetic stand, washed twice using 
100µl of nucleic acid wash solution and cRNA eluted with 40µl of preheated 
elution buffer (55ºC). cRNA was quantified by nanodrop as described in 
Chapter 3.3.3 and 455ng/µl of template added to 2µl of random primers and 
incubated for 5mins at 70ºC, 5mins at 25ºC and 2mins at 4ºC. Second-cycle 
master mix (8µl 2nd-cycle buffer, 8µl 2nd-cycle enzyme) was added to each 
sample and incubated for 10mins at 25ºC, 90mins at 42ºC, 10mins at 70ºC and 
2mins at 4ºC.  
 
iii) Purification of Second-cycle cDNA 
Samples were treated with RNase H (2µl) and incubated for 45min at 37ºC, 
5min at 95ºC and 2min at 4ºC to hydrolyse cRNA template. cDNA binding mix 
Nucleic acid binding beads were prepared as previously described, diluted with 
18µl of nuclease-free water and 120µl ethanol and incubated with samples for 
2mins on a plate shaker. Nucleic acid binding beads were isolated using a 
magnetic stand, washed twice using 100µl of nucleic acid wash solution and 
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cDNA eluted with 40µl of preheated elution buffer (55ºC). Quantification of 
cRNA and cDNA was conducted as described in Chapter 3.3.3. 
 
iv) GeneChip Array Hybridisation 
cDNA was fragmented by the addition of 8µl of 5x fragmentation buffer, diluted 
to a total of 40µl with RNase-free water and incubated for 1hr at 37ºC, 2mins at 
93ºC and 2mins at 4ºC.  Fragmented cDNA (45µl) was added to 12µl 5x TdT 
buffer, 2µl TdT and 1µl DNA labelling reagent (5mM) and incubated for 1hr at 
37ºC, 10mins at 70ºC and 2mins at 4ºC for labelling of samples. A hybridisation 
cocktail was prepared using the following reagents; 5µl control oligonucleotide 
B2 (3nM), 3µl herring sperm DNA (10mg/ml), 3µl bovine serum albumin 
(50mg/ml), 150µl 2x hybridisation buffer, 30µl DMSO, RNase-free water up to 
300µl and 15µl 20x eukaryotic hybridisation controls (bioB, bioC, bioD, Cre). 
Hybridisation cocktail was added to each cDNA sample (15µg) and heated for 
5mins at 99ºC. Probe arrays were equilibrated to room temperatre and filled 
with 80µl hybridisation cocktail and hybridised for 16h at 45ºC with rotation 
(60rpm). Probe arrays were washed using an automated washing and staining 
protocol on a fluidics work-station. Arrays were scanned on an Affymetrix 3000 
GeneChip scanner (Affymetrix, USA). 
 
v) Probe Array Analysis 
The scanned probe array image for each sample was inspected for artifacts and 
a grid placed over the image to demarcate each probe cell. Hybridisation of an 
oligonucleotide B2 control was used for correct alignment of the grid. Spot 
signal intensity was analysed using Expression Console software (Affymetrix, 
USA). The robust multi-array analysis (RMA) algorithm was used to normalise 
data, correct for background fluorescence, perform probe summarisation and 
scale the intensity values obtained (Tukey’s Bioweight average). 
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A3. qPCR Amplification efficiency 
 
Gene Slope Efficiency (%) 
Actb -3.49 93 
Gak -3.28 102 
Phd1 -3.30 101 
Phd2 -3.34 99 
Phd3 -3.18 106 
Hif2a -3.43 96 








Figure A2 Representative qPCR amplification curves 
Amplification curves of (A) Phd2 standard serial dilutions and (B) unknowns with 
fluorescence plotted as log10 against cycle number, sample amplification is 
recorded when the plot passes through the threshold (green line). (C) Phd2 
serial dilutions are used to plot a standard curve of amplification cycle number 
against standard concentration (n) plotted as log10 from which unknowns can 





A5. Representative whole-membrane western blots 
 
 
Figure A3 Representative PHD1 western blot 
A single discrete band for PHD1 with a molecular weight of 51kDa (predicted 
44kDa) was observed. An additional band with a molecular weight of 18kDa 
was also observed mainly in the cytoplasm. 
 
Figure A4 Representative PHD2 western blot 
A single discrete band for PHD2 with a molecular weight of 53kDa (predicted 
46kDa) was observed. Some diffuse background staining was also apparent. 
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Figure A5 Representative PHD3 western blot 
Multiple bands were present in PHD3 immunoblots possibly resulting from the 
polyclonal antibody used. The PHD3 band was selected on the basis of the 
observed molecular weight of 36kDa (predicted 27kDa). Of interest a band of 
equal intensity was present in nuclear extracts (lane 6 and 7) with an observed 
molecular weight of 47kDa. 
 
Figure A6 Representative αTubulin western blot 
An intense αTubulin (αTUB) band with a molecular weight of 55kDa (predicted 
50kDa) was observed. Residual Histone H3 (His H3) staining was apparent. 
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Figure A7 Representative Histone H3 western blot 
A discrete Histone H3 (His H3) band with a molecular weight of 22kDa 










Figure A8 Cellular fractionation of fresh and snap frozen murine kidney 
Kidney samples will be used to assess the effects of Phd2 gene deletion and 
pharmacological PHD2 inhibition. Do to the constraints of harvesting a large 
number of samples tissue must be snap frozen.  The effect of snap freezing of 
tissues on cellular fractionation is unclear. To assess this freshly isolated and 
snap frozen kidney samples were subject to nuclear cytoplasmic extraction. 
Fractionation was assessed by immunoblotting for the cytoplasmic (C) marker 
αtubulin and the nuclear (N) marker Histone H3. αTubulin was well segregated 
to the cytoplasm in both fresh and frozen kidney samples while Histone H3 was 
enriched in the nuclear fraction of both samples, although to a greater extent in 
fresh kidney samples. 
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A7 Thrombus PHD2 immunohistochemistry 
 
 
Figure A9 Representative PHD2 immunohistochemistry in the resolving 
venous thrombus 
Localisation of PHD2 in the resolving venous thrombus at (A) Day 1 (B) Day 3 








B1. Thrombus resolution in constitutive Phd2 gene knockouts 
 
Supplementary Data File 
The accompanying Excel spreadsheet provides data at the level of individual 
replicates for histological measurements of thrombus volume, vein lumen 
recanalisation, thrombus neovascularisation, thrombus macrophage content 












Figure A9 Segmentation of 3D-HFUS scans 
(A) Scans analysed in Osirix software are first calibrated in the z axis so that 
slices are spaced 110µm apart. (B) Using a closed polygon tool the thrombosed 
segment of the vein is demarked. (C) This segmentation is repeated across the 
length of the thrombus providing individual measurements of thrombus cross 
sectional area. (D) This data was used to generated 3D volume renders of the 
thrombus from which measurements of thrombus volume can be made. 
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C2. Visualisation of the thrombus by 3D-HFUS 
 
Supplementary Video File: 
The accompanying video file is of a day 1 thrombus imaged by 3D-HFUS. The 
video starts at the iliac confluence moving proximally along the IVC towards the 
renal veins and the site of stenosis. The thrombus presents as a hyperechoic 





C3. Thrombus resolution in inducible Phd2 gene knockouts 
 
Supplementary Data File: 
The accompanying Excel spreadsheet provides data at the level of individual 
replicates for 3D-HFUS measurements of thrombus volume and rate of 
thrombus resolution. Histological measurements of thrombus volume, vein 
lumen recanalisation, thrombus neovascularisation, thrombus macrophage 











Figure A10 Segmentation of a day 1 thrombus imaged by contrast 
enhanced microCT 
Using ITK-SNAP software (A) a small region of interest was selected (red box). 
(B) The scan was processed to restrict “bubble propagation” to regions of hypo-
intensity (white area). (C) Small “bubbles” were placed along the length of the 
thrombus and (D) propagated until the thrombosed region was filled. (E) The 
segmentation was manually refined until all of the thrombus was selected 
before (F) a 3D volume render was generated from which a measurement of 
thrombus volume was taken.  
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D2. Visualisation of thrombus by contrast-enhanced microCT 
 
Supplementary Video File: 
The accompanying video file is of a day 1 thrombus imaged by contrast-
enhanced microCT. The video starts at the level of the renal veins moving 
distally towards the iliac confluence. The thrombus presents as a hypoperfused 









D3. Thrombus resolution after PHD inhibitor treatment 
 
Supplementary Data File: 
The accompanying Excel spreadsheet provides data at the level of individual 
replicates for contrast enhanced microCT measurements of thrombus volume 
and rate of thrombus resolution after treatment with AKB-4924. Histological 
measurements of thrombus volume, vein lumen recanalisation, thrombus 
neovascularisation, thrombus macrophage content and thrombus collagen 








E1. Thrombus resolution after treatment with the VEGFR inhibitor axitnib 
 
Supplementary Data File 
The accompanying Excel spreadsheet provides data at the level of individual 
replicates for histological measurements of thrombus volume, vein lumen 
recanalisation, thrombus neovascularisation, thrombus macrophage content 
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